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Abstract
Molecular Classification and Prediction of Metastatic Potential in
Early Malignant Melanoma:
Improvement of Prognostic Accuracy by
Quantitative in situ Proteomic Analysis

Aaron J. Berger
2006
The incidence o f cutaneous malignant melanoma continues to increase every year,
and remains the leading cause of skin cancer death in industrialized countries. In spite of
the aggressive nature o f advanced melanoma, there are no standard biological assays in
clinical usage that can predict metastasis. This may be due, in part, to the inadequacy of
reproducible assessment of protein expression using traditional immunohistochemistry.
This dissertation will discuss the use of tissue microarrays combined with quantitative in
situ molecular analysis of protein expression to allow prediction of melanoma metastasis.
Through the identification and validation of novel prognostic biomarkers, we seek to
identify subsets of patients that are at high or low risk for melanoma recurrence or
melanoma-related death. Some of these biomarkers may also serve as potential targets
for future biologic therapy in melanoma, a disease for which no effective medical
treatment is currently available. We demonstrate that quantitative assessment of a small
number of markers is predictive of metastasis and outcome, augmenting the current
system o f prognosis.
The dissertation begins with a brief introduction on the current state of melanoma
diagnosis, staging, and treatment, as well as a review of current efforts to understand the
biology o f melanoma progression and metastasis. The fundamentals of tissue microarray
technology are then described. Critical aspects of quantitative immunohistochemistry,
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including a description o f the Automated Quantitative Analysis (AQUA) system
developed in our laboratory, are also addressed. The second chapter demonstrates the use
of tissue microarray technology to examine melanoma specimens by the current field
standard, with a study of activating transcription factor 2 (ATF2); an example of semiquantitative immunohistochemical analysis of protein expression. The third chapter
provides validation of the AQUA technology on melanoma tissue by evaluation of the
human homologue of murine double minute 2 protein (HDM2). Chapter four
demonstrates an example of the critical—and beneficial—aspect of subcellular
compartmentalization that the AQUA system provides, demonstrating that the ratio of
cytoplasmic-to-nuclear expression of activator protein 2 (AP-2) predicts outcome in
melanoma patients. The last chapter draws these concepts together and presents results
from the analysis of 50 protein biomarkers in melanoma. It also introduces the use of a
number of statistical methods (traditional and novel) employed to develop an optimal
biomarker set for future analyses.
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This dissertation is dedicated to the memory of my friend Marco Palma. If he were alive,
I think he’d be doing this type of work. I miss him with each day that passes.
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Chapter 1: Introduction

Current Understanding and Treatment of Melanoma
Malignant melanoma is currently the most rapidly increasing malignancy in the
United States.1 It is currently the sixth most common cancer in the US; for 2005, 59,580
new cases will be diagnosed and the disease will be responsible for approximately 7,770
deaths. 2 Melanoma is also the most common fatal malignancy among young adults. 3
Among cancers, its mortality rate is surpassed only by lung cancer.4 Current estimates
predict that 1 in 71 individuals will develop melanoma during their lifetime, up from an
initial estimate of 1 in 600 in 1960 and 1 in 150 in 1985.1 There is no clear explanation
for this increase in incidence, though a combination of increased recreational sun
exposure and global ozone depletion have been held partly responsible.5 However, the
relationship between sun exposure and melanoma remains complex.
The cell of origin is the melanocyte, and melanoma can arise in normal-appearing
skin, solar lentigo, or atypical, benign melanocytic lesions.4 Studies on familial, as well
as sporadic, melanoma have demonstrated that there are clear genetic underpinnings to
the evolution of this disease.6' 14 It appears that the genetic pathways of melanoma
involve many genes with probable links to ultraviolet light exposure. 12 The definitive
diagnosis of melanoma is often quite complicated and uncertain even in the hands of the
most skilled dermatopathologists. In addition, while a number of clinical and pathologic
factors have been described and established as markers of prognosis, there is room for
significant improvement in terms of accuracy. There are currently no accepted
histopathological, molecular, or immunohistochemical markers to define subsets of this
neoplasm.15
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Regarding prognosis, early detection and treatment are critical and result in
improved patient survival rates. Surgical excision remains the mainstay of treatment but
many new promising therapies are being investigated.16 However, non-surgical treatment
•
7 * literature regarding effective
of advanced disease
has been largely unsuccessful. 1 The
adjuvant therapy for melanoma is questionable at best, and experts tend to recommend
that patients with advanced disease enroll in a clinical trial.18
The prognosis of isolated, primary cutaneous melanoma remains favorable, with a
5-year overall survival rate above 90%. However, the discovery of metastatic disease
dramatically affects outcome. The presence of regional lymph node metastases reduces
5-year overall survival rates to 10-46%.19 Although the use of sentinel lymph node
biopsy has improved the staging of melanoma, there is a critical need to determine the
metastatic potential of melanoma early in disease progression. It is not uncommon to
have widely disseminated disease at the time of initial diagnosis. The fact that patients
with local or nodal recurrences fare as poorly as those with overt distant metastases
implies that the former events are predictors of subclinical systemic disease.20 A more
precise staging system is needed; one which will take into account the aggressive nature
of the disease.
The histopathologic progression of melanoma is thought to progress through a
series o f defined stages, yet melanoma has been shown to arise spontaneously in the
context of normal-appearing skin. Normal skin typically has an even distribution of
melanocytes at the basal layer of the epidermis, with one melanocyte found for every 4 or
5 basal cells.21 The compound nevus, a benign proliferation of melanocytes, is defined
by uniform nests of melanocytes. The dysplastic nevus demonstrates irregular and
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bridging nests of atypical melanocytes. In situ melanoma remains confined to the
epidermis. Early melanoma development is characterized by the radial growth pattern. A
vertical growth phase can follow, which is thought to indicate the transition to a more
aggressive and lethal condition, characterized by tumor invasion into the underlying
dermis and subcutis, and often presages metastasis to distant sites. While melanoma
tends to spread to nonvisceral sites such as skin or lymph nodes, it is notorious for its
ability to metastasize to practically any organ, including lung, liver, brain, bone, and
small intestine. 22
Initial management of the primary lesion is by surgery. A wide local excision
removes the tumor along with a margin of normal appearing skin. Current clinical
guidelines dictate that the margin of excision be proportional to the depth of tumor
invasion into the skin. If the tumor depth is < 1 mm, a 1 cm margin is recommended,
while a depth of 1-2 mm suggests a 1-2 cm margin. When the tumor depth exceeds 2
mm, guidelines recommend a 2 cm margin of normal skin. 23 ’24 The surgical treatment of
melanoma, in particular, can range from a marginal biopsy to wide local excision with
regional lymphadenectomy, and advance in some cases to include extraction of distant
metastases.
Adjuvant therapy for melanoma is limited at best. Over the past 20 years,
numerous agents have been evaluated in a series of both nonrandomized and randomized
adjuvant therapy trials in melanoma patients. While many of these clinical trials suffered
from serious methodological problems such as inadequate statistical power, use of
inappropriate controls, and/or lack of stratification for known prognostic factors, the
major obstacle to the success of adjuvant therapy of melanoma has been the lack of active
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agents. Popular agents that have demonstrated little or no benefit include: BCG,
levamisole, interferon gamma, interleukin-2, retinoids, dacarbazine, and megestrol
acetate.25
High-dose interferon (IFN) alpha-2b is the only FDA-approved agent for the
adjuvant treatment of melanoma in the US. This treatment is used predominantly for
high-risk, stage III (i.e., lymph node disease) patients with cutaneous primaries; these
patients have a 50-85% risk of further metastasis.19 However, the benefit of this
treatment is controversial. The initial multicenter study, in 1995, reported improved
long-term and disease-free survival in melanoma patients.26 However, more recent
clinical trials have demonstrated that while there is an approximate 10% reduction in risk
of recurrence, there is no effect on overall survival. In addition, despite 20 years of
study, the mechanisms of IFN’s antitumor activities remain unknown. Studies speculate
that its efficacy may lie in its immunomodulatory functions, its antiangiogenic activities,
or it may have direct antiproliferative effects on melanoma.27 Without understanding its
mechanism of action, surrogate markers of response/remission cannot be used to guide
dose selection and duration of therapy.
The absence o f effective medical treatment for melanoma leads many patients
with advanced disease to enroll in clinical trials. Current experimental treatments for
melanoma are based on immunotherapy, through immune-boosting cytokines (e.g., IL-2
or GM-CSF) and/or vaccines against melanoma-specific antigens, or molecularlytargeted therapy with specific inhibitors.

4
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Prognostic Indicators in Melanoma
Prognosis in melanoma is currently determined by a number of factors unique to
the primary lesion, as well as the presence of loco-regional (lymph node and in-transit
metastases) and distant metastatic disease. Over the past 30 years, a number of models
have been developed to predict patient outcome for cutaneous melanoma based on
characteristics unique to the primary lesion. The information gleaned from these studies,
through both univariate and multivariate analyses, has been incorporated into the most
recent Melanoma Staging System of the American Joint Committee on Cancer (AJCC).
The first published reports of variables to predict survival in primary melanoma
78 70

came with publications from A Breslow ’ and WH Clark

70

in the 1970s. The models

they described have changed little and remain the most powerful and reliable predictors
of survival based on characteristics of the primary cutaneous lesion. The figure below
demonstrates how each o f these criteria are measured:

Breslow
Thickness

Clark’s
Level
Granular cell layer

77

Boundary

I

Intra-epidermal

Epidermis

II

Breaching of the epidermal-dermal
basement membrane and involves
the papillary dermis

Papillary dermis

III

Tumor fills the papillary dermis
forming a cohesive nodule or plaques

'Reticular dermis

IV

Invasion into reticular dermis

Subcutaneous fat

V

Invasions into subcutaneous fat

Figure 1 (adapted from Chin et al. ). Cross-section o f skin demonstrating the methods for
measurement o f Breslow depth and Clark level.

Wallace Clark first described the phenomenon of the ‘early radial’ and Tate
vertical’ growth phases in primary cutaneous melanoma. He also demonstrated that the
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radial growth phase is only rarely associated with the development of metastases, while
the vertical growth phase is more commonly associated with subsequent metastatic
disease. From these observations, he developed a classification system for staging
primary cutaneous melanomas, in which the depth of tumor invasion is measured relative
to the anatomical layers of the skin. Alexander Breslow’s classification suggests that
incidence of metastasis in primary cutaneous melanoma is proportional to maximal tumor
thickness; it is based on the direct measurement (depth in millimeters) of invasion from
the lowest level of the epidermis to the deepest level of invasion.
Clark’s measurement is an indirect measure of tumor thickness and is not as
accurate as Breslow’s in predicting metastases because of the marked variation in
thickness within each level30, which can also vary depending on anatomical location.
The marked variability in skin layers and the difficulty in discriminating those layers
from each other leads to a great deal of interobserver variability amongst pathologists.
For these reasons, the Breslow depth remains a stronger and more reliable predictor of
metastatic potential.
The current AJCC Staging Sytem for local disease is based on the following
criteria: tumor thickness (Breslow thickness), ulceration, and— in the case of very thin
lesions— level of invasion (Clark level).19 However, there are a number of other factors
that have shown significant prognostic value in melanoma. 31 Among the clinical
TO

prognostic factors are: age '

'X f*

7 ^ 77

(older age is unfavorable); gender '
i f

improved survival over men); and anatomical location

i o

’

(females have

nn

(head, neck and axial

melanomas fare worse than melanoma on the extremities).
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In addition to Breslow measurement and Clark level, a number of other
histopathological characteristics in melanoma have been observed to correlate with
disease outcome. Other strong histological predictors of outcome include: lesion
ulceration35’41"46, mitotic rate47, and microscopic satellitosis (discrete nests of tumor cells
separated from the main body of the tumor by normal subcutaneous tissue). Less
powerful histopathological factors include: histologic subtype (i.e., superficial spreading,
nodular, lentigo maligna, acral lentiginous, desmoplastic; acral and nodular melanomas
may be more aggressive than other types4), angiogenesis48, vascular invasion, regression,
and tumor infiltrating lymphocytes. Of all clinical and pathological criteria, the majority
of studies demonstrate that tumor thickness (Breslow) is the most reliable independent
prognostic factor in cutaneous melanoma.28,35,39,40,42,43,49"54
Current methods of prognosis in cutaneous melanoma are far from precise, and,
aside from minor adjustments, have not changed much over the past 30 years. It should
be noted that the mortality rate from melanoma is decreasing but this has been associated
with earlier clinical recognition (on the part of patients and their physicians) and
expedited surgical treatment. It is important to note that the histopathologic
characteristics of the primary tumor may not necessarily be indicative of tumor
aggressiveness. There are a surprisingly large number of cases of melanoma in which
tumor thickness does not predict outcome; cases in which thin melanoma turns out to be
aggressive36,38,44,54-76 or thick melanoma indolent77-80.
Regarding loco-regional or metastatic disease, the “up”-staging of melanoma has
become dependent upon sentinel lymph node (SLN) biopsy. It is imperative to determine
if a patient has metastatic disease—regional or distant— at the time of initial diagnosis for

7
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proper staging. Originally developed to aid in the prognosis and treatment of penile
carcinoma, it has become common practice in the diagnostic evaluation of a number of
*
cancers, particularly melanoma. 81 The procedure for SLN biopsy
involves the injection
of a colored dye, as well as a radiotracer, to determine the lymphatic drainage of a
primary tumor and identify the first lymph nodes in a regional group. The SLN serves as
a guide to the status of the rest of the nodes in the respective lymph node basin. If the
SLN is negative for disease, it can be assumed that rest of the regional nodes are also
negative. If this is the result, the patient will be spared an “unnecessary”, invasive and
debilitating procedure.
Techniques in surgery and nuclear medicine have advanced so rapidly that SLN
biopsy is now a well-established standard procedure in many countries.82 It is a relatively
accurate mechanism for predicting the pathologic status of regional lymph nodes, and, in
turn, aiding in the prediction of patient outcome.

O'}

Shown to be the most important

prognostic factor in determining survival in melanoma , it has become an essential
component of the AJCC TNM classification of melanoma.19
The decision to perform a sentinel lymph node biopsy (in the absence of clinically
apparent LN disease) is typically based upon the Breslow depth of the primary lesion.
The criteria necessary to go forth with this procedure varies from surgeon to surgeon. It
is often based on the surgeon’s discretion. Generally, the threshold for performing a
sentinel lymph node biopsy in the absence of clinical lymph node involvement is a
.

oc

primary lesion around 1 mm thick , and the procedure is quickly becoming the standard
of care for patients with primary melanoma greater than 1 mm in thickness.86 The true

8
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benefit of this procedure lies in its ability to aid in the accurate staging of patients for
prognostic purposes.
The degree of sentinel lymph node disease, in which the lymph node disease
ranges from only detectable at the molecular level (i.e., through RT-PCR analysis for
melanoma-specific markers) to grossly apparent (i.e., large pigmented deposits in lymph
nodes), and its relevance to prognosis is under investigation by a number of groups.
Because of the precision afforded by SLNB, the AJCC revised its staging system for
melanoma.19 Nodal involvement is distinguished first on the basis of the number of
nodes with disease, and then on micro- versus macro-scopic involvement. It should be
noted that IHC increases detection rate in SLN by at least 10% over H&E alone.87 The
staging system is demonstrated by the tables below:

9
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Table 1. Melanoma TNM Classification (adapted from Balch et al.)19
T classification
T1

Thickness
<1.0 mm

T2

1.01-2.0 mm

T3

2.01-4.0 mm

T4

>4.0 mm

N classification
N1

No. of Nodes
1 node

N2

2-3 nodes

N3

> 4 nodes

M classification
M ia

Site
Distant skin, subcutaneous, or nodal
mets
Lung metastases
All other visceral metastases
Any distant metastases

M lb
M lc

Ulceration Status
a: without ulceration
b: with ulceration or Clark level > III
a: without ulceration
b: with ulceration
a: without ulceration
b: with ulceration
a: without ulceration
b: with ulceration
Nodal Metastatic Mass
a: only detected by pathology
b: clinically detectable
a: only detected by pathology
b: clinically detectable
c: in transit mets without nodal disease

Serum LDH

Normal
Normal
Normal
Elevated

Table 2. Stage Grouping for Cutaneous Melanoma (adapted from Balch et al)19
Stage

T

N

M

0
IA
IB

Tis
T la
Tib
T2a
T2b
T3a
T3b
T4a
T4b
Any T
Any T

NO
NO
NO

M0
M0
M0

NO
NO
NO
NO
NO
N1 or N2 or N3
Any N

M0
M0
M0
M0
M0
M0
Any M l

IIA
IIB
IIC
III
IV

10
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The following graph demonstrates Kaplan-Meier survival curves for 17,600
melanoma patients, grouped by the new staging system. The AJCC staging system for
melanoma appears to be quite reliable for predicting survival based on primary tumor
characteristics and nodal/metastatic status.19

3.0
0.9

-

0,7

*

m0.4

•

0,3

•

8,2

•

8 .1

-

0.0
SURVIVAL (y ears)

Figure 2 (adapted from Balch et al.19). Fifteen-year survival curves comparing localized
melanoma (stages II and I), regional metastases (stage III), and distant metastases (stage IV). The
numbers in parentheses are patients from the AJCC melanoma staging database used to calculate
the survival rates. The differences between the curves are significant (P < .0001).

To date, there have not been any widely accepted immunohistochemical— or
other molecular—markers to predict patient outcome or guide therapy in melanoma.
There is a need for a more precise diagnosis of melanoma through molecular staging,
similar to the use o f HER2 in breast cancer. One of the major impediments to the
development of useful molecular assays for melanoma is the absence of any molecularlytargeted therapy for the disease. In fact, there are no effective biological,
chemotherapeutic, or biochemotherapeutic treatments for melanoma. There have been

11
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some attempts to develop molecularly targeted therapies for melanoma but success, at
even the level of cell culture, is rare; translation to the clinical setting is rarer still.
There have been a number of studies that have evaluated markers on an individual
basis and on a relatively small number of patients.88,89 In addition, none of these studies
have made use of automated quantitative analysis. Differences in expression levels in the
tissues have been based on those that are perceptible only by the human eye. Those
molecular markers that have not shown statistical significance may not have been
evaluated on a large enough patient cohort.
The advent of high-throughput genomic technologies has made it possible to
survey the expression of a large number of genes simultaneously in cancer tissue.
Additionally, the availability of quantitative analysis introduces the ability to more
accurately discriminate expression levels within tumors and relate those to recurrence,
survival, and response to therapy.
While a number of clinical and pathologic factors have been established as
markers of prognosis, no marker, molecular or morphologic, can exceed the predictive
strength of assessment of metastasis to lymph nodes. The presence of metastasis to
lymph node metastases reduces 5-year overall survival rates by between 10 and 30%, for
any given stage of the disease.90
The use of sentinel lymph node biopsy has significantly improved the staging of
melanoma, but this procedure is both morbid and imperfect. In a recent series by our
collaborator, Dr. Stephan Ariyan, only 11% of 263 patients showed metastasis in the
sentinel node. Although this rate is somewhat lower than other larger series91, highest
numbers from other studies are near 25% and related to the depth of the primary tumor.

12
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Overall, between 75% and 90% of the procedures are done unnecessarily. Furthermore,
of the 10% of the patients in the Yale study that developed local recurrence or distant
metastasis, only about half were predicted by positive sentinel nodes. In other studies as
many as 25% of negative nodes will ultimately develop recurrent disease.

92

Thus, there

is a critical need to predict which patients will have nodal disease, or more importantly,
which patients have a disease subclass that will progress compared to those that will not.
This clinical problem is compounded by the fact that the amount of tissue
available for making this determination is often very small. It has, historically, been
difficult to look at low stage melanomas since the material is nearly completely
exhausted at diagnosis. A number of new developments that have been advanced in the
last few years can now be combined to address this issue.

Molecular Classification of Melanoma
While the morphological biology of melanoma progression is well described, the
genetic changes that take place as lesions invade deeper and ultimately become metastatic
are not well understood. Work is under way in a number of laboratories to describe these
changes and use them for their prognostic potential (to help predict aggressive potential)
and ultimately develop therapies that target these changes. No single marker has
distinguished itself in a manner that it has been broadly accepted, but many markers have
shown promise in small, single institution studies or in basic cell biological studies.
These efforts provide a good starting place for our goal of predicting metastatic potential.
We aim to take advantage of these efforts to select markers whose expression is likely to
be correlated with metastasis, based on the historic, basic and translational work related
to each marker. Data from cDNA array studies suggest numerous markers will be

13
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required for disease classification or prediction of metastasis. We believe this will also
be true of protein markers, although we believe substantially fewer markers are required.
A number of studies have been performed identifying gene expression profiles
unique to melanoma relative to normal melanocytes or nevi. In addition, a number of
relatively small-scale immunohistochemical and in situ mRNA-DNA hybridization
studies have been published over the past few years. Additionally, it has been
demonstrated that previously unrecognized gradations of melanoma can be distinguished
by gene expression profiling.

15

We seek to discover a set of molecular markers that can be used as an
independent predictor of survival, to be used on a regular basis to aid in patient
prognosis. Assessing a small battery of markers at the time of initial diagnosis will aid
clinicians in the prognosis of their patient’s disease, and may, in some cases, provide
therapeutic guidance. Though the current aim of this project is to define aggressive
melanoma from ‘benign—less aggressive’ melanoma, a number of molecular targets will
be defined that may have therapeutic potential.

14
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Table 3. Previous IHC Studies demonstrating markers with prognostic potential:
Author/Date

Markers

Patient/Sample Number

Correlation with Survival

Eliopoulos, P. M R 2002”

• HER-2

51 lesions > 10 mm / 1 lesions < 1 mm

• HER -2 overexpressed in 29.4% o f thick lesions;
none in thin.
• N o prognostic significance in this study.

Ferrier, CM. B J C 200094

• tPA
• uPA
• PAI-1

214 primary m elanomas (only local disease at
tim e o f acquisition)

• High tPA expression correlates with good
outcome.

Florenes, V A J P a th 200395

• Cyclin A
• Ki-67

172 primary (110 sup + 62 nod) / 73 mets / 10
nevi

• Cyclin A independent predictor o f survival
(p = 0.0003) in SSM .
• Cyclin A & K i67 correlate with depth in SSM.

Florenes, VA. C C R 2000”

• Cyclin D1
• Cyclin D3

172 primary (110 sup + 62 nod) / 73 mets / 1 0
nevi

• Cyclin D I expression correlates with SSM
relapse (p <0.001) and early death (p =0.009)

Florenes, VA. A J P 1998'"

• p27

113 primary / 45 metastases (36 distant) / 4 nevi

• Inverse correlation with DFS (stronger in nodular
than SSM ).

G radilone” A. JC O 2003

•
•
•
•

36 S L N ’s evaluated by RT-PCR (and IHC in
som e cases)

• Survivin expression correlates with survival, but
not bcl-2, bax, or bcl-X.

Flieken, TJ. C ancer 1999”

• p53
• p i integrin
• 33 integrin

111 interm ediate-thickness primary melanomas

• p53: no association with survival.
• p i integrin: correlates with survival (p =0.0004)
• p3 integrin: correlates with survival (p =0.0001)

Kageshita, T. B JD 2001 ™

• P-catenin

91 primary / 50 mets / 50 nevi

• Loss o f P-cat expression associated with disease
progression. T hickness inversely correlates with
B-cat.

Karjalainen, JM. A J P 2 0 0 0 191

• CD44
• Hyaluronan

292 stage I melanomas

• Reduced cell surface C D 44 and H A levels
associate with poor prognosis.

Kunz, M. A D V 2 0 0 2 192

• Thom bospondin2
• Desm oglein 2

Tbsp2: 5 primary and 5 mets
Dsmg2: 20 primary and 20 mets

• Neither antibody stained w ell in primaries, but
all mets sh ow ed expression o f Thrombospondin 2
and D esm oglein 2.

Massi, D. H um Path 1999™

• Osteonectin

188 thin primaries

• Osteonectin overexpression correlates with
progression and betastasis.

Miranda, E. J S O 2003"“

• PAI-2
• uPAR

Survivin
bcl-2
bax
bcl-X

• A po D

32 invasive / 8 in situ / 1 0 benign lesions

• A po D expression higher in nodular (p = 0 .0 1 1).
• Signifcant corr w ith Clark (p =0.046)

Morgan, MB. A JD P 1999"°

• p27 (k ip l)

21 m elanomas / 21 Spitz nevi / 21 compound
nevi

• N o difference in staining betw een groups.
• N o t useful in distinguishing betw een lesions.

Niezabitow ski, A. JS O 1999106

•
•
•
•

93 patients

• K i-67, PCN A, & HM B45 overexpression
correlate with decreased survival.

Ostmeier, H. C ancer 1999lu/

• VL A-2
• HLAABC
• HLADR
• NK Ibeteb
• M el 14

•
•
•
•

> 500 primary melanomas

• N on e o f these markers improved the prognostic
m odel that included Breslow, localization, or
mitoses.

Ostmeier, H. B JD 2 0 0 I 1"*

• Ki-67
• HLADQ
• HLADP
• M uc 18

• A - 10-33
• Transferrin
receptor
• H -2-8-10

B iop sies from 688 patients

• K i-67 (n =399) and H LA -DQ (n=452) retain
prognostic significance in multivariate analyses.

P o lsk y D J N C 1 2002™

• H DM 2
• p53
• Ki-67

134 patients

• H D M 2 overexpression correlates with survival.

Salti, GI. CR 2 0 0 0 1"1

• MiTF

63 intermediate thickness (l-4 m m ) melanomas

• Increased M iTF expression correlates with
im proved survival.

Sparrow, LE. A J D P 1998*11

• MIB-1

• Strong correlation with Clark (r=0.71)and
B reslow (r=0.77)

Straume, O. A J P 2 0 0 2 112

•
•
•
•

11 thin that later m etastasized / 11 thin control
tumors (nonprogressors)
25 benign and 70 malignant melanomas
202 VG P m elanoma cases / 68 mets from 58
p t’s

Straume, O. C C R 2000*

• pi 6
• K i-67
• p53

Straume, O. A /P 2001 * 1U

• VEGF
• Flt-1, kdr
• Tsp-1
• p l6
• p53

Straume, O. / J C \ 9 9 1 Ui

Vaisanen, A. J P ath 1998“ *

• S100
• HM B45
(gplOO)
• Vimentin

Ki-67
PCNA
p53
Vimentin

VEGF-C
FLT-4
bFGF
FGFR-I

• MM P-2

ICAM-1
K -l-2
G -7-E2
H -2-4-7

• IL-8
• EphrinA1
• EphA2

• Ephrin-Al con-elated directly with Breslow
(p = 0.017), Clark (p =0.004), & ulceration
(p = 0.006)

Sam e as above

• loss o f nuclear p l6 = increased K i-67 and poor
prognosis
• absence o f p53 correlates with improved survival

102 nodular melanomas

• L oss o f p l6 expression con-elates with reduced
survival & recurrent disease (p =0.013)
• p53 was not prognostically important.

50 primary skin m elanomas

• High M M P-2 expression indicates an
unfavorable prognosis.

Although some of the studies listed above have demonstrated that the levels of
melanoma-associated proteins can serve as markers to predict disease outcome, there are
15
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a multitude of genes and gene products with prognostic potential in patients with
localized melanoma. The expression of thousands of genes in melanoma tumors and cell
lines can be surveyed using cDNA microarrays. It has been proposed for various cancers
that a discrete and previously unrecognizable cancer taxonomy can be identified by
assessing the systemized data acquired from gene expression experiments.15 Most gene
expression studies reported thus far have been based on cell lines, which may not be
entirely representative o f in vivo tumor biology. The data acquired must be validated on
in vivo models and patient samples.

Differential expression of genes discovered by cDNA microarrav analysis
Melanoma is an unpredictable cancer. It is not clear what genetic changes take
place in melanoma progression. Through comparative gene expression studies, a number
of investigators are intensively trying to understand the molecular pathogenesis of
melanoma. As this cancer remains refractory to virtually every pharmacologic treatment,
and has an incredible potential for aggressive growth, it is not surprising that many
melanoma patients submit themselves to toxic and experimental therapies.116 The
products from cDNA microarray analyses not only provide validation of previously
identified biomarkers, but also offer new genes that might be useful in molecular
diagnosis, pathogenesis studies, and possible molecular targets for therapeutic
interventions.
In collaboration with Dr. Ruth Halaban, we have participated in a study which
sought to profile genome-wide changes in melanoma.

117

Using cDNA microarrays,

global expression changes were assessed in melanomas compared to normal melanocytes
(harvested from newborn foreskins). Affymetrix and spotted oligonucleotide microarrays
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were used to assess global differential gene expression comparing normal human
melanocytes with six independent melanoma cell strains from advanced lesions. The
data, validated at the protein level for selected genes, confirmed the overexpression in
melanoma cells relative to normal melanocytes of several genes in the growth
factor/receptor family that confer growth advantage and metastasis. In addition, novel
pathways and patterns of associated expression in melanoma cells not reported before
emerged, including the following: (a) activation of the NOTCH pathway; (b) increased
Twist expression and altered expression of additional transcriptional regulators
implicated in embryonic development and epidermal/mesenchymal transition; (c)
coordinated activation of cancer/testis antigens; (d) coordinated down-regulation of
several immune modulation genes, in particular in the IFN pathways; (e) down-regulation
of several genes implicated in membrane trafficking events; and (j) down-regulation of
growth suppressors, such as the Prader-Willi gene NECDIN, whose function was
confirmed by overexpression of ectopic Flag-necdin. Validation of differential expression
using melanoma tissue microarrays showed that reduced ubiquitin carboxy-terminal
esterase LI in primary melanoma is associated with worse outcome and that increased
expression of the basic helix-loop-helix protein Twist is associated with worse outcome.
Some differentially expressed genes reside on chromosomal regions displaying common
loss or gain in melanomas or are known to be regulated by CpG promoter methylation.
These results provide a comprehensive view of changes in advanced melanoma relative
to normal melanocytes and reveal new targets that can be used in assessing prognosis,
staging, and therapy of melanoma patients.

17
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In summary, the data demonstrate that changes take place in previously
recognized melanoma-activated pathways (e.g., upregulation of transcriptional proteins,
activation of cancer/testis antigens, downreguation of immunomodulatory gene
expression and growth suppressor expression), as well as some novel associations (e.g.,
upregulation of the NOTCH pathway). The figure below demonstrates unsupervised
hierarchical clustering of gene expression profiles in these melanoma cell lines and
normal melanocytes.

Figure 3 (adapted from Hoek et al.117). Hierarchical Clustering. Cluster map and
phylogenetic tree resulting from a hierarchical cluster analysis of normalized intensity
data across two control (melanocytes; NM) and six sample (melanoma, as indicated) data
sets. Genes were selected for clustering according to a fold change and signal intensity
cutoff protocol described in the text. Clustering was performed using GeneSpring 6.0
(Silicon Genetics, Inc.).

Bittner et al.15 examined the expression profiles for 31 melanomas—biopsies and
cell lines—relative to 7 control cell lines. Using a matrix of Pearson correlation
coefficients from complete pair-wise comparison of all experiments, the authors
developed a hierarchical clustering dendrogram as well as a three-dimensional
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multidimensional scaling (MDS) plot. The MDS plot displays the position o f each tumor
sample in relative Euclidean space; the distance between them represents their
approximate degree o f correlation.118 With this plot, the authors were able to distinguish
a gene expression profile unique to 19 of the melanomas. The figures below display the
dendrogram and MDS plot showing the major cluster of 19 samples (within the cylinder)
and the relative expression of the top 22 genes used to discriminate this cluster. Their
analysis is by no means complete, and they state that “the extent to which melanoma
samples can be clinically subdivided by expression patterns remains to be elucidated.”
The information their ‘weighted’ list of genes provides should allow for the dissection of
other clinically relevant subsets for melanoma.

MDS Plot

Dendrogram

J'i

34 :
35 :
■J 1

t:

4 ■

<1 - i ;.
-t.fi

.i

Figure 4 (adapted from Bittner et al.15). [Left] Hierarchical clustering dendrogram demonstrating
a unique cluster o f 19 melanomas at the centre. [Right] MDS three-dimensional plot of all 31
cutaneous melanoma samples showing major cluster of 19 samples (blue, within cylinder).
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Top 22 Genes
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Figure 5 (adapted from Bittner et al.15). After MDS analysis, ranking genes according to their
impact on minimizing cluster volume and maximizing centre-to-centre inter-cluster distance, this
clustergram demonstrates the top 22 genes obtained by these criteria listed in order of decreasing
weight.

Based on the results of the above study, Weeraratna et al. investigated the role of
WNT5A in melanoma further. In transfected cell lines, they demonstrated that WNT5A
expression correlates with increased cell motility and invasiveness. They were also able
to show that WNT5A expression in human melanoma biopsies correlates directly with
increasing tumor grade, and inversely with patient survival.119
Valery et al.120 identified the target genes of ultraviolet (UV) stress response by
culturing normal human melanocytes in the presence of UV irradiation. Out of the -9000
genes on their cDNA microarray, they noted that 198 were found to be modulated >1.9
times over the non-irradiated cells. The majority of the genes they identified are involved
in DNA or RNA binding/synthesis/modification or ribosomal proteins. Others included
transcription factors, receptors, tumor suppressors and oncogenes. Although they did not
perform any cluster analyses, they did compare their results with those of the Bittner15
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study (Table 4). Although the identified genes are not necessarily melanoma-specific,
they are potential markers of disease, capable of being used in the development of new
molecular-based strategies for risk prediction in melanoma patients.

Table 4. Comparison of genes between Valery et al. and Bittner et al. studies.
IValery

Clones

e t a l.

| Bittner

e t a l.

C oncordant Up-Regulation
Actin-related protein 2/3 com plex, subunit IB (41 kDa)

4-

4-

|

Actin, gam m a 1

4-

4-

|

Adenine phosphoribosyltransferase

4-

+

|

Adenylate cyclase 9

4-

4-

J

A quaporin 4

f

+

J

ATP synthase, H+ transporting, m itochondrial FO com plex, subunit c (9) isoform 3

4-

4-

j

ATP synthase, H+ transporting, m itochondrial FI com plex, a-subunit, isoform 1, cardiac m uscle

4-

4-

|

Receptor (calcitonin) activity m odifying protein 1

4-

+

Guanylate kinase 1

4-

+

1
J

Human clone 23815 m RNA sequence
M annosidase, alpha, class 2B, m em ber 1

4-

+

|

4-

4-

|

NADH dehydrogenase (ubiquinone) 1 beta subcom plex, 7 (18 kDa, B18)

4-

4-

]

Phosphofructokinase, liver

4-

+

|

Protein tyrosine phosphatase, receptor type, c polypeptide-associated protein

4-

4-

|

Ribose 5-phosphate isom erase A (ribose 5-phosphate epimerase)

4-

4-

|

Ribosom al protein LI 0

4-

4-

|

Ribosom al protein LI 9

4-

4-

|

Ribosom al protein S 14

4-

4-

j

Syndecan 4 (am phiglycan, ryudocan)

4-

4-

Concordant Down-Regulation
Apoptosis inhibitor hiap-1

-

-

DEAD/H (A sp-G lu-A la-A sp/H is) box polypeptide 15
DEAD/H (A sp-G lu-A la-A sp/H is) box polypeptide 5 (RNA helicase 68 kDa)

-

-

-

-

E74-like factor 1 (ets dom ain transcription factor)

-

-

Fibronectin 1

-

-

Hypoxia-inducible factor 1, alpha subunit (basic h elix ~ Io o p —helix transcription factor)

-

-

Interferon regulatory factor 2

-

-

M itogen-activated protein kinase kinase kinase 7

-

-

M ultimerin

-

-

Protein tyrosine phosphatase, nonreceptor type 12

-

-

Ribosomal protein S6 kinase, 90 kDa, polypeptide 3

-

-

Solute carrier fam ily 12 (sodium /chloride transporters), m em ber 3

-

-

SON DNA binding protein

-

Translin-associated factor X

-

Zinc finger protein 184 (Kruppel-like)

-

Zinc finger protein 38 (KOX 25)

-

Discordance
arsA (bacterial) arsenite transporter, A TP-binding, hom olog 1

4-

-

C3H-type zinc finger protein; sim ilar to D, m elanogaster m uscleblind B protein

-

+

Chromodom ain helicase D NA binding protein 1

-

+

|

Coatomer protein com plex, subunit beta

-

4-

|

Hypothetical protein PI p373c6

-

4-

|

Interferon, gam m a-inducible protein 16

|

+

Kinesin fam ily m em ber 5B

4-

Laminin receptor 1 (67 kD a, ribosom al protein SA)

4-

Leucine-rich repeat (in FLII) interacting protein 1

+

Maior histocom patibility com plex, class I, C

4-
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1

Clones

Valery et al. [Bittner et al. |

M yosin, light polypeptide 1, alkali; skeletal, fast

+

M yosin, light polypeptide 6, alkali, sm ooth muscle and nonm uscle

+

Pre-B-cell colony-enhancing factor

+

+

Proteasom e (prosom e, macropain) subunit, beta type, 6
RAN binding protein 2 like 1

-

R as-G TPase-activating protein SH3-domain-binding protein

+ and +

|

|
]

Ribosom al protein L28

f

Ribosom al protein S23

f

Serum /glucocorticoid regulated kinase
Solute carrier fam ily 24 (sodium /potassium /calcium exchanger), m em ber 1

-

+

|

-

-l-

|

+

|

Suppression o f tum origenicity 16 (m elanom a differentiation, ST16)
Transducin-like enhancer o f split 4, hom olog o f D rosophila E (sp l)

+

UDP-glucose ceram ide glucosyltransferase

-

v-yes-1 Yam aguchi sarcom a viral related oncogene hom olog
Zinc finger protein 7 (KOX 4, clone HF.16)

-

+

J

+•
+-

|
|

+ = overexpressed; - = underexpressed

I

Seykora et al.121 demonstrated differences in gene expression between nevi and
melanomas. Nevi mRNA was pooled from four benign melanocytic lesions, while
melanoma mRNA was collected from two nodular primaries and two metastatic lesions.
It is not clear how pooling samples from different locations (and possibly different
patients) may have affected the results of their experiments, but they do provide a chart
demonstrating genes that can be used to classify nevi and melanoma.
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Table 5. Differentially expressed genes in Seykora et al. study.
Expressed
similarly in
melanoma
and nevi
Expressed
preferentially
in melanoma

Expressed
preferentially
in nevi

GADPH
HLA Class I
Matrix metalloproteinase 14 precursor
Fibroblast growth factor 8
Glia-derive neurite-promoting factor
Cdc2-related protein kinase
Cyclin D 1
PCNA
c-Jun N-terminal protein
c-Myc binding protein MM1
Notch 2
CD59
P4 integrin
Matrix metalloproteinase 17
Nucleoside diphosphate kinase B
Early growth response protein 1
Pleiotrophin
40S ribosomal protein
Growth factor receptor bound protein 2
Glutathione-S-transferase homolog
Fibronectin
a3 integrin

Ratio of Expression in
Melanoma Relative to Nevi
0.9
1.3
0.9
1.0
1.1
3.5
2.7
1.3
3.3
13.5
4.3
10.25
3.7
3.3
3.5
5.2
33
3.5
0.8
0.8
0.6
0.7

Using the DermArray® DNA microarray, Dooley et al.122 investigated novel
markers of human melanocytes in two experiments. The DermArray DNA microarray
contains over 26,000 unique human cDNAs, with a number o f them (important in
dermatology research) spotted in triplicate to aid in statistical analyses. In their first
experiment, they compared normal melanocyte cells to keratinocytes and fibroblasts. In
the second experiment, they compared normal melanocytes to two melanoma cell lines;
one primary (MS7) and one metastatic (SKMel-28).
Clark et al.123 devised a clever study to identify novel genes specific for
melanoma metastases. Starting with weakly metastatic parental cell lines (mouse and
human melanomas), they performed an in vivo serial selection scheme in mice to derive a
robust metastatic cell line. The gene expression profiles of subsequent metastatic
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pulmonary tumors were compared to the primary tumors. The table below demonstrates
the thirty-two out of approximately 7000 genes with enhanced expression levels (>2.5
fold) in the metastatic tumors.
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Table 6. (adopted from Clark et. al123). Enhanced gene expression in metastatic
melanomas
Gene Name
Fibronectin
RhoC
Thymosin (34
t-PA
Angiopoietin 1
IEX-1/Glu96
RTP/NDR1
Fibromodulin
Hsp70
IL13 Receptor
Sec61J3
snRNP, polypep C
Collagen Ia2
UBE21
TGF|3 superfamily
Surfactant protein C
Lysozyme M
KIAA0156
Matrix Gla protein
Tsa-1
Collagen Illal
Biglycan
a-catenin
Valosin-cont. protein
ERK-1
a-actinin 1
calmodulin
EIF4y
a-centractin
IQGAP1
cathepsin S
EF2

Pulm.
Met #1
10.1
4.7
3.3
5.2
4.3
9.1
8.6
8.3
7.8
7.6
3.8
3.8
2.5
3.6
3.4

Fluman A3 7 5
Pulm.
Pulm.
Met #2
Met #3
3.2
4.0
3.1
4.0
3.5
3.6
5.2
9.6
9.4
3.3
3.3
4.5
5.4
4.7
4.7
8.2
4.2
5.0
2.9
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5.6
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5.4
7.2
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7.3
5.5
2.6
3.6
3.2
3.1
2.9

The most interesting genes expressed in the highly invasive tumors included
genes involved in cytoskeletal organization and cell migration (an observation also
observed in Bittner et al.). Three of the genes identified by Clark et al. — those encoding
fibronectin, thymosin 04 and RhoC — showed increased expression in all of the human
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and mouse melanoma-derived metastases. Anne Ridley suggests in a News and Views
article that these genes operate in a coordinated fashion to attain metastatic status.124
Cell m ovem ent

Contractile
actom yosin: RhoC?

Adhesion-site
turnover: RhoC?

Matrix deposition:
Fibronectin

Figure 6.124 Molecular model for melanoma invasion and metastasis. Cell migration involves
protrusion o f the plasma membrane (lamellipodium extension) at the leading edge o f the cell; the
formation o f new sites of adhesion to the extracellular matrix at the front; the release of old
adhesion sites at the back; and contraction of actomyosin-based cytoskeletal filaments in the cell
body to move the bulk of the cell forward. Rho proteins regulate actomyosin-based contractility
and adhesion turnover, implicating it in these steps of cell migration. Thymosin beta4 buffers
monomeric actin in cells, and could act to provide actin monomers for rapid polymerization into
actomyosin filaments in lamellipodia. Fibronectin is an extracellular matrix protein, and
deposition o f fibronectin by the cell could promote migration by signalling through specific
receptors on the cell surface.

A recent study published in Cell by McGill et al.125 used cDNA microarrays to
identify the transcriptional targets of the micropthamia gene, Mitf, a transcription factor
essential for melanocyte development. M itf also appears to be a highly sensitive and
specific histopathological melanocyte marker for melanoma.126,127 In their article,
McGill et al. demonstrate that Bcl-2, an antiapoptotic factor, is one of the major targets of
Mitf, and is critical for melanocyte and melanoma survival. A number of histopathologic
studies have evaluated the relevance of Bcl-2 expression in melanomas, and although its
association with aggressive potential is unclear128'143, it has been targeted in clinical trials
using Bcl-2 antisense oligonucleotides144.
Another recent study be de Wit et al.145 used the Affymetrix Hu6800 and Hu35K
array set to identify genes associated with metastasis by comparing the mRNA expression
of two human melanoma cell lines with different metastatic behavior; 1F6 is poorly
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metastatic, leading to metastases in only 4% of mice, while Mel57 leads to metastases in
all injected mice. Among known genes (-5000 on the Hu6800), 29 were up-regulated
and 62 were down-regulated, using a 3.5-fold cutoff. Of the 35,000 EST sequences on
the other array, 94 were up-regulated and 133 were down-regulated. Based on the results
of this study, it appears that a relatively small number of genes are responsible for the
differences between these two cell lines. They were able to validate most of their results
in the cell lines, by Northern blot or RT-PCR analysis, but could not always show the
same correlations in human tissue. Regarding in vivo melanocytic tumor progression
they were able to validate the array results for five selected genes: APOCII, TGFp, and
PACE4 show up-regulation, whereas hCDCIO and DYRK1A are down-regulated. The

graph below displays the up- and down-regulated genes categorized by cellular function.
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Figure 7.145 Categorization of differentially expressed genes. Genes showing differential
expression in 1F6 and Mel57, identified with the Affymetrix Hu6800 array, were subdivided into
categories representing particular cellular processes or specific function of proteins. A positive
average fold change correlates with upregulation in Mel57, and a negative average fold change
with downregulation.
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Brem et al.146 performed an experiment very similar to that described above.
They compared the expression profile of metastatic (NMCL-1) versus non-metastatic
(530) melanoma cells. They used the Affymetrix HuGene FL array, containing 6800
genes. They found that genes involved in a multitude of processes (e.g., transcriptional
control, cell cycle regulation, proteolysis, cell adhesion, immune response, and signaling)
were differentially expressed. They especially note that genes involved in MHCinteractions and cell adhesion were down regulated.
Somewhat unrelated to the scope of this project, as it focuses on treatment
response prediction, Wang et al.147 utilized gene expression profiling in melanoma to
search for molecular predictors of treatment outcome. The authors compared the gene
expression profiles of subcutaneous melanoma metastases before and after various
immunotherapy treatments. They were unable to demonstrate subsets of melanoma
predictive of clinical outcome, based on gene expression profiles. It seems that the extent
of immune responsiveness may be predetermined and not dependent on the level of
immune response elicited by a particular therapy. They did show that melanoma
metastases express a heterogeneous array of cytokines, growth factors, and
metalloproteinases; a number of which have chemotactic properties (e.g., BLC, eotaxin,
IL-1, IL-8, IL-16, lymphotactin, MCP-1, MCP-3, MCP-4, RANTES) or inflammatory
action (e.g., IL-6, M IP-la, MIP-ip, MIP-2a, TNF-y).
Time and testing will reveal the accuracy and clinical relevance of these various
genes in melanoma progression. These experiments are yielding new insights into the
molecular genetics of this truly unpredictable disease. The results will be important for a
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complete understanding of melanoma, and equally important for the development of new
treatments.116
It is unfortunate that most cDNA microarray studies have been performed on cell
lines instead of fresh human melanocytic tumor lesions. However, it is difficult to run
cDNA array analyses on these tissues because the amount of mRNA required for these
studies would be inadequate in most cases. In addition, even with the specificity of laser
capture microdissection, it is difficult to distinguish expression in the stroma versus
tumor tissue. This is a major problem with all forms molecular biological analysis that
require homogenization of tissue.
The findings from these studies provide ‘potential’ biomarkers. They must be
validated by another method (i.e., quantitative RT-PCR or Northern blots at the RNA
level, and immunodetection by ELISA or Western blots). In addition, further evaluation
must be performed to determine their clinical significance on human tissues. This is the
place for TMAs, allowing one to screen hundreds of markers on hundreds of tissues.
Although DNA microarray technology is becoming omnipresent in research
laboratories, the results require rigorous evaluation by competent biologists, with
expertise in molecular biology, cell biology, biochemistry, genetics, and bioinformatics.
In this ‘post-genomic’ era, it is important to avoid over-interpretation of the significance
of data obtained through DNA microarray experiments. However, these tools still remain
a valuable tool for identifying the genes altered in the metastatic progression of tumor
cells.
Selection of markers from cDNA microarray expression profiles incorporated the
known biological significance of genes and their products, as well as cross-validation of
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multiple studies. Comparison of “Melanoma vs. Normal Nevus” and “Benign Melanoma
vs. Aggressive Melanoma ”, as well as a marker type stratification system was developed.
DNA microarray studies, such at those detailed above and our own work led by Dr.
Halaban117, have identified numerous very promising markers which are just beginning to
be validated. From these lists, as well as recommendations from experts in the melanoma
field148 and functional studies on individual genes and gene products, a series of
approximately 50 markers were selected based on the availability of good antibodies and
their performance in validation studies.
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Tissue Microarray Technology

Tissue microarray (TMA) technology was first described by Kononen and
Kallioniemi in 1997.149 Consisting of an ordered array of tissue cores—up to 2,000—on
a single glass slide, tissue microarrays provide a mechanism for the maximal use of
scarce tissue resources.149 Most tissue microarrays are currently constructed from
pathology tissue block archives, and the coordinate clinical data can be correlated with
experiments performed on these tissues. TMAs allow for the validation of new concepts
in cell and molecular biology on human tissue.150’151 They are the ultimate step in the
association of gene expression information with human tissues and human disease.
Tissue microarrays supply a mechanism for conservation of tissue, while
providing the ability to evaluate hundreds of archival tissue specimens on one microscope
slide. As illustrated in the figure below, tissue microarrays are constructed from
formalin-fixed, paraffin-embedded tissues. Under the guidance of a pathologist, the
target tissues are core-biopsied with a 0.6 mm diameter needle, and the cores are placed
in a ‘recipient’ paraffin block. The maximum number of specimens one block can hold
varies from 600 to 2000 (with new smaller diameter needles). The block containing the
array is sectioned in an identical fashion to any paraffin tissue block. The maximum
number of sections a block can provide ranges from 100 to 200, depending on the size of
the original tumors and the skill of the histotechnologist.149-151
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Figure 8.152 Tissue microarrray construction. Cores are removed from paraffin-embedded tissue
“donor” blocks, and placed into a “recipient” block. A grid format is created, and the position of
each “donor” specimen is recorded for later analyses. The recipient block is then sliced at a
thickness o f 5um on a digital microtome, and transferred onto a slide. A sample of a stained tissue
microarray is shown in the inset.

In addition to providing a means of preserving human tissues, which are always in
limited supply, the ability to examine many histological specimens on a single slide is of
great value. By exposing all tissues to precisely the same conditions, the slide-to-slide
variability inherent to immunohistochemistry and in situ hybridization is minimized.
Unlike DNA microarrays, where each microscopic spot represents a unique
cloned cDNA or oligonucleotide, the spots on tissue microarrays are larger and contain
histologic tissue sections from unique patients or tumors. This technology reverses the
typical array paradigm. Instead of testing one sample for expression of thousands of
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genes, tissue microarrays allow testing of one gene (or more typically a protein) on
hundreds or thousands of samples (patients).
It is estimated that there are over 30,000 genes within the human genome,
encoding over 100,000 proteins. Researchers are currently beset with the task of filtering
through the vast number of gene and protein targets to identify those with clinical
relevance and diagnostic/prognostic/therapeutic potential. Target validation is a critical
step in sifting through such targets. Traditionally, target validation was done with static
assays such as Northern blot analysis, RT-PCR, macroarray, microarray, and gene chips.
These technologies simply provide evidence of differential expression of specific genes
and only rudimentary clinical information is obtained. For most techniques in molecular
biology, tissue is homogenized to isolate RNA or protein for expression analysis.
Unfortunately, the tissue obtained is not necessarily composed solely o f the cells of
interest. The tissue homogenate can contain normal cells, tumor cells, blood cells,
muscle cells, and other cell types that may result in misleading information. Critical
spatial information is lost in these studies, convoluting the results and making truly wellinformed mechanistic explanations nearly impossible. Tissue microarrays provide an
optimal venue for establishing the clinical importance of various gene products.
A key criticism of tissue microarrays is that the small tissue disk is not
representative of the entire tumor. This is particularly problematic when the tumors are
highly heterogeneous, on both a morphological and a molecular level. To evaluate this
issue, numerous studies have compared IHC findings on TMAs with their corresponding
traditional whole tissue sections153' 172, with the vast majority revealing a high level of
concordance.154' 166,168,169,171 Most of these studies used multiple cores from donor
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blocks in order to determine how many samples are needed to obtain results on TMAs
that are concordant with whole tissue sections. It has been generally found that two to
three samples are needed to achieve a good concordance level. However, this number is
highly dependent on the tumor type and the design of the study. In our effort on breast
cancer, Camp et al. analyzed estrogen and progesterone receptors and HER2 on 2-10
cores per breast cancer donor block. It was found that analysis of two cores was
sufficient to obtain identical results as compared with the corresponding whole tissue
sections in 95% of cases; four cores yield a concordance of 99%.161 It is important to
recognize that these studies are based on the assumption that traditional whole tissue
sections, the current gold standard for molecular tumor tissue analysis, are representative
•
•
o f an entire tumor. 173 A section
from a tumor that measures 3 x 2 cm in diameter,
cut 3

pm thick, has a volume of 0.0018 cm3. This volume is only 1/19,000 of a tumor with a
diameter of 4 cm or 1/150,000 of a tumor with a diameter of 8 cm. A TMA sample
measuring 0.6 mm in diameter represents a tumor volume of 0.00000108 cm3, which is
1/1600 of a 3 cm x 2 cm x 3 pm whole section tissue slice. Based on these numbers, the
representivity problem is about 100-times greater between the entire tumor and a
traditional large section than comparing results obtained on large sections and TMA
sections.173 In addition, it should be noted that the tissues on the TMA are carefully
selected to be representative of tumor on the whole tissue section.

35

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Quantitative Immunohistochemistry

Oxidation and Storage

Tissue microarrays have facilitated the evaluation of large cohort studies with the
use of formalin-fixed, paraffin-embedded tissues that can sometimes be almost a century
old. The current method of archival storage of tissues— formalin fixation followed by
paraffin embedding—is a remarkably resilient method of specimen and antigen
preservation. However, once the samples from such blocks are cut into 5 micron sections
and deparaffmized, the tissue is exposed to ambient air and the potential effects of
oxidation. Several studies have demonstrated the detrimental effects of storing pre-cut
tissue slides under ambient conditions.174' 178 For some proteins (i.e., estrogen receptor),
pre-cut slides stored in room air lose all detectable antigenicity in one month, with a
statistically significant difference from fresh cut seen by 6 days179; demonstrated in
Figure 9. Unfortunately, there is not a universally accepted method for storing slides that
reduces the loss of antigencity. Cold storage of slides at 4°C has shown some promise,
but still results in significant loss of antigenicity.176,177 One method of antigen
preservation that has demonstrated moderate success is paraffin coating of pre-cut
slides.176 Non-formalin-based fixatives have been tested and have some benefits, but
they do not reduce the loss of antigenicity due to oxidation.180' 185 While these fixatives
show great promise in overcoming some of the deleterious effects of formalin-based
fixation, they are not useful for retrospective studies on paraffin-embedded archival
tissues, the vast majority o f which are formalin-fixed.
The advent of tissue microarrays as a tool for the study of immunohistochemical
stains has renewed interest in finding methods for cut-slide preservation. To avoid
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repeatedly facing the paraffin block containing a TMA, serial sections are typically cut at
one time and stored as individual slides. While this procedure increases the quantity of
high quality slides that can be cut from a particular TMA block, it necessitates rigorous
slide storage techniques that will ensure antigen preservation. Our laboratory has
developed a reliable method for the long-term storage of TMA slides that entails paraffincoating of slides followed by (long-term) storage in a nitrogen dessication chamber.

17 0

This method of cut-slide storage maintains tissue antigenicity comparable to fresh-cut
slide for up to 3 months.

Fresh-cut

Day 2

Day 6

Day 30

Figure 9.186 Effects of oxidation on tissue antigenicity. Estrogen receptor immunohistochemistry
is abrogated by storage under ambient air conditions. Matched histospot of breast cancer from
freshly-cut slide, as well as slides stored for 2, 6, and 30 days in ambient air. Slides were stained
for ER and visualized with DAB. Staining is localized to the tumor nuclei when assayed under
high power.

Fixation and Antigen Retrieval

For over 100 years, pathologists have relied upon formalin— a 37% solution of
formaldehyde gas in water—for fixation of tissue specimens. 187 Formalin has several
advantages over alcohol and other precipitative (non-cross-linking) fixatives, in that it
maintains excellent preservation of morphologic detail. Quick and effective fixation of
fresh tissue is necessary to fix antigens in situ, prior to the onset of autolytic changes.
Although the biochemical mechanisms of the fixation process are not entirely understood,
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it is clear that formaldehyde-based fixation involves the formation of cross-links of amino
groups188' 190, among other reactions, recently summarized by Shi et al.191 These
formalin-induced protein cross-linkages can result in partial or complete loss of
immunoreactivity of various antigens, either through intramolecular crosslinks within the
epitope region o f the target antigen, or cross-linking of unrelated proteins to the epitope.
Although formalin fixation will allow some epitopes to emerge unchanged
(formalin-resistant), others will undergo substantial changes (formalin-sensitive).
Despite the loss of immunoreactivity by many antigens as a result of formalin fixation,
formalin-fixed paraffin-embedded (FFPE) tissue remains the medium of choice for
clinical and research studies because of the superior preservation o f morphology.
Various alternatives to formalin have been tested, and it is likely that an ideal
fixative will never be found.192,193 To counteract, or ‘reverse’, the effects of formalin
fixation—to improve the immunoreactivity of FFPE tissues— a number of unmasking
techniques, such as enzymatic digestion and heat-induced antigen retrieval, were
introduced. The first attempts to ‘improve’ IHC involved the use of tryptic digestion
prior to immunofluorescent staining.194 Other proteolytic enzymes (e.g., bromelain,
chymotrypsin, ficin, pepsin, pronase) were tried for restoration of immunoreactivity to
tissue antigens with varying degrees of success.195 Proteolytic digestion compensates for
the impermeable nature of the non-coagulant fixatives by “etching” the tissue and
allowing hidden determinants to be exposed. Use of these enzymes may however also
entail the risk of destroying some epitopes.
Currently, the principle of antigen retrieval is based upon the application of heat
for varying lengths o f time to FFPE tissue sections in an aqueous medium. The
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technique, initially developed by Shi et al. in 1991, is a high-temperature heating method
to recover the antigenicity of tissue sections that has been masked by formalin fixation.196
A number of modalities for heat generation have been tested, including microwave oven,
pressure cooker, steamer and autoclave. The advantages and disadvantages of various
heating modalities and retrieval solutions are the subject of ongoing experiments.191
Alternate terminology used for “antigen retrieval” includes epitope retrieval, heatinduced epitope retrieval, target retrieval and target unmasking. The latter two versions
have more generic appeal and have also been applied to the retrieval of nucleic acid
targets for in situ hybridization. In general, antigen retrieval refers to a technique, used
widely in pathology and other fields of morphology, which improves IHC staining on
archival FFPE tissue sections by reducing detection thresholds of immunostaining
(increases sensitivity) and retrieval of some antigens (e.g., Ki-67, ER-1D5, androgen
receptor, many CD markers) that are otherwise negative in IHC. Antigen retrieval serves
as a pre-treatment amplification step, in contrast to amplification in the phases of
detection (e.g., multistep or polymeric detection systems) or post-detection (i.e.,
enchanced substrated such as DAB using metal, imidazole, CARD, anti-end product,
gold-silver enhancement).197
Although the molecular mechanism of antigen retrieval is not entirely clear at this
time, it is apparently influenced by the pH of the antigen retrieval solution as well as
temperature and time of heating.191 A number of hypotheses have been proposed,
including: loosening or breaking of the formalin-induced cross-links198,199; protein
denaturation200; hydrolysis of Schiff bases201; chelation of cage-like calcium complexes,
which may develop during formalin fixation202 ’203 ; heat-induced reversal of chemical
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modification to protein structure that occurs during formalin fixation199. This topic has
been most recently characterized by the Mason group in a series of papers that look at the
biophysical effects of formalin on RNAse.204,205
The technique of antigen retrieval, a heat-induced remodification of formalininduced modification of protein conformation, may contribute to standardization of IHC
staining of FFPE tissue by equalizing the intensity of IHC staining under variable
conditions of fixation and processing.197 While the molecular mechanisms of antigen
retrieval are the subject of intense investigation, the main concern is that the procedure
works and provides reproducible results. Importantly, antigen retrieval has become
increasingly more useful in research and diagnostic pathology, as it provides increased
sensitivity for the demonstration of molecular markers not previously demonstrable in
standard tissue sections. A number of different antigen retrieval techniques are in
development, and it is essential that scientists and pathologists focus on standardization
of antigen retrieval, which will likely entail optimization for individual antigens.206

Standardization of Immunohistochemistry

The Biological Stain Commission (BSC) was founded in 1944 as a nonprofit
organization to address the problem of standardization of chemical stains in pathology.

207

The BSC was able to achieve considerable success with regard to biological dyes, but the
introduction of immunohistochemistry brought new challenges. The origins of
immunohistochemistry date back to 1941, when Coons et al. established an
immunofluorescence technique for detection of bacteria.

It was many years before it

became a common part of diagnostic pathology. In 1977, the National Cancer Institute
held a workshop to address the standardization of immuno-reagents in diagnostic
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pathology.209 From its inception and until recently, the use of IHC was limited to
qualitative assessments of expression. The major application of the method in pathology
was in the detection of cellular lineage markers to diagnose poorly differentiated
malignancies. Interpretation of results was a matter of positive or negative, present or
absent. Little attempt was made to distinguish degrees of staining, or differences in
intensity.210
The introduction of immunoperoxidase methods and increasingly sensitive
detection systems in the mid-1970s provided the ability for broad application of IHC on
routine FFPE tissues. With the promise of unparalleled specificity, IHC transformed
histopathology from something resembling an art into something more closely
■
resembling a science. 211 The application of IHC to routinely processed tissues
represented a new era for the demonstration of antigens in situ, allowing pathologists to
correlate immunologic findings directly with traditional cytologic and histologic
criteria.212
Immunohistochemistry typically follows a series of universal steps. A)
Pretreatment (antigen retrieval), often with pressure-cooking of tissue in citrate buffer to
unmask antigens hidden by formalin cross-links or other fixation. Other agents used for
antigen retrieval include proteases, such as pepsin, trypsin, bromelain. B) Application of
primary antibody; antibody binds to antigens of interest. C) Wash off excess primary
antibody. D) Application of labeled anti-IgG antibody (secondary antibody), which binds
to the primary antibody. The secondary antibody is typically conjugated to biotin or
horseradish peroxidase. E) Application of detection chemicals, including a chromagen
(color changing reagent), usually 3, 3’ diaminobenzidine (DAB). It is necessary add an
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avidin-biotin-peroxidase complex prior to DAB in the case of biotinylated antibodies.
The slide is then counterstained with hematoxylin to identify all nuclei. This is the
standard method for the ‘brown stain’.
While immunohistochemistry has become an established method in research and
clinical pathology, a surprising lack of standardization and reproducibility exists among
different laboratories. Enormous variability has developed in terms of the reagents
available, the detection methods used, and, most importantly, the interpretation and
reporting of immunohistochemical findings.213 Although efforts have been made to
standardize immunohistochemistry, difficulties remain.
Recently, the need for IHC standardization has expanded due to the inception of
bio-specific therapies that are approved with partner pharmco-diagnostics. Quantitative
(or at least semiquantitative) IHC is likely to become more critical as pathologists are
required to accurately distinguish expression levels of markers to determine whether or
not a patient is a candidate for a specific therapeutic. The classic example is the
evaluation of HER2-2/neu expression to aid in prognosis of breast cancer. Although this
marker is an “easy one”, there has still been considerable literature on the inaccuracy of
of the pathologist-based test. More recently, market forces have resulted in standardized
test kits, such as the HerceptTest (DAKO, Carpinteria, CA) and INFORM DNA probe
test (Ventana Medical Systems, Tucson, AZ), that have been approved by the FDA.
None-the-less, the accuracy and comparability of these methods is somewhat
controversial.214
Efforts to standardize immunohistochemistry have focused on three areas: (1)
antibodies and reagents, (2) technical procedures, and (3) interpretation of IHC findings
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for research and diagnostic uses. There has been recommendation for a Total Test
Approach to standardization of IHC213, requiring that the pathologist pay close attention
to each and every step of the procedure: from excision of the biopsy, including the type
and duration of fixation, through the antigen retrieval method and detection procedure, as
well as interpretation of the resulting stain. Much of the variability in staining is
introduced by differences in fixatives or fixation times

215
, and these can be reduced, if not

eliminated by the use of an optimized antigen retrieval protocol

210
. In addition to

optimization of antigen retrieval, the authors suggest simplification of IHC staining
method, and the implementation of quantitative IHC.

Quantitative Immunohistochemistry

Although the current gold standard for diagnosis amongst pathologists relies upon
morphological criteria, histochemistry—immunohistochemistry in particular—has
provided a more accurate mechanism for diagnosis, as well as the ability to assess
molecular interactions in situ. The primary usage has been as an ancillary test to assist in
classifying tumors or in making a diagnosis. But there is now a trend toward increased
usage of this test as a mechanism to predict response to therapy. This trend, as well as
advances in computation power, is driving numerous efforts toward quantitative
assessment of expression. The critical information that makes techniques such as
immunohistochemistry and in situ hybridization so valuable is that they provide
molecular information within the architectural context of tissues. This information,
including architectural and subcellular localization, can be critical for classifying tumors,
or providing prognostic or predictive information. This information needs to be
maintained as a unique part of the molecular information package that now includes
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various molecular-based techniques, which typically rely on suspensions or extracts of
cells or tissues, such as PCR, DNA sequencing, FACS and ELISA assays.
Quantitative immunohistochemistry (QIHC) is composed of two general
methodologies, manual and automated analysis. Pathologists typically perform the
manual method of QIHC. After identifying the region of interest within a tissue section
(i.e., tumor or other diseased tissue), estimation of intensity or percentage of IHC staining
is determined. This method is presently more commonly used, and is well recognized in
the literature. However, this approach is relatively subjective, based on visual estimation
of the intensity and percentage of positive staining of IHC. The immunoreactive grading
system provides a visual aggregate of intensity/percentage, denoted by "0, 1+, 2+, 3+",
representing negative, weak, moderate, and strong staining, respectively. Semiquantitative systems have been invented and some have seen extensive usage, including
the H-score system216 and the Allred system.217 Both are based on the product of staining
intensity and the percentage of positive cells. Though widely used, the manual system of
QIHC is imperfect, based on human fallibility, which suffers from a high degree of interand intra-observer variability.

71 R 91 Q

’

Automated systems for QIHC begin with acquisition and storage of digital
images, followed by image correction and enhancement, segmentation of objects within
the images, and ultimately image measurement. 220 Several commercial systems are
■

currently available for image analysis of brown stain IHC slides. Among these systems,
the CAS system, originally invented by James Bacus 221, was perhaps the most popular as
judged by the number of units sold, although now it is outdated. The CAS 200 system,
and its successor, the BLISS system, is designed for quantitative analysis of “brown”
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stained IHC material. The optical density of the reaction product is determined through
conversion of the light transmission, or gray level, and the relative area o f the staining
reaction is also determined. Other systems with similar functionality are listed below.
T a b le 7. C o m m e r c ia lly A v a ila b le A u to m a te d A n a ly sis S y ste m s

System

Source

Bliss

Bacus Laboratories, Inc.

http://www.bacuslabs.com

Chromavision ACIS®

Clarient

http://www.chromavision.com

IVision and GenoMx™

Biogenex

http://www .bio genex .com

Scanscope® Systems

Dako Cytomation

httn ://www. aperio.com

Ariol SL-50

Applied Imaging

http://www.aicom.com

PATHIAM

Bioimagene, Inc.

http://www.bioimagene.com

Discovery

Molecular Devices

http://www.moleculardevices.com

TissueAnalytics

Tissue Informatics, Inc.

http://www.tissueinfomiatics.com

LSC

CompuCyte Corporation

http://www.compucvte.com

AQUA™

HistoRx

http://www.historx.com

These systems generally cost between $200,000 and $300,000. In addition, some
investigators have developed analysis systems on their own

222

223

’

or using commercially

available software.224,225
Because these systems are designed to analyze brown stain IHC, they rely upon
absorbance (i.e., optical density) to compute an intensity score. In spectrophotometry,
Beer's Law (A = e 1 c) states that the absorbance (A) of a species at a particular
wavelength of electromagnetic radiation, is proportional to the concentration (c) of the
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absorbing species and to the length of the path (1) of the electromagnetic radiation
through the sample containing the absorbing species. The extinction coefficient (s), also
known molar absorptivity, is dependent upon the wavelength of the light and is related to
the probability that the species will absorb light of a given wavelength. When A equals
zero, no photons are absorbed; when A equals 1.0, 90% of photons are absorbed, i.e.,
10% detected; when A equals 2.0, 99% of photons are absorbed, i.e., 1% detected. Most
brown stains are optimized by eye for signal to noise such that the absorbance of a
‘positive’ case is over 1.0 and often over 2.0. Thus, only a tiny percentage of the light is
detected, which decreases the dynamic range of the assay and makes co-localization more
challenging. Fluorescence-based imaging could circumvent these problems, but that
imaging modality has other problems. As a result, very few companies have developed
quantitative analysis on the basis of this platform.

Fluorescence-based Platforms for Quantitative Analysis

Although fluorescence-based methods have numerous advantages with respect to
dynamic range and co-localization, they have not been broadly used for numerous
reasons. Firstly, formalin fixed tissue generally has a substantial amount of auto
fluorescence, especially in the wavelengths of the most common fluorophores. Red cells
are a particular problem. A second issue is the higher cost and limited accessibility of
epifluorescent microscopy equipment. Perhaps the greatest barrier is the inability of the
pathologist to judge the surrounding tissue and architectural context. This can be seen as
a huge disadvantage, or, arguably, an advantage if the goal is to reduce subjectivity. In
flow cytometry, pathologists do not see any cells, but that is not seen as a disadvantage.
Furthermore, recent studies suggest that pathologists tend to select non-representative
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regions when they select an area to score (Gann et al, personal communication). This can
decrease the overall accuracy of assessment of protein expression levels.
A small number of laboratories have now begun developing analysis systems for
fluorescence-based quantification. The following paragraphs describe our lab’s efforts in
this area.226 The assembly consists largely of off-the-shelf microscopy equipment based
on an Olympus AX51 automated microscope, with a Cooke digital camera, and
computerized image acquisition based on the DP Lab software (v3.54, Scanalytics, Inc.).
The imaging system captures stacks of images that are then analyzed on custom software
developed in our laboratory, written by Robert Camp called AQUA (Automated
Quantitative Analysis, Figure 3). The underlying principle behind the software is that
spatial information is maintained, but that all localization is based on molecular
information, rather than feature identification or morphology. Thus, the steps for analysis
of each image include identification of a mask to separate tumor from non-tumor,
followed by definition of compartments on the basis of other molecular interactions. For
example, keratin may be used as a mask (for cells of epithelial origin) and DAPI to define
a nuclear compartment. Then, the target of interest is measured (for example estrogen
receptor) in a quantitative fashion only in the pixels that are within the mask and
compartment defined by the previous markers. The intensity then divided by the area of
the compartment to define a normalized value that is directly proportional to the protein
concentration of the target. The following is a detailed description of the process.
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Figure 10. AQUA software. The windows of the AQUA software are shown including the
algorithm description window, the settings window, score window and 4 image windows for the
images of different raw images or processed images. For example the upper left image is the
keratin immunofluorescence image from which the upper right mask image was constructed.

Image acquisition: Images of microarrays are obtained using an Olympus Motorized
Reflected Fluorescence System and software (IP lab v3.54, Scanalytics, Inc.), with an
attached Cooke Sensicam QE High Performance camera through an Olympus BX51
microscope with automated x, y, z stage movement. Low power images of microarrays
are stitched together using multiple low-resolution images of the microarray (64 x 64
pixel) at approximately 7-micron resolution.
Histospots are identified using a custom written spotfinder algorithm (written by
Robert Camp) based on the signal from DAPI or other tags. This signal is gated (i.e., a
threshold of pixel intensity is set) to create a binary image of the microarray. Histospots
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are identified using size criteria. Rows and columns of histospots are then identified, and
missing histospots filled in, allowing each histospot to be identified based on its
row/column grid position. The coordinates of each histospot are then recorded.
Subsequently, monochromatic, high-resolution (1024 x 1024 pixel, 0.5-micron
resolution) images are obtained of each histospot, both in the plane of focus and 8
microns below it, and recorded in an image stack as bitmaps. This depth, slightly below
the bottom of the tissue, was determined to be optimal for 5-micron histologic sections.
A resolution of 0.5 microns is suitable for distinguishing between large subcellular
compartments such as the cell membrane and nuclei. Efforts are underway to
accommodate smaller subcellular compartments (for example, mitochondria, nucleoli)
using high power objectives. Images are obtained using a pixel intensity dynamic range
o f 0-255.

RESA/PLACE algorithmic analysis o f images: Through the use of two algorithms, RESA
(rapid exponential subtraction algorithm) and PLACE (pixel-based locale assignment for
compartmentalization of expression), AQUA carries out the following functions:
•

Identification of the tumor locale within the histospot (“tumor mask”)

•

Identification of subcellular compartments (nuclei, membranes,
cytoplasm, etc.)

•

Defines the localization and intensity of the “target”

First, a tumor-specific mask is generated by thresholding the image of a marker
that differentiates tumor from surrounding stroma and other non-tumor material. This
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creates a binary mask (each pixel is either ‘on’ or ‘off). Keratin is the most common
mask used for epithelial neoplasms and S I00 protein is used for melanocytic lesions. As
formalin-fixed tissues can exhibit autofluorescence, analysis may give multiple
background peaks. The RESA/PLACE algorithms determine which of these peaks is
predominant and sets a binary mask threshold at a slightly higher intensity level. This
provides an adaptive (unique to each histospot) thresholding system that ensures that only
the target signal from the tumor and not the surrounding elements is analyzed.
Thresholding levels are verified by spotchecking a few images and then automated for
the remaining images. This binary mask can be modified using standard image
manipulations. In most cases this involves filling holes of a particular size (for example,
less than 500 pixels, to fill in tumor nuclei that do not stain for S I00) and removing
extraneous single pixels. Once set, these image manipulations are performed
automatically on all images. All subsequent image manipulations involve only image
information from the masked area.
Next, two images (one in-focus, one slightly deeper) are taken of the
compartment-specific tags and the target marker. A percentage of the out-of-focus image
is subtracted from the in-focus image, based on a pixel-by-pixel analysis of the two
images. This percentage is determined according to the ratio of the highest/lowest
intensity pixels in the in-focus image - representing the signal-to-noise ratio of the image.
By using an exponential scale, this allows RESA to subtract low intensity pixels in
images with a low signal-to-noise ratio less heavily than low intensity pixels from images
with a high signal-to-noise ratio. The overall degree of subtraction is based on a userdefined percentage for each subcellular compartment. For most applications this is
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empirically set to 40% of the total signal, and remains constant for images from an entire
microarray. RESA thus eliminates nearly all of the out-of-focus information. The
algorithm has the added benefit of enhancing the interface between areas of higher
intensity staining and adjacent areas of lower intensity staining, allowing more accurate
assignment o f pixels of adjacent compartments. In contrast to the compartment-specific
tags, the RESA subtraction of the target signal is uniform and not based on overall
intensity o f the image intensity. This ensures that the same amount of subtraction occurs
with the target signal from all specimens.
Finally, the PLACE algorithm assigns each pixel in the image to a specific
subcellular compartment. Pixels that cannot be accurately assigned to a compartment to
within a user-defined degree o f confidence (usually 95%) are discarded. This is
accomplished iteratively by determining the ratio of signal from two compartmentspecific markers that minimizes the spillover of marker from one compartment into
another. Once each pixel is assigned to a subcellular compartment (or excluded as
described above), the signal in each location is added up. This data is saved and can
subsequently be expressed either as a percentage of total signal or as the average signal
intensity per compartment area. The score is expressed on a scale of 1 to 1000 as the
total intensity divided by the area of the compartment to 3 significant figures. A step by
step illustration o f this process is illustrated in the schematic in figure 4. These
algorithms are described in further detail in a patent of this technology owned by Yale
University.
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Figure 11. The schematic above demonstrates a step-by-step methodology for RESA and PLACE
algorithms used by AQUA in the assessment o f P-catenin expression in colon cancer.226 A) Anticytokeratin is used to distinguish colon carcinoma cells from the surrounding stroma. B) Gating
of that image creates a binary mask. C) The mask is enhanced by filling holes and removing small
objects. D) Anti-a-catenin serves as a membrane tag. E) The membrane tag image is
exponentially subtracted using RESA. F) DAPI identifies the nuclei. G) The nuclear tag image is
exponentially subtracted using RESA. H) The membrane and nuclear tag images are merged, and
overlapping pixels are removed. White pixels represent overlap. J) Anti-P-catenin is the target
marker o f interest. K) The target marker image is exponentially subtracted using RESA. L) The
intensity o f the marker is divided into the various subcellular compartments. Graphically, this is
represented by red (membrane), green (cytoplasm), and blue (nuclei). In this tumor, P-catenin is
predominantly localized to the membrane (red).

The results o f this assay (or other quantitative microscopy systems) are a
“number” that represents an objective continuous variable for subsequent analysis. This
allows statistical analysis of histologic data in a manner more similar to other quantitative
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areas o f medicine (blood glucose, liver enzymes, or drug levels). Although these systems
remove the subjectivity in assessment, there are still other issues that must be
systematically addressed, including sample selection (the region analyzed) and a
multitude o f steps related to processing. However, the addition of quantitative analysis
removes the most subjective step and allows the typical rigorous QC and QA of
laboratory tests. It is easy to envision future application of these technologies in the
clinical lab. Specifically a likely application is the assessment of biopsy tissue for the
qualification of cancer patients for new biospecific therapies, based on quantitatively
assessed levels of target protein expression.

Statistical Approaches to Tissue Microarray Data

Survival analysis: Kaplan-M eier
In medical research, we often seek to display a summary of the survival
experience o f a group of patients. Typically, the most convenient method for
demonstrating a survival function is by graphical presentation. In this form, it is typically
referred to as a survival curve. The horizontal axis usually represents time since
diagnosis and the vertical axis represents the probability or chance of survival (or any
other well-defined end-point, such as recurrence), expressed as a percentage.227
First proposed by Kaplan and Meier in 1958228, the Kaplan-Meier (K-M) estimate
can also be called an actuarial estimate. The Kaplan-Meier method is a nonparametric
(actuarial) technique for estimating time-related events. It is a univariate analysis and is
an appropriate technique for determining the association of a single variable with
survival. It estimates the proportion of individuals alive at a particular time, starting from
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the time of diagnosis (time zero). It is especially applicable when length of follow-up
time varies from patient to patient, and takes into account those patients lost to follow-up
or not yet event-free at the end of study (censored patients, assuming the censoring is
non-informative). Since the estimated survival distribution for the cohort study has some
degree o f uncertainty, 95% confidence intervals may be calculated for each survival
probability on the “estimated” curve.
A variety of tests (log-rank, Wilcoxan and Gehen) may be used to compare two or
more Kaplan-Meier “curves” under certain well-defined circumstances. Median
remission time (the time when 50% of the cohort has reached remission), as well as
quantities such as three, five, and ten year probability of remission, can also be generated
from the Kaplan-Meier analysis, provided there has been sufficient follow-up of patients.
In summary, the Kaplan-Meier technique is a useful method of evaluation for individual
nominal (or categorical) markers.

Survival analysis: Cox Proportional Hazard Analysis
In some cases it is necessary to determine whether survival is influenced by one
or more factors, called "predictors" or "covariates", which may be categorical (such as the
kind of treatment a patient received) or continuous (such as the patient's age, weight, or
the dosage o f a drug). For simple situations involving a single factor with just two values
(such as drug vs. placebo), the method of Kaplan-Meier analysis followed by log-rank
testing will suffice for comparing the survival curves of two groups of subjects. For more
complicated situations, a special type of regression is required; one that provides
assessment o f the effect of each predictor on the shape of the survival curve.
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To understand the method of proportional hazards, first consider a "baseline"
survival curve. This can be thought of as the survival curve of a hypothetical "completely
average" subject— someone for whom each predictor variable is equal to the average
value of that variable for the entire set of subjects in the study. This baseline survival
curve doesn't necessarily have any particular formula representation; it can have any
shape whatever, as long as it starts at 1.0 at time 0 and descends steadily with increasing
survival time. The baseline survival curve is then systematically "flexed" up or down by
each of the predictor variables, while still keeping its general shape.
The proportional hazards method computes a coefficient for each predictor
variable that indicates the direction and degree of flexing that the predictor has on the
survival curve. Zero means that a variable has no effect on the curve (i.e., it is not a
predictor at all); a positive variable indicates that larger values of the variable are
associated with greater mortality while a negative variable indicates that larger values are
associated with improved survival. Knowing these coefficients, it is possible to construct
a "customized” survival curve for any particular combination of predictor values. More
importantly, the method provides a measure of the sampling error associated with each
predictor's coefficient. This allows for assessment of which variables' coefficients are
significantly different from zero, in turn, providing a determination of which variables are
significantly related to survival.
Cox analysis incorporates proportional hazards regression to predict relative risk.
When incorporating several variables into a Cox model, the relationship between the
variables is assessed by multiple regression, taking into account multiple variables and
the proportional changes in the dependent variable (survival time and censor status) that
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can be expected related to changes in explanatory variables (clinical parameters, protein
expression levels). Relative risk is a measure of how much a particular risk factor (say
cigarette smoking) influences the risk of a specified outcome (say, death by age 70). For
example, a relative risk o f 2 associated with a risk factor means that patients with that
risk factor have a 2-fold increased risk of having a specified outcome compared to
persons without that risk factor. One overall p-value tests the overall null hypothesis that
the relative risk of the population is 1.0 and that none of the variables influence patient
prognosis. Individual p-values for different markers or clinical variables each have their
own p-value that tests the null hypothesis that a variables’ particular relative risk is 1.0 in
light of other variables.

Hierarchical Cluster Analysis
A major method for analyzing and demonstrating data from gene expression
profiling experiments, the use of cluster analysis has increased dramatically over the past
few years. Cluster analysis includes a diverse collection of techniques that can be used to
classify objects, with the goal of finding subgroups of data within a larger dataset. All
cluster analysis algorithms seek to maximize the similarity of “within-cluster”
observations while maximizing differences between clusters. The underlying
mathematics of most clustering methods are relatively simple but large numbers of
calculations are needed. Classification depends on the particular method used, and there
are many ways to measure similarity and dissimilarity.
Hierarchical clustering methods attempt to create groups of observations through
merging or dividing, with the resultant classification consisting of an increasing number
of nested classes. The result resembles a phylogenetic classification, in which
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hierarchical tree dendrograms denote the relatedness between genes/samples; branch
length denotes the level of similarity. There are two main categories of hierarchical
clustering: agglomerative and divisive. Agglomerative clustering methods begin with
each observation representing a single cluster. At each step, two clusters are merged until
only one cluster remains. The researcher determines the step to stop clustering and, thus,
how many clusters to retain. Divisive clustering methods begin in an opposite manner.
Initially, all the observations begin in one large cluster, and at each step a cluster is
divided until all members represent their own cluster. Again, the researcher determines
the number o f clusters to retain.
The results of clustering analysis are typically displayed as a two-color heat map,
demonstrating both the direction of fold change (indicated by color) and the magnitude of
the change (indicated by the intensity/brightness of the color). The phytogenies (one for
genes and one for patients/specimens) are displayed adjacent to the heat map. The most
popular pieces o f software for these analyses— CLUSTER and TREEVIEW—were
developed in Michael Eisen’s laboratory
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in order to demonstrate genome-wide

expression data from DNA microarray hybridization experiments; standard statistical
algorithms are used to arrange genes according to similarity in pattern of gene expression.
Unfortunately, this use of gene expression data does not always identify cancer
subtypes that are related to patient survival. There are two main approaches in the
literature to identify cancer subtypes. The first approach, described above (e.g.,
hierarchical clustering), is called “unsupervised” as it does not use any of the clinical
information about the patient. There have been a few studies that have demonstrated
success in identifying clinically relevant cancer subtypes through unsupervised
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hierarchical clustering analysis.
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However, unsupervised learning procedures, by

definition, do not use clinical data to identify subtypes, and thus, there is no guarantee
that the subtypes they identify will be correlated with clinical outcome. The second
approach to identifying subtypes of cancer is based exclusively on clinical data. For
example, patients can be assigned to a “low-risk” or “high-risk” subgroup, depending on
whether they are alive or their tumor has metastasized after a certain time period. This
approach has been used successfully to develop procedures to diagnose patients based on
their gene expression profile.
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Unfortunately, this process of grouping patients may

not be biologically meaningful, leading to the misclassification of patients in future
applications of the model. A third, less commonly used procedure— semi-supervised
clustering—was recently proposed by Bair and Tibshirani238, in which both gene
expression data and clinical data is used to identify cancer subtypes. The crux of the idea
is to use the clinical data to identify a list o f genes that correlate with the clinical variable
of interest and then apply unsupervised clustering techniques to this subset of genes.
In summary, hierarchical clustering is a useful tool for visualizing large datasets
and generating hypotheses about the relationship of markers and tumors. While it has
been the cornerstone of DNA microarray analyses, in which the expression of thousands
of genes is simultaneously evaluated in a small cohort of specimens, the procedure is
gaining ground in tissue microarray studies, where the expression of a few genes are
evaluated in hundreds to thousands of patients. A few groups have demonstrated the
ability to immunoprofile cancer through hierarchical clustering of TMA data, including
classification by binarized ER, HER2, COX-2, p53 and VEGF expression

, analysis of

breast cancer expression of neuroendocrine markers240, the relationship between
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differential protein expression and cytogenetic alteration patterns241, and prognosis
prediction242’243. Unfortunately, most of these attempts have been made in breast
carcinoma and none have been reported for melanoma.

Genetic Algorithms
First introduced by John Holland in 1975244, Genetic algorithms (GA) are a novel
tool for the investigation of combinatorial optimization problems. A number of books
have been published in recent years that review the application of genetic algorithms to
optimization problems.245'247 Briefly, genetic algorithms represent a type of cooperative
search method, in which a number of searches are run in parallel and information is
exchanged between them. They are a class of algorithms that mimic some of the major
characteristics of Darwinian evolution. That is, mutations, cross-overs and replication
operating on strings, are ultimately subjected to some form of selection. Mutations can
be thought of as operations within a single search trajectory, and cross-overs provide a
means of information exchange between trajectories.
A general description of GAs follows. An initial population of trial solutions is
established, represented by strings. Mutations are introduced independently into each
string. After some number of mutations has been performed, new strings are created by
cross-over operations. That is, two new population members are created by joining parts
of two separate strings. The operation of creating new strings is repeated until a new
population of accepted strings is established and then another phase of mutations is
entered. Along the way, the new populations are subjected to a fitness function. Usually,
only changes that increase fitness are accepted, though, in some cases, less-fit changes
may be allowed.
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Basic terminology of genetic algorithms, as applied to data in this dissertation,
includes genes (algorithms) and chromosomes (solutions). In order to avoid confusion
with the original meaning of these biologic terms, both terminologies will be used
together.

X-tile Analysis
The ability to parse tumors into subsets based on biomarker expression has many
clinical applications; however, there is no global way to visualize the best cut-points for
creating such divisions. Robert Camp, in our laboratory, has developed a graphical
method, the X-tile plot that illustrates the presence of substantial tumor subpopulations
and shows the robustness of the relationship between a biomarker and outcome by
construction of a two-dimensional projection of every possible subpopulation.

748

In theory, associations between tumor biomarker expression and patient outcome
should reveal the existence of biologically meaningful tumor classifications; however in
practice, there is no universal method for discovering, assessing or displaying such
associations. Consequently, studies generally group tumors into set divisions (e.g.,
quartiles, deciles), which fails to reflect the underlying biology of most markers.
Microarray technology has magnified this problem by accelerating the discovery of
tumor markers for which there is no known biological basis. In such cases, there is no
foreknowledge about how (or whether) a marker parses a population into subsets.
X-tile plots provide a single, global assessment of every possible way of dividing
a population into low-, medium-, and high-level marker expression. X-tile data are
presented in a right triangular grid where each point represents a different cut-point. The
intensity of the color of each cutoff point represents the strength of the association. The
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X-tile software allows the user to move a cursor across the grid and provides an "on-thefly" histogram of the resulting population subsets along with an associated Kaplan-Meier
curve. This type of graphical representation can provide insight into the biological nature
of a marker (e.g., does it show a linear distribution relative to survival, does it reveal
distinct sub-populations, or does it manifest a U-shaped relationship to outcome).
Because it is statistically invalid to test multiple divisions and accept the best P value,
rigorous statistical evaluation is achieved by defining divisions in a "training set" and
then validating them in a separate patient cohort ("validation set"). The X-tile software
provides a method of dividing a single cohort into training and validation subsets for P
value estimation when separate training and validation cohorts are not available. In
addition, the software can perform standard Monte Carlo simulations (e.g., crossvalidation) to produce corrected P values to assess statistical significance of data assessed
by multiple cut-points.
In summary, X-tile plots present a new tool for (a) the assessment of biological
relationships between a biomarker and outcome; and (b) the discovery of population cutpoints based on marker expression. Clinically, the ability to effectively define such
subpopulations is important for the development of novel therapeutics that may be
effective for only a limited subset of tumors. Furthermore, this method may have value in
other fields (materials testing, actuarial questions, etc.) where cut-point selection is
complicated by time-dependent assessment of outcome.

M odel Selection and M odel Assessm ent
Statistical learning—the process of learning from data (i.e., creating a model for
outcome prediction)—plays a key role in many areas of science, finance, and industry. In
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its simplest form, a prediction model is used to predict an outcome measurement, which
can be quantitative (e.g., a stock price) or categorical (e.g., alive or dead), based on a set
o f features (e.g., diet and clinical measurements). The first step involves a training set of
data, in which feature measurements and outcome are observed for a set of objects (e.g.,
patients). Using this data, a prediction model, or learner, is developed, with the gaol of
predicting the outcome for new unseen objects.
The generalization performance of a learning method relates to its prediction
capability on independent test data. Assessment of this performance is critical, as it
guides the choice o f learning method or model, and provides a measure of the quality of
the ultimately chosen model. There are, in fact, two separate goals at hand:
Model selection: estimating the performance of different models in order to choose the
(approximate) best one.
Model assessment: having chosen a final model, estimating its prediction error
(generalization error) on new data.
In a data-rich situation, the best approach for both goals is to randomly divide the
dataset into three parts: a training set (typically 50%), a validation set (usually 25%), and
a test set (also 25%). The training set is used to fit the models; the validation set is used
to estimate prediction error for model selection; the test set is used for assessment of the
generalization error of the final chosen model. In many cases, there is insufficient data to
split into three parts. There is no ‘standard’ regarding how much training data is enough,
but a major factor in this consideration is the signal-to-noise ratio of the underlying
function, as well as the complexity of the models being fit to the data. There are a couple
statistical methods available for approximation of the validation step either analytically
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(e.g., Akaike or Bayesian information criterion, minimum description length, structural
risk minimization) or by efficient sample re-use (e.g., cross-validation and
bootstrapping). In addition to assisting in model selection, these methods are also helpful
m estimating test error. 249
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Chapter 2: Subcellular Localization of Activating Transcription Factor 2 in
Melanoma Specimens Predicts Patient Survival

Abstract
The transcription factor activating transcription factor 2 (ATF2) has been shown to be
associated with melanocytic oncogenesis and melanoma tumor proliferation in preclinical
models. The clinical significance of ATF2 expression is unknown. To determine the
prognostic value o f ATF2 in melanoma, we evaluated the pattern and level of ATF2
expression in a large cohort of melanoma specimens. Immunohistochemical staining was
performed on a tissue microarray representing 544 patients with a mean follow-up time
of 60 months. Expression was evaluated semiquantitatively and correlated with overall
survival and other clinicopathological data. Strong cytoplasmic ATF2 expression was
associated with primary specimens rather than metastases (P < 0.0001) and with better
survival (P = 0.0003). Strong nuclear ATF2 expression was associated with metastatic
specimens (P < 0.0001) and with poor survival (P = 0.0008). Patients who had both weak
cytoplasmic and strong nuclear ATF2 staining had the worst outcome, both among the
full cohort of patients (P < 0.0001) and among the patients with localized disease (n =
269; P < 0.0001). On multivariate analysis of the primary cutaneous specimens, weak
cytoplasmic staining and strong nuclear staining was an independent predictor of poor
outcome, as was Clark level. Nuclear ATF2 is likely to be transcriptionally active,
whereas cytoplasmic ATF2 probably represents an inactive form. These findings support
other preclinical findings in which transcriptionally active ATF2 is involved in tumor
progression-proliferation in melanoma. Moreover, our findings suggest that ATF2 might
be a useful prognostic marker in early-stage melanoma.
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Introduction
The only clinically reliable markers used to predict outcome in malignant
melanoma are Breslow depth, Clark level of invasion, presence of ulceration and lymph
node involvement.19 These parameters form the basis of the new American Joint
Committee on Cancer Staging System. However, within each stage there is significant
variability in outcome, and while the staging is helpful in determining prognosis and
therapy at the time of diagnosis, more accurate measures based on tumor biology are
needed.19 Better predictors of poor outcome in resected melanoma could enhance our
ability to appropriately select patients in need of adjuvant therapy.
Numerous tissue and serological markers have been studied, as reviewed by Li et
al 250 Among them, a number of transcription factors, including Activating Transcription
Factor 2 (ATF2), have been shown to be associated with tumor growth and metastasis

251

’

252 in cell culture and animal models, but their prognostic role in melanoma has not been
determined. ATF2 is among the primary transcription factors regulated by p38, MAP
Kinase and JNK signaling pathways.253,254 Phosphorylation of ATF2 by these kinases is
central in determining its stability255 and transcriptional activity, which is dependent upon
its heterodimerization with other members of the bZIP family, c-Jun, CREB, NFkB and
retinoblastoma (Rb).253,256-258 ATF2 plays an important role in acquisition of resistance
of melanoma cells to chemotherapeutic drugs and radiation.259'261 Inhibition of ATF2
activity efficiently inhibits melanoma growth, ability to metastasize, and sensitizes
melanoma to a range of chemotherapeutic agents and radiation.262,263
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In this study, we sought to evaluate the prognostic role of ATF2 by studying the
pattern and levels of ATF2 expression using a large cohort melanoma tissue microarray,
and associating expression with clinical and pathologic data.
Materials and Methods
Tissue Microarray Construction:

The tissue microarray was constructed as previously described.150 A total of 570
tissue cores (553 melanomas with duplicate spots for 9 patients, 17 normal skin)
measuring 0.6 mm were spaced 0.8 mm apart on a single glass slide. The cohort was
constructed from paraffin-embedded formalin-fixed tissue blocks obtained from the Yale
University Department of Pathology archives. The specimens were resected between
1959 and 1994, with a follow-up range between 2 months and 38 years with a median
follow-up time of 60 months. Treatment information was not available for the entire
cohort. Some of the stage III patients were treated with interferon based therapy, and the
stage IV patients were treated with a range of therapies including chemotherapy,
biological therapy, vaccine therapy and supportive care.

Slides from all blocks were

reviewed by a pathologist to select representative areas of invasive tumor to be cored.
The cores were placed on the tissue microarray using a Tissue Micorarrayer (Beecher
Instruments, Silver Spring, MD). The tissue microarrays were then cut to 5 pm sections
and placed on glass slides using an adhesive tape-transfer system (Instumedics, Inc.,
Hackensack, NJ) with UV cross-linking.
Immunohistochemistry:

The tissue microarray slide was deparaffmized by rinsing with xylene, followed
by two changes o f 100% ethanol and two changes of 95% ethanol. The slides were then
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boiled in a pressure cooker containing 1 mM EDTA (pH 7.5) for antigen retrieval.
Endogenous peroxidase activity was blocked with 2.5% methanol in hydrogen peroxide
for 30 minutes at room temperature. After washing with Tris Buffered Saline, the slides
1
were incubated at room temperature for 30 minutes in 0.3% BSAV1X
TBS 2 to reduce
non-specific background staining. The primary antibody, rabbit polyclonal anti-ATF2
IgG (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was then added at a dilution of
1:50, and the slides were incubated overnight at 4°C in a wet chamber, and then rinsed
three times in IX TBS/0.05% Tween-20.

Biotinylated goat anti-rabbit IgG (Vector

Laboratories, Burlingame, CA) was added for 1 hour, and the slides were washed in
TBS-Tween as above, incubated for with VECTASTAIN® ABC-AP Reagent (Vector
Laboratories, Burlingame, CA) for 1 hour, washed again in TBS-Tween as above and
incubated for 30 minutes with an alkaline phosphatase substrate solution (Vector
Laboratories). The slides were then rinsed in water, counterstained with hematoxylin and
mounted with Immunomount (Shandon, Pittsburgh, PA).
Evaluation of the Immunohistochemical Staining:

The regions of most intense staining were scored by eye for each spot.
Cytoplasmic and nuclear staining of the melanoma cells were scored separately. Because
of the small size of the histospot (0.6 mm in diameter), no area variable was included in
the scoring. The staining was graded using the following scale: 0 - no staining; 1 - weak
staining; 2 - moderate staining; 3 - intense staining.

Specimens with no invasive

melanoma, or specimens that were not interpretable were excluded from the analysis.
The tissue microarray was scored separately by two independent observers (A.B. and
1Bovine Serum Albumin
2 Tris Buffered Saline
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H.K.), with a very high correlation between scorers (PO.OOOl). A consensus score was
determined for spots with discrepant scoring between the observers.
Statistical Analysis:

JMP 5.0.1 and Statview 5.0.1 (SAS Institute Inc., Cary, NC) software were used
for data analyses. The correlation between the consensus score and the relationship of
ATF2 expression and clinicopathological parameters were done using the Chi Square
test. The prognostic significance of the parameters was assessed for predictive value
using the Cox proportional hazards model with overall survival as an end point. Survival
curves were calculated using the Kaplan-Meier method, with significance evaluated using
the Mantel-Cox long-rank test.
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Results
Immunohistochemical Staining of Melanoma Tissue Microarrays

Of the 553 melanoma tumors on the tissue microarrays, 479 (87%) were
interpretable for cytoplasmic and nuclear ATF2 staining.

Spots that were deemed

uninterpretable had insufficient tumor cells in the spot, loss of tissue in the spot or an
abundance of necrotic tissue. Of the 479 interpretable specimens, 400 (84%) also had
associated survival information.

Figure 12 demonstrates histospots representative of

scores 3+ for cytoplasmic and for nuclear staining. The cases included 269 primary
cutaneous melanoma specimens, 20 local recurrences, 18 melanomas originating in
mucous membranes (vulva, anus, nasal mucosa and rectal), 118 lymph node metastases,
68 cutaneous metastases and 51 distant metastases. The site was not known for 4 of the
patients. There was a strong correlation between nuclear ATF2 expression and lymph
node or metatstatic sites (chi squared test PO.OOOl), while cytoplasmic ATF2 expression
correlated with primary lesions (P<0.0001).
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Figure 12. Immunohistochemical staining on representative histospots showing strong cytoplasmic ATF2
staining (A) and strong nuclear ATF2 staining (B). The Figures are at 10X magnification, and the insets at
60X magnification.

Survival Analysis

The cytoplasmic and nuclear ATF2 expression levels were each evaluated for
association with overall survival.

Kaplan Meier survival curves generated for

cytoplasmic and nuclear ATF2 were split by ordinal score, as shown in Figure 13. These
curves show that increased cytoplasmic expression was correlated with better outcome
(P=0.0005).

Conversely, increased nuclear ATF2 staining was associated with worse

outcome (P=0.0013). Although these data are only semi-quantitative, the curves suggest
a splitting of the data to define scores of 0 and 1 as “low” or “negative” expression and 2
and 3 as “high” or “positive” for both nuclear and cytoplasmic staining. The curves for
scores of 0 and 1 overlap each other, likely secondary to the difficulty in determining the
difference between absent or very weak staining by eye, particularly for weak or absent
nuclear staining in the presence of strong cytoplasmic staining and vice versa. Therefore
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the designations of “high” or “low” expression are used for the remainder of the analyses.
This result is shown in a Kaplan Meier plot in Figure 13.
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Figure 13. Kaplan-Meier survival curves for ATF2 staining for the entire cohort of patients over a 30 year
period, with time given in months: (A) The four intensities of ATF2 cytoplasmic staining (0,1,2,3) (B) The
four intensities of ATF2 nuclear staining (0,1,2,3) (C) High and low cytoplasmic staining for ATF2 (D)
High and low nuclear staining for ATF2.

There were a relatively large number of patients that had high cytoplasmic ATF2
expression with low nuclear expression and vice versa. Therefore to further stratify the
patients, they were divided into three risk groups: 1) high cytoplasmic expression, low
nuclear expression, 2) low cytoplasmic expression and high nuclear expression and 3)
high cytoplasmic and nuclear expression or low cytoplasmic and nuclear expression. The
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Kaplan Meier survival curves for these three groups of patients are shown in Figure
14(A).
For clinicians treating melanoma patients, perhaps the greatest need for
determining prognosis occurs at initial presentation, when patients have a biopsy
performed on a changing skin lesion. Therefore, further survival analysis was performed
using the primary skin lesions only. When dividing the primary skin lesions into the
three ATF2 prognostic groups mentioned above, patients with high cytoplasmic, low
nuclear ATF2 expression did better than those with low cytoplasmic, high nuclear
expression, and the group with low cytoplasmic, low nuclear or high cytoplasmic, high
nuclear expression demonstrated intermediate overall survival (PO.OOOl), as can be seen
in Figure 14(B).

O High Cyt, Low NucATF2
H High Cyt, High Nuc or
Low Cyt, Low Nuc ATF2
X Low Cyt, High NucATF2

O High Cyt, Low Nuc ATF2
B High Cyt, High Nuc or
" Low Cyt, Low Nuc ATF2
X Low Cyt, High NucATF2

Qg> OP fOCl 080 Q Q—

Survival Months

Survival Months

Figure 14. Kaplan Meier survival curves for 3 risk groups of patients: low risk patients (high cytoplasmic
and low nuclear ATF2 expression), intermediate risk patients (high cytoplasmic and high nuclear or low
cytoplasmic and low nuclear ATF2 expression) and high risk patients (low cytoplasmic and high nuclear
ATF2 expression) as shown in the figure legend. Curves include (A) all patients and (B) primary cutaneous
lesions only.

Univariate analysis was performed using the Mantel Cox test. High cytoplasmic
ATF2 expression was associated with good overall survival; hazard ratio=0.618 (95%
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C.I.3 0.474-0.806, P=0.0003). High nuclear ATF2 expression was associated with poor
overall survival; hazard ratio=1.25 (95% C.I. 1.1-1.4, P=0.0009), and the combination of
low cytoplasmic ATF2 and high nuclear ATF2 was associated with worse survival,
hazard ratio 1.33 (95% C.I. 1.15-1.53, PO.OOOl). The pattern of ATF2 expression for
primary and regional/metastatic disease and its association with survival is shown in
Table 8. The ATF2 expression pattern was only predictive of survival among the primary
specimens, and not the regional/metastatic specimens.

Confidence Interval
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Table 8. Univariate analysis of ATF2 expression by tumor site and subcellular localization.
Location of
r •
Lesion
Primary
Lesions

Metastatic
lesions

Location of
Lesion
Primary
Lesions

M etastatic
lesions

Location of
Lesion

Primary
Lesions

M etastatic
lesions

. .
. .,,,,,,
Cytoplasmic ATF2

„
,
Count

Median Survival
Months (Range)

Low

70

47(1-463)

High

157

97 (0-444)

Low

138

47 (1-305)

High

93

39(1-415)

N uclear ATF2

Count

Median Survival
Months (Range)

Low

153

83 (0-463)

High

74

77 (1-377)

Low

98

44(4-415)

High

133

42(1-387)

ATF2 Risk

Count

Median Survival
M onths (Range)

Low

111

93 (0-444)

Intermediate

88

77 (1-463)

0.81 (0.57-1.13)

High

28

52 (1-309)

2.14(1.46-3.04)

Low

38

41 (6-415)

Intermediate

115

46 (1-387)

0.90 (0.71-1.13)

High

78

43 (1-305)

1.04 (0.81-1.33)

r

Hazard ratio
x
,,
(95% confidence interval)

O M i I'D ^ 9 - 0 X M

1 0 9 ((\ R 6 1

Hazard ratio
(95% confidence interval)

„
.
P value

0.001

0.80

P value

1.37(1.08-1.74)

0.011

1.03 (0.88-1.23)

0.70

H azard ratio
(95% confidence interval)

P value
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0.0004

0.64

Clinicopathological Correlations and Multivariate Analyses

Using the Cox Proportional Hazards Model, we performed multivariate analyses
to assess the independent predictive value of ATF2 expression among the primary
cutaneous lesions. We included the following prognostic variables for melanoma,;
Breslow depth, Clark level, ulceration,
lymphocytes at diagnosis.

microscopic satellites and tumor infiltrating

We used a combined cytoplasmic and nuclear ATF2 risk

grouping with low cytoplasmic and high nuclear ATF2 staining presenting the highest
risk group. Our high risk ATF2 pattern remained an independent prognostic indicator in
primary lesions, as did Clark level. Results of the multivariate analysis are shown in Table
9.

Table 9. Multivariate Analysis of ATF2 Expression Pattern and Other Histopathological
Variables among Primary Lesions
V a r ia b le
C la r k L e v e l
(I-III v s. IV -V )
B r e slo w
(< lm m v s. > lm m )
T IL s
(p r e se n t v s. a b se n t)
U lc e r a tio n
(p r e se n t v s. a b se n t)
M ic r o sc o p ic S a te llite s
(p r e se n t v s. a b se n t)
A T F 2 R isk
(h ig h v s. in te r m e d ia te + lo w )

H a z a r d R a tio
(9 5 % c o n fid e n c e
in te r v a l)

L ik e lih o o d -R a tio

x2

P v a lu e

1.67(1.17-2.47)

8.25

0.0041

1.28 (0.80-2.07)

1.08

0.30

1.13 (0.83-1.51)

0.63

0.43

0.83 (0.63-1.10)

1.73

0.19

0.75 (0.57-1.01)

5.00

0.025

1.81 (1.34-2.40)

13.6

0.0002

Correlation between clinicopathological variables and the ATF2 risk pattern was
further examined. The high risk ATF2 pattern was most strongly associated with thick
lesions (P < 0.0001), and had a weaker association with Clark level (P = 0.01). There was
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no significant association between the pattern of ATF2 expression and the site of primary
lesion, age or gender.
Discussion
Numerous preclinical studies have shown that ATF2 contributes to melanoma
growth and metastasis, tumor cell survival and resistance to chemotherapy and radiation.
Here we demonstrate, for the first time, that the ATF2 expression pattern is associated
with patient survival.
Our data show that strong nuclear ATF2 expression was more frequent in
metastatic sites (lymph nodes, bone metastases or visceral metastases) than in primary
cutaneous specimens (PO.OOOl).

Furthermore, our data show that nuclear ATF2

expression is a strong predictor of poor survival and that cytoplasmic ATF2 expression is
a strong predictor of good outcome in melanoma patients. Among the primary cutaneous
specimens, patients that had weak cytoplasmic and strong nuclear staining had poor
survival (P<0.0001), and vice versa for strong cytoplasmic and weak nuclear staining.
The expression pattern o f ATF2 retained independent prognostic value on multivariate
analysis, as did Clark level. Breslow depth was predictive of outcome on univariate
analysis. However, when evaluated in multivariate analyses with ATF2, it was not an
independent predictor of survival. This is likely due to the correlation between Breslow
depth and ATF2 expression.
Our data suggest that subcellular ATF2 localization might be a very useful
prognostic marker in primary cutaneous melanoma, and might affect decisions regarding
patient management, such as the appropriateness of staging evaluation and adjuvant
therapy for patients with early stage melanoma.
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ATF2

has been primarily implicated

as

a transcription

factor which

heterodimerizes with c-Jun and mediates transcriptional activities by Jun responsive
elements.253,264 ATF2 is among early response genes that are activated following stress
and DNA damage, depending on its phosphorylation by upstream kinases, including JNK
and p38. ATF2 has been identified as one of the primary transcription factors that bind to
Jun2-like elements in human melanoma cells.

9 SO

Earlier studies that elucidated the

possible role of ATF2 in human melanoma have established it plays an important role in
the acquisition of resistance to chemotherapy and radiation therapy.259"261 ATF2 alters
melanoma susceptibility to undergo apoptosis, in part, due to its ability to alter the
balance between TNF and Fas signaling.261 Inhibition of ATF2 activities, either by co
expression with its dominant negative forms or via short peptides that out-compete the
endogenous protein, was found to be an efficient mechanism for sensitizing human and
mouse melanoma cells to radiation-induced apoptosis.

Furthermore, expression of a

small peptide that abolishes ATF2 transcriptional activities inhibited melanoma growth in
several mouse tumor models.262,263 Collectively, these studies suggest a critical role for
ATF2 in melanoma progression and resistance to therapy.
The current findings are compatible with the preclinical data and provide insight
into the importance of this transcription factor in the development of melanoma. Of
particular interest is the finding that nuclear localization of ATF2 correlates with poor
prognosis. As a transcription factor, ATF2 is active within the nuclear compartment,
where it elicits its transcriptional activities. Strong nuclear staining of ATF2 therefore
suggests that ATF2 is constitutively active in these tumors. These findings are consistent
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with the notion that it is necessary to inhibit ATF2 activities in order to sensitize these
tumors to treatment.
ATF2 phosphorylation is a prerequisite for its stability and transcriptional
activities.

’

ATF2 kinases are often active in melanoma cells

constitutive phosphorylation and activity.

, thereby enabling its

Interestingly, ERK has been shown to be

capable of phosphorylating ATF2 on the same residues as Jnk263, thereby establishing a
possible link between B-RAF, which is constitutively active in a large percentage of
human melanoma tumors266, and the activation of ATF2.

Nevertheless, the possible

existence o f another kinase which may be activated in the course of melanoma
progression, and which would trigger the nuclear localization of ATF2, cannot be
excluded.
In summary, our data suggest that the level and localization of ATF2 expression
may be clinically useful for assessing prognosis, particularly in primary cutaneous
melanoma specimens, warranting prospective confirmation. Furthermore, our findings
suggest that ATF2 might be a useful target for new drug development.
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Chapter 3: Automated Quantitative Analysis (AQUA) of HDM2 Expression in
Malignant Melanoma Shows Association with Early Stage Disease and Improved
Outcome

Abstract
The incidence of cutaneous malignant melanoma continues to increase every year, and
this disease remains the leading cause of skin cancer death in industrialized countries. In
spite of the aggressive nature of advanced melanoma, there are no standard biological
assays in clinical usage that can predict metastasis. This may be due, in part, to the
inadequacy o f reproducible assessment of protein expression using traditional
immunohistochemistry. We have previously described a novel method of quantitative
assessment of protein expression (AQUA) with the continuity and accuracy of an ELISA
assay but with maintenance of critical spatial information. Here, we modify this
technology for the evaluation of protein expression in melanoma. Using a tissue
microarray cohort of 405 melanoma lesions and 17 normal skin samples, we analyzed
expression of HDM2, the human homolog of MDM2 (murine double minute 2) with
AQUA. We show that expression levels in the nucleus are significantly higher in
primary melanomas than in metastatic lesions. Furthermore, high levels of expression are
predictive of better outcome. This study demonstrates that quantitative assessment of
protein expression is useful in melanoma to validate potential tissue biomarkers, and
suggests that HDM2 may be a valuable prognostic tool for management of malignant
melanoma.
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Introduction
Malignant melanoma is currently the malignancy with the most rapid increase in
incidence in the United States.1,267 The fifth most common cancer2, melanoma is the
most common fatal malignancy among young adults3 with 53,600 new cases diagnosed in
2002268. Current estimates predict that 1 in 71 individuals will develop melanoma during
their lifetime, up from an initial estimate of 1 in 600 in 1960 and 1 in 150 in 1985.1
A number of clinical and pathologic factors have been described as markers of
prognosis in cutaneous malignant melanoma, however, there are currently no routinely
used, broadly accepted molecular, or immunohistochemical markers to define subsets of
this neoplasm15 or predict outcome. The current methods of prognosis in cutaneous
melanoma have not changed much since the 1970s when Breslow28 and Clark29 first
published reports indicating the importance of dermal invasion in prognosis. The models
of Breslow and Clark remain the most powerful and reliable predictors of survival in
primary melanoma42, in spite of the molecular “revolution” of the past 30 years.
To develop a better understanding of melanoma biology and development, as well
as discover molecular markers of potential benefit in melanoma prognosis, a number of
studies have evaluated immunohistochemical (IHC) markers on an individual basis and in
numerous relatively small cohorts. Very few, however, have been performed on
melanoma tissue microarrays

* )f \Q
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and none have made use of quantitative analysis.

Differences in expression levels in the tissues have been limited to those that are easily
detectable by the human eye. The current IHC technology is susceptible to high levels of
inter- and intra-observer variability and fraught with variability as a function of the lack
of standardization of antibody-based techniques.218
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Tissue microarrays provide a highly efficient and economical way to evaluate
hundreds o f tumors on a single slide.149 The use of tissue microarray (TMA) technology
eliminates the slide-to-slide variability inherent to IHC as all tissues are present on the
same slide and are exposed to the same experimental conditions. The use of archival
tissues allows for a retrospective study with the benefit of long-term patient follow-up.
In addition to improving our understanding of key molecular events in cancer
progression, TMAs provide an excellent mechanism for the discovery of outcome
predictor models, particularly when coupled with quantitative analysis.
We have developed a system for compartmentalized, automated quantitative
analysis of histological sections (AQUA).271 AQUA provides highly reproducible
analysis of target signal expression in tissues on a continuous scale, while preserving
spatial information, particularly subcellular localization. Quantitative analysis enables
precise discrimination of expression levels in tissues, providing measurements on a
continuous scale not previously attainable by traditional, or manual, scoring methods.
The use of this technology was originally described in colon cancer271, and has since been
applied to breast

777

and prostate

777

carcinoma. Briefly, the system identifies and tags

tumor tissue within each histospot, based on the expression of tissue specific proteins,
such as cytokeratin in carcinomas, and then evaluates the expression level of a target
antigen within the ‘tumor mask’ and inside user-defmed subcellular compartments. For
this study, the AQUA system was modified to accommodate melanoma by substituting
SI 00 protein for cytokeratin (Figure 15). A review of the pertinent literature
demonstrated that SI 00 is expressed in 97.4% of all melanomas274, and some
investigators suggest this number may exceed 98%275. Here, we validate the technology
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by assessing the expression of HDM2 (human homologue of ‘murine double minute 2’)
and demonstrate its utility in evaluating a prognostic marker in a large retrospective
cohort.
HDM2 is a transcriptional target of the tumor suppressor protein p53, that, in turn,
marks p53 for degradation.
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It is predicted that disruption of this negative feedback

loop, through either p53 mutation or overexpression of HDM2, would be a negative
prognostic marker for cancer progression. The association between HDM2 and clinical
• ■
•
outcome has been investigated intensively in a number of cancers 279 with the anticipation

of using HDM2 as a clinical prognostic marker. However, only a handful of studies have
evaluated HDM2 expression in melanoma.
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In the largest study, Polsky et al.

demonstrated that over-expression of HDM2 in a cohort of 134 melanoma patients
unexpectedly correlated with improved clinical outcome, having a statistically significant
association with longer disease free- and overall survival.109 The quantitative assay we
describe in the work confirms and extends these observations.
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Materials and Methods
Tissue Microarray Construction:

The tissue microarray was constructed as previously described.

i

ca

’

282

A total of

570 tissue cores representing 542 total melanoma cases and a small series of controls
measuring 0.6 mm were spaced 0.8 mm apart on a single glass slide. The cohort was
constructed from formalin-fixed paraffin-embedded tissue blocks obtained from the
archives of the Department of Pathology at Yale University School of Medicine. A
pathologist examined each case to select the region for inclusion in the TMA. Core
biopsies from the specimens were placed on the tissue microarray using a Tissue
Micorarrayer (Beecher Instruments, Sun Prairie, WI). The tissue microarrays were then
cut to 5-pm sections and placed on glass slides using the adhesive tape transfer system
(Instumedics, Inc., Hackensack, NJ) with UV cross-linking. The specimens were all
drawn from archives of tumors resected between 1959 and 1994, with a follow-up range
of 2 months and 38 years (median follow-up time, 60 months). The cohort characteristics
are demonstrated in Table 1. For the primary cutaneous lesions (269), a single reviewer
measured Breslow depth, Clark level, microscopic satellites, tumor infiltrating
lymphocytes, and the presence of ulceration. Treatment information was not available
for the entire cohort. Some of the stage III patients were treated with Interferon-based
therapy, and the stage IV patients were treated with a range of therapies including
chemotherapy, biological therapy, vaccine therapy, and supportive care.
Immunohistochemistry:

The tissue microarray slide was stained as described previously.271 In brief, the
slides were deparaffinized by rinsing with xylene, followed by two changes of 100%
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ethanol and two changes of 95% ethanol. Antigen retrieval was performed in a pressure
cooker containing 1 mM EDTA (pH 7.5), and endogenous peroxidase activity was
blocked with 2.5% hydrogen peroxide in methanol for 30 min at room temperature. The
slide was washed with TBS, incubated in 0.3% BSA/1X TBS for 30 min at room
temperature to reduce nonspecific background, and then stained with the a combination
of anti-MDM2 mouse mAb 1B10 (1:100, Novocastra, Ltd., Newcastle upon Tyne, UK)
plus anti-SlOO rabbit polyclonal (1:6,000, DAKO Corporation, Carpinteria, CA) diluted
in BSA/TBS, at 4°C overnight. The IB 10 mAb was chosen because it was validated by
numerous studies in which HDM2 expression was assessed in tumors relative to normal
tissues.283'285 The secondary antibodies Alexa 488-conjugated goat anti-rabbit (1:100,
Molecular Probes, Eugene, OR) plus Envision anti-mouse (neat, DAKO) diluted in
BSA/TBS were applied for 1 hour at room temperature. DAPI (4, 6-Diamidino-2phenylindole) was included with the secondary antibodies to visualize nuclei. The slide
was washed with BSA/TBS (3X for 5 min), and then incubated with Cy5-tyramide
(Perkin Elmer Life Science Products, Boston, MA), activated by HRP resulting in the
deposition of numerous covalently associated Cy5 dyes immediately adjacent to the
HRP-conjugated secondary antibody. Cy5 was used because its emission peak (red) is
well outside o f the green-orange spectrum of tissue autofluorescence. The slides were
sealed with cover-slips with an antifade-containing mounting medium (with 0.6% npropyl gallate)
Automated Image Acquisition and Analysis:

The AQUA automated image acquisition and analysis was performed as
described.271 Briefly, images of the TMA were captured through an Olympus BX51
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microscope with automated x, y, z stage movement using an Olympus Motorized
Reflected Fluorescence System and software (IP lab v3.54, Scanalytics, Inc.), equipped
with Cooke Sensicam QE High Performance camera. Low power images of the
microarray were stitched together using multiple low-resolution images of the microarray
(64 x 64 pixel) at approximately 7-micron resolution. Histospots were identified
employing the signal from DAPI and/or SI 00 tags. Rows and columns of the histospots
were then identified, missing histospots filled in, allowing each histospot to be identified
by its coordinates, and recorded based on its position in the grid. Subsequently,
monochromatic, high-resolution (1024 x 1024 pixel, 0.5-micron resolution) images were
obtained of each histospot, both in the plane of focus, and 8 microns below it, recorded in
an image stack as bitmaps. A resolution of 0.5 microns is suitable for distinguishing
between large subcellular compartments such as the cell membrane/cytoplasm and nuclei.
Images were obtained using a pixel intensity dynamic range of 0-1024.
A visual demonstration of the AQUA analysis process is depicted in Figure 15.
For each histospot, areas of tumor are distinguished from stromal elements by creating a
tumor mask from the S I00 protein signal, visualized under the Alexa 488 fluorophore.
The tumor mask is determined by ‘gating’ the pixels in this image, in which an intensity
threshold is set by visual inspection of histospots (ranging from lowest to highest
intensity), and each pixel is recorded as “on” (tumor) or “o ff’ (non-tumor) based on the
threshold. In addition, small objects (<50 pixels) are removed and small holes filled.
The DAPI image, used to identify the nuclei, is subjected to RES A (rapid exponential
subtraction algorithm), which improves signal-to-noise ratio by subtracting the out-of
focus image from the in-focus image, in order to clearly define the nuclear
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compartment.

271

Removal of the pixels assigned to the nuclear compartment from the

tumor mask provides a designation of the cytoplasmic compartment. After application of
RESA, the signal intensity of the target antigen, acquired under the Cy5 signal (HDM2),
is scored on a scale of 0-1024, and the AQUA score within the sub-cellular compartments
(i.e., nucleus, cytoplasm) is calculated by dividing signal intensity by the area of the
specified compartment. This score has three significant figures and is directly
proportional to the number of molecules per unit area.

•Binary G ating
•Holes Filled
•Small O b je cts
Rem oved

S10Q P ro te in (Cy2)

C y to p la sm ic C o m p a rtm e n t
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N u c le a r C o m p a r tm e n t
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T a r g e t a f t e r RESA

C o m p a r tm e n ts

T a rg e t L o calizatio n
Red * N uclear
G reen = C ytoplasm ic

Figure 15. Schematic demonstration of AQUA protocol applied to melanoma. Images on the left are raw.
Images on the right have been generated by AQUA. The top horizontal set of panels demonstrates tumor
mask in a melanoma histospot, based on S I00 protein expression (Alexa 488), distinguishing tumor cells
from stroma. The S I00 image is gated to form a binary mask. This binary image is enhanced by filling
holes and removing small objects. DAPI is used to tag the nuclei, and after application o f RESA (Rapid
Exponential Subtraction Algorithm) and identification of only those pixels within the tumor mask, this
image designates the nuclear compartment. After application o f RESA to the Alexa 488 image, the nuclear
compartment is subtracted from the tumor mask to provide a designation o f the cytoplasmic compartment.
An image of the target-specific marker, HDM2, is taken (Cy5), and after exponential subtraction using
RESA, the intensity o f the marker is divided into the subcellular compartments by pixel-based locale
assignment for compartmentalization of expression (PLACE algorithm). An AQUA score (intensity/area) is
generated for the target within the subcellular compartments. This information is graphically represented by
the target localization image.
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Data Analysis:
Histospots containing <10% tumor as assessed by mask area were excluded from
further analysis. Previous studies have demonstrated that the staining from a single
histospot provides sufficient representative sample to judge outcomes.

’

In the case

of HDM2, staining was always nuclear; analyses using the nuclear-specific AQUA score
of HDM2 yielded parallel results to analyses using the total AQUA score. Univariate
survival analyses were assessed using the Kaplan-Meier method for nominal variables
and the Cox regression method for continuous variables. Multivariate analyses were
performed with the Cox proportional hazards model. Mantel-Cox log-rank score was
used to assess statistical significance. Analyses were performed with JMP 5.0.1 (SAS
Institute Inc., Cary, NC). Patients were deemed uncensored if they died of melanoma
within 30 years of their initial date of diagnosis.
Results and Discussion
Validation of Microarray Cohort:

We sought to validate our tissue microarray cohort of 542 melanomas using
several traditional histopathological markers of malignancy. As described previously282
and demonstrated in Table 10, unique patient-specific cases on the TMA include 287
primary specimens, 233 metastatic specimens, and 20 local recurrences. Using univariate
analysis of long-term disease-related survival, primary versus metastatic status predicted
improved survival (p<0.0001). (Figure 16A) For the primary cutaneous specimens, we
found that tumor depth (Breslow and Clark) (pO.0001), ulceration status (p=0.0028),
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microscopic satellitosis (p<0.0001), tumor infiltrating lymphocytes (TILs) (p=0.0007),
and histologic subtype were all significant predictors of survival (Figure 16B-F).
Table 10. Tissue Microarray Characteristics
269 Cutaneous
Primary Lesions (287)
18 Mucosal
118 Lymph Node
65 Cutaneous & Subcutaneous
11 Lung
Metastatic Lesions (233)
8 Bone
2 Brain
26 Other Distant
3 Unknown
Local Recurrences (20)
Unknown (2)
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Figure 16. Melanoma TMA characteristics. Kaplan-Meier survival curves demonstrating disease-specific
survival based on lesion location (i.e., primary versus metastatic), as well as the role o f standard
histopathological criteria on survival in this cohort, which includes Breslow depth (T1-T4), Clark levels (IIV), the presence or absence of ulceration, the presence or absence o f microscopic satellites and presence of
infiltrating lymphocytes.
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Automated Analysis of HDM2 Expression in Melanoma:
After image acquisition for each histospot, AQUA was performed to establish the
intensity of HDM2 expression per unit area within each histospot (Figure 15). HDM2
expression was confined to the cell nuclei, and analysis of AQUA scores of HDM2
within the nuclear compartment yielded similar results to analysis of HDM2 expression
within the overall tumor mask, suggesting nearly all of the expression is in the nucleus.
AQUA score calculation results in a continuous scale in contrast to manual
scoring, which is based on an ordinal scale with arbitrary values. Regression analysis has
•

previously demonstrated a good correlation between the two methods.

271 272

’

Of the 542

total histospots, 405 contained sufficient tumor tissue to provide an AQUA score for
HDM2. The loss of histospots is random, but reduces the number of cases available for
analysis in remainder o f this study. Of the 405 cases analyzed, 200 were primary lesions
and 190 were metastases, 13 were local recurrences, and 2 were of unknown origin.
AQUA scores in the melanoma-specific nuclear compartment of all specimens ranged
from 19.62-150.72 and from 21.84-145.98 within nuclear compartment of primary
lesions. The histogram in Figure 17A demonstrates the continuous nature and bell
shaped distribution of the AQUA scores for all of the specimens. Note that in other
systems, we have evidence that the scores are directly proportional to the number of
molecules per unit area. This is probably also true for F1DM2, but purified protein
standard controls were not available to validate this prediction.
HDM2 expression in the primary lesions was compared to expression in
cutaneous metastases, lymph node metastases, and distant metastases. Figure 17B shows
that loss of HDM2 is more common in later stage disease. This may be related to specific
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classes of tumor with low expression having a great propensity for progression. The
significance of the difference between the means of the AQUA scores for each tissue type
(i.e., skin metastases, lymph node metastases, distant metastases) from the AQUA scores
of primary lesions was determined by t-tests, demonstrated in the Table 11.

Table 11. HDM2 Protein Expression within Tumor Nuclei by AQUA Analysis
Comparison with Mean of Primaries
Mean

n

SE

95% Cl
Difference

Std Error

t test

DF

p value

Primaries

200

65.73

1.57

62.63-68.83

Skin Mets

52

58.37

3.24

51.98-64.76

7.36

3.64

2.02

250

0.0445

98

53.72

2.28

49.23-58.21

12.01

2.78

4.31

296

<0.0001

40

49.22

3.52

42.28-56.15

16.51

3.86

4.28

238

<0.0001

190

54.05

1.63

50.85-57.24

11.68

2.27

5.15

388

<0.0001

LN
Mets
Distant
Mets
All Mets

Mets, metastatic tumor; LN, lymph node; Cl, confidence interval

Survival Analysis:

Since the AQUA scores are of a continuous nature, the HDM2 expression scores
were analyzed by univariate Cox regression. This univariate parametric survival analysis
demonstrated that high HDM2 expression was associated with improved survival in all
specimens (p=0.0154), and in the primary lesions alone (p=0.0318). However, when
HDM2 expression was evaluated in only the metastatic specimens, it did not show a
significant association with survival (p=0.9330). To graphically depict the influence of
HDM2 on survival in melanoma, the scores were divided into quartiles and Kaplan-Meier
survival curves were constructed for HDM2 expression. The p values for these curves
were determined by the Mantel-Cox log-rank method. Assessment of survival in all
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specimens demonstrated that high expression of HDM2 is associated with better diseasespecific survival (p=0.0382) (Figure 17C). Examination of HDM2 expression in relation
to survival in only the primary specimens followed the same trend, revealing improved
outcome for high expressers (p=0.0211) (Figure 17D). The quartile cut-points
established for AQUA scores in all specimens were maintained in evaluation of the
primary lesions.
Clinicopathologic Correlations:

Table 11 and Figure 17B demonstrate that decreased expression of FIDM2 is associated
with metastasis. Within primary lesions, there is a relationship between HDM2
expression and lesion progression. Table 12 demonstrates that HDM2 exhibits an
association with Breslow thickness, Clark level, and tumor infiltrating lymphocytes, but
not with microscopic satellites, ulceration, primary tumor location, age, or sex. These
data indicate that HDM2 expression decreases as lesions progress deeper into the dermis
(Breslow thickness and Clark level). Multivariate analysis revealed that HDM2 is not
independently predictive presumably due to its tight association with variables defining
depth of invasion (data not shown).
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Table 12. HDM2 Expression and Clinicopathologic Features of Primary Lesions
HDM2 Expression within Tumor Nuclei (Quartiles)
Bottom 25%
(n=31),
No. (%)

25-50%
(n=48),
No (%)

50-75%
(n=55),
No (%)

Top 25%
(n=66),
No (%)

0(0)

10(17.9)

16 (28.6)

30 (53.6)

1.01-2.Omm (T2)

7(15.6)

10(22.2)

15 (33.3)

13 (28.9)

2.01-4mm (T3)

9(18.8)

16(33.3)

13 (27.1)

10 (20.8)

>4mm (T4)

12(30.8)

9(23.1)

8 (20.5)

10 (25.6)

3

3

3

3

I

0(0)

0(0)

0(0)

0(0)

II

0(0)

0(0)

8 (38.1)

13 (61.9)

III

10(14.7)

19(27.9)

18 (26.5)

21 (30.9)

IV

14(17.5)

19 (23.8)

23 (28.8)

24 (30)

V

3(15)

8(40)

4(20)

5(25)

4

2

2

3

1 (2.1)

11 (23.4)

14 (29.8)

21 (44.7)

20 (20.2)

26 (26.3)

26 (26.3)

27 (27.3)

Absent

7 (16.3)

9(21.0)

13 (30.2)

14 (32.6)

Unknown

3

2

2

4

<60

9 (8.9)

27 (26.7)

30 (29.7)

35 (34.7)

>60

17 (20.2)

20 (23.8)

22 (26.2)

25 (29.8)

5

1

3

6

Present

12 (20.3)

15 (25.4)

17 (28.8)

15 (25.4)

Absent

14(11.4)

28 (22.8)

35 (28.5)

46 (37.4)

Factor

P value

Breslow Thickness
< lm m (T l)

<0.0001

Unknown

Clark Level

Unknown

0.0029

TILs
Brisk/Diffuse
N onbrisk/N ondiffuse

0.0392

Age
0.1797

Unknown

Ulceration
0.2585
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HDM2 Expression within Tumor Nuclei (Quartiles)
Bottom 25%
(n=31),
No. (%)

25-50%
(n=48),
No (%)

50-75%
(n=55),
No (%)

Top 25%
(n=66),
No (%)

5

5

3

5

Male

12(14.3)

19 (22.6)

27 (32.1)

26 (31.0)

Female

15 (15.3)

25 (25.5)

22 (22.5)

36 (36.7)

Unknown

4

4

6

4

Present

7(18.0)

9(23.1)

8 (20.5)

15 (38.5)

Absent

19(13.5)

33 (23.4)

44 (31.2)

45 (31.9)

Unknown

5

6

3

6

Axial

12 (15)

20 (25)

24 (30)

24 (30)

Extremity

9 (9.5)

26 (27.4)

25 (26.3)

35 (36.8)

10

2

6

7

Factor
Unknown

P value

Sex
0.5304

Microscopic Satellites
0.5535

Primary Tumor Location
0.5701

Unknown
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Discussion
HDM2 overexpression correlated positively with poor prognosis in sarcoma,
glioma, and pediatric acute lymphocytic leukemia, but negatively for non-small cell lung
cancer, ERa-positive breast carcinoma, and melanoma.279 Pathologist-based, traditional
analysis of HDM2 expression in a melanoma cohort of 134 patients demonstrated that
HDM2 over-expression was unexpectedly associated with improved survival.109 The
method of scoring used by Polsky et al. was based on a scale of nuclear
immunoreactivity, ranging from undetectable (0%) to homogeneous staining (100%).
Their choice o f cut point was based on prior experience with this antibody in other
cancers (i.e., bladder, prostate, squamous cell carcinomas, and sarcomas), in which the
20% cut point stratified patients in a clinically relevant fashion, but they acknowledged
that the appropriate cut points for cutaneous melanoma remain to be established.109
The continuous nature of AQUA scores makes it difficult to determine a cut-point for
survival analyses; however, expression of HDM2 diminished as lesions became more
invasive (Table 11 & Table 12, Figure 17B). Therefore, the AQUA scores of HDM2
expression were stratified into quartiles and survival curves were plotted to predict
outcome. In concordance with Polsky et al., we also found that high expression of
HDM2 predicted a favorable prognosis (Figure 17C). The ability to predict survival was
more apparent when the analysis was limited to primary lesions (Figure 17D).
The apparent paradox of HDM2 over-expression having a protective effect, was
suggested to indicate the presence of a functional p53 exerting an inhibitory effect on
tumor proliferation and activating the HDM2 promoter as part of its normal
autoregulatory feedback loop.109 The p53 tumor suppressor plays a critical role in the
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cellular response to DNA damage, preventing altered, pre-malignant cells from
progressing to cancer. In response to DNA damage, the p53 protein initiates a variety of
stress-specific transcriptional response programs that lead to growth arrest, apoptosis, or
senescence.276 In addition to inducing these response programs, p53 also tightly regulates
its own intracellular level via an autoregulatory feedback loop with HDM2.
Transcription o f HDM2 is stimulated by p53, and HDM2, in turn, directly ubiquintinates
p53 and targets it to proteasomal degradation.278 Recent experiments by Lahav et al. on
the dynamics of the p53-MDM2 feedback loop demonstrate that this negative-feedback
system functions in a ‘digital’ fashion, in which expression of repair enzymes occurs in
defined linear quanta rather than a binary switch-like (all-or-nothing) response.288 Cells
probably express frequent pulses of HDM2 induction when exposed to damage, and
histologic sections may represent a snapshot of this dynamic result. That is, a set of cells
undergoing pulses that are more frequent would be more likely to be expressing HDM2 at
the time of excision and fixation.
However, in light of all the examples demonstrating the regulatory functions of
MDM2/HDM2 on p53, there is mounting evidence demonstrating p53-independent
functions of HDM2.289 This protein has been shown to interact with multiple factors
(e.g., ARF, MDMX, ATM, c-abl, H IF-la, RB, PML, E2F) that can play a role in
transformation, affecting cell cycle control, differentiation, DNA synthesis, RNA
biosynthesis, transcription, and cell surface receptor turnover.290 Like p53, which plays
roles in both transcriptional regulation and mediation of apoptosis in mitochondria

291

,

HDM2 may also have a second role, unrelated to its interaction with p53. It should also
be noted that a number of other oncoproteins, such as Ras

292 293

’

, Raf-1

294

, and Bcl-2
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295

,

have recently been shown to possess secondary, growth inhibitory functions. These dual
function oncoproteins, including HDM2, may be essential to the proliferation of normal
cells equipped with growth suppressor activities that have not been fully characterized.296
The AQUA system provides a unique method for the analysis of tissue
microarrays not previously possible using standard pathologist-based techniques. The
system is precise, highly reproducible and quantitative resulting in continuous
measurements similar to that obtained from ELISA assays. In addition, AQUA allows
for accurate subcellular localization, with the ability to discriminate between the
cytoplasmic and nuclear compartments in melanoma cells. With increased resolution, the
analyses will expand to include additional ‘virtual’ compartments (e.g., mitochondria,
lysosomes, endoplasmic reticulum, Golgi, etc.). The system has been effectively
demonstrated on colon

271

272

, breast

, and prostate

273

carcinomas. The automated nature of

this technology can allow high-throughput screening of tissue microarrays, facilitating
their use in discovery of chemotherapeutic targets and biomarker validation.
In summary, AQUA-based analysis was used to demonstrate that HDM2 is a
marker of melanoma progression. As might be expected of a marker of progression, it is
also useful for prognostication independent of all conventional histologic markers except
those related to tumor depth of invasion. In primary lesions, this biomarker may
represent a mechanism to predict survival in a tumor type without standard molecular
tools for prediction of outcome.
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Chapter 4: Automated Quantitative Analysis of AP-2 subcellular expression in
Melanoma Tissue Microarrays Correlates with Survival Prediction

Abstract
The activator protein-2a (AP-2) transcription factor plays a key role in regulating the
expression of many genes involved in tumor growth and metastasis of human melanoma.
Loss of AP-2 expression has been shown to result in the deregulation of several genes
with AP-2 binding motifs such as c-Kit, MCAM/MUC18, MMP-2, and PAR-1
expression, all of which contribute to the increased metastatic potential of human
melanoma. In this study, we sought to assess the prognostic significance of AP-2
expression and its role in the transition of nevi to radial growth phase (RGP) and to
vertical growth phase (VGP, metastatic phenotype) in human melanoma. Two cohorts
were analyzed using the tissue microarray format. The first was a “progression” array
containing melanoma specimens from M.D. Anderson Cancer Center representing 168
melanocytic cores (84 individual cases) from benign nevi (BN, 19), dysplastic nevi (DN,
21), radial and vertical growth phase melanoma (MM, 22) and metastatic melanoma
(MMM, 27). The second array was a retrospective cohort collected at Yale University
representing 214 primary melanomas and 293 metastases with long term clinical follow
up. The MDCC array was analyzed using Laser Scanning Cytometry (LSC) and Yale
array was analyzed using Automated Quantitative Analysis (AQUA) systems for analysis
of AP-2 expression, respectively. Both systems permit the continuous and quantitative
analysis of protein expression at the single cell level, including sub-cellular localization,
in tissue sections. Analysis of total AP-2 expression using two, independent quantitative
systems revealed no correlation with diagnosis group (i.e., BN, DN, MM, or MMM).
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Laser Scanning Cytometry (LSC)-mediated sub-cellular analysis demonstrated that the
nuclear expression of AP-2 was highest in the BN group (11.85%) and significantly
decreased in each phase of melanoma progression to 0.39% in the MMM group. Using
Automated Quantitative Analysis (AQUA™)-based analysis, neither nuclear nor
cytoplasmic expression levels correlated with outcome. However, the ratio of
cytoplasmic over nuclear AP-2 was highly predictive of outcome in the entire population,
as well as in the primary tumors alone. Furthermore, the AP-2 ratio directly correlated
with other clinicopathological factors such as Breslow depth (R=0.334, p < 0.001).
Employing two different automated quantitative systems, we demonstrate that a high
level of AP-2 expression in the cytoplasm relative to the nucleus correlates with poor
prognosis. Together, these results confirm the biological hypothesis and provide
quantitative evidence that the loss of AP-2 expression in the nucleus is associated with
malignant transformation and progression of melanoma.
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Introduction
The incidence and mortality rate of melanoma has increased significantly over the
last fifty years, with more than 59,000 new cases expected this year.

297

This increase in

incidence combined with the lack of effective therapy for advanced melanoma
emphasizes the need to develop better markers that correlate with clinical outcome.
Since the 1970s, the Breslow depth and Clark level of invasion remain the most widely
used and reliable predictors of survival in primary melanoma.

298 299

’

However, withm

each stage of melanoma there is a significant variability in outcome. Thus, more accurate
molecular markers for melanoma progression are needed to stratify and treat patients with
malignant melanoma.
Previously, our collaborators have shown that the 52-KDa transcription factor
Activator Protein 2-a (AP-2) is involved in the progression and metastasis of human
melanoma through the regulation of several target genes such as c-KIT, MCAM/MUC18,
E-cadherin, p 21, PAR-1 and MMP-2 genes.300'305 The loss of AP-2 results in the
suppression of endogenous AP-2 transactivator function that may inhibit melanoma cells
^AA

to respond to growth and differentiation-regulatory signals.

AAH

’

Furthermore,

inactivation of AP-2 by means of dominant-negative AP-2 gene resulted in an increase of
tumorigenicity and metastasis potential in primary cutaneous melanoma cells. 302 Indeed,
screening human melanoma cells in vitro for AP-2 protein expression has shown that the
majority of highly metastatic cells express low levels of nuclear AP-2.
Few studies have evaluated AP-2 immunohistochemical staining in melanoma
prognosis.306,309 These studies, however, were based on individual cases or on small
patient cohorts using semiquantitative methods. Manual quantification is limited by the
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pathologist’s ability to detect low level staining patterns with the eye, rapidly and
reproducibly score on a continuous scale, and accurately quantify subcellular expression
levels. In addition, the analysis of histological sections is complicated by the fact that
tumor tissue contains a heterogeneous mixture of cell types, necrotic regions and
extracellular material. Better research tools are needed to facilitate discovery of
molecular markers of prognosis that reduce variability often observed using antibodybased techniques.
Tissue microarrays provide a high-throughput approach to simultaneously screen
hundreds o f patient samples in a uniform fashion.310,311 Analysis of tissue arrays permit
the molecular profiling of a large number of different molecules at the DNA, RNA, and
protein levels that are potentially involved in tumor development and/or progression.

'ii')

’

313 Microarray technology reduces the variability between specimens because all tissue
cores on the slide are simultaneously exposed to the same technical conditions. Another
benefit of tissue microarrays is that automated quantitative analysis systems such as LSC
or AQUA can be used to generate accurate, reproducible measurement of antigen
levels.314'316 Consistent measurements made across thousands of cells can help identify
subtle differences in expression that are not easily detectable by the human eye.

317

Furthermore, quantitative analysis provides continuous scoring as opposed to pathologistbased categorical scoring. This is particularly important when validating putative
prognostic markers that display large variation in expression, especially when analyzing a
large cohort as in a tissue microarray.
Here we report two innovative, automated quantitative analysis systems, LSC and
AQUA, to measure the subcellular expression of AP-2 in two independent melanoma
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tissue microarrays. The LSC platform combines features of both flow and static image
cytometry analysis. LSC data acquisition captures quantitative information by detecting
single cell nuclei in tissue sections, eliminating the need to acquire multiple images for
performing complex algorithms. For this study, LSC-mediated analysis of AP-2 was
performed by using Melanoma Antigen Recognized by T Cells l(M ART-l) to detect
melanocytic cells. MART-1 or Melan-A is a recently discovered melanocyte
■3 1 O

differentiation antigen recognized by autologous cytotoxic T lymphocytes.

The gene

that encodes MART-1 is expressed in retina, skin, and melanocytic cell lines thereby
making it an ideal marker for automated detection of melanocytes.319
AQUA uses a pair of novel algorithms that allow highly reproducible analysis of
target expression in subcellular compartments in tissue sections. Validation using the
AQUA system has been previously reported.314 This system identifies tumor tissue
within each histospot based on the expression of tissue-specific proteins (such as SI 00)
and then evaluates the expression of target antigen, e.g., AP-2, within the tumor mask and
inside user defined subcellular compartments. Because SI 00 is expressed in 98% of all
melanomas

320

, this protein has been used to create the tumor mask in melanoma.

315 321
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Recently, AQUA was used to demonstrate that HDM2 is a marker of melanoma
progression and may be used to predict survival in primary lesions.315 Thus, AQUA is
designed to read tissue microarrays and optimized for high throughput quantitative
analysis.
We hypothesized that AP-2 should be active in the nucleus while cytoplasmic
expression should be associated with loss of function. Employing two independent
automated quantitative analysis systems, we further demonstrate herewith that the loss of
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AP-2 in the nucleus is a crucial event in the progression of human melanoma and that
subcellular localization of AP-2 is the critical factor in predicting survival.
Materials and Methods
Patients and Case Selection

Specimens obtained from the Department of Pathology, M.D. Anderson Cancer
Center consisted of 84 cases comprised of melanocytic lesions including benign nevus
(19), dysplastic nevus (21), primary melanoma (22, including superficial spreading,
nodular, acral, and lentigo malignant melanoma, and metastatic melanoma (27) to
subcutaneous tissue, lymph node and visceral organs, and normal melanocyte controls
(8). Specimens obtained from the Department of Pathology, Yale University consisted of
214 primary melanomas, 293 metastases, 14 local recurrences, 22 nevi and 15 cell block
controls. The specimens were resected between 1959 and 1994, with a median follow-up
time o f 60 months. Both studies involving human tissues were approved by the
Institutional Review Board at each institution.
Tissue Microarray Construction

Tissue sections from each block were stained with hematoxylin and eosin (H&E)
and reviewed by a pathologist to define the selective areas to be punched. To preserve
the original tissue block, either 0.6 mm (biopsies) or 1.0 mm (excision specimens)
cylindrical cores of tissue were punched out from donor blocks. Selected tissue cores
were inserted in a standard 4.5 x 2 x 1 cm recipient block using a Tissue Microarrayer
(Beecher Instruments, Silver Spring, MD, USA) with an edge-to-edge distance of 0.1 or
0.15 mm.
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The tissue microarrays were then cut to 5 |im sections and placed on glass slides
using an adhesive tape transfer system (Instumedics, Inc., Hackensack, NJ) with UV
cross-linking. One section from each array was stained with H&E to verify the presence
o f diagnostic lesional cells and to facilitate case selection for LSC and AQUA-mediated
quantitative analysis. At least two cylindrical cores from each case were obtained to
construct the three tissue microarrays evaluated at M.D. Anderson Cancer Center as
previously described316. Two tissue microarrays were constructed at Yale University,
with cores (0.6mm) taken from different parts of the tumor for each microarray as
previously described

315
.

Immunofluorescent Detection of MART-1 and AP-2 for Laser Scanning Cytometry
Analysis

Sections (5 pm) were prepared from each block, deparaffmized in xylene,
rehydrated in alcohol, and transferred to PBS. Antigen retrieval was performed by
steaming using antigen retrieval solution (Dako, Carpinteria, CA) by boiling tissues in 10
mM citrate buffer, pH 6.0 for 10-20 minutes followed by cooling at room temperature for
20 minutes. Next, tissues were washed three times for 3 minutes with PBS and incubated
with protein block (5% normal horse serum in PBS) for 15 minutes at room temperature.
Protein block was drained, and tissues were incubated with a 1:50 dilution of rabbit antiAP-2 (Serotec, Raleigh, NC) in protein block overnight at 4°C. Tissues were washed
with PBS three times for 3 min. Avoiding exposure to light, tissues were incubated with
a 1:400 dilution o f secondary goat anti-rabbit conjugated to Alexa 488 for 2 h at room
temperature. Tissues were washed with PBS containing 0.1% Brij for 3 minutes two
times, and once with PBS for 3 minutes. Next, tissues were incubated with a 1:200
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dilution of mouse monoclonal anti-MART-1 (Dako) in protein block overnight at 4°C.
Tissues were washed with PBS three times for 3 min and then incubated with a 1:400
dilution of secondary anti-mouse conjugated to phycoerythrin (PE). Tissues were washed
with PBS three times for 3 minutes and incubated with 1 pg/ml propidium iodide for 10
minutes at room temperature to counterstain total cell nuclei.
Laser Scanning Cytometry Analysis

Laser Scanning Cytometry (CompuCyte Corporation, Cambridge, MA) combines
flow cytometry, image analysis, and automated fluorescence microscopy to enable
fluorescence-based quantitative measurements at the single cell level. The LSC consists
of an Olympus BX50 fluorescent microscope and a computer controlled optics unit
coupled to an Argon, HeNe, and Violet laser. Multiple lasers are used to simultaneously
excite different fluorochromes in cellular specimens that emit discrete wavelengths
detected by a set o f photomultiplier tubes. Together these features permit the ability to
generate high-content stoichiometric data on heterogeneous populations of large numbers
of cells. Thus, the LSC was used very much like a fluorescent activated cell sorter
(FACS) to obtain three-color immunofluorescence intensity information from the tissue
microarrays.
We selected each fluorochrome based on the experimental endpoint of the study
and compatibility with the LSC. Importantly, each probe was independently tested to
ensure non-overlapping emission between filters. Propidioium iodide was used as a
nuclear counterstain to contour and quantify single cells within each tissue core. To
determine subcellular expression of AP-2, the peripheral contouring feature was selected
to simultaneously analyze the cytoplasmic versus nuclear expression level. Using the
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Wincyte™ software, Argon and HeNe lasers were selected with the appropriate filters to
detect red (cell nuclei), long-red (MART-1) and green (AP-2) fluorescence. Once the
scan region was selected using the epifluorescent microscope, slides were scanned using
a 200x objective and detector gain voltages were set so that a maximum of 50%
saturation was achieved for the brightest maximum pixel event scanned for each
fluorochrome. The minimum area threshold was set to optimize contouring of single cell
nuclei. To determine the percentage of MART-l-positive/AP-2-positive cells, a
scattergram was created to define four quadrants that determined which cells were
positive. Each gate of the scattergram was set based on the fluorescent properties of the
negative control sample stained with each fluorescent probe. Once each slide was
scanned, the data file was replayed to determine the percentages of each cell population,
e.g., MART-1-positive/AP-2-positive cells for each tissue core. AP-2-positive cells were
analyzed separately for nuclear or cytoplasmic expression. The relocation feature was
used to confirm positive cellular expression.
Immunofluorescent Detection of S100 and AP-2 for AQUA Analysis

The tissue microarray slide was stained as described previously.314,315 In brief,
the slides were deparaffmized by rinsing with xylene, followed by two changes of 100%
ethanol and two changes of 95% ethanol. Antigen retrieval was performed in a pressure
cooker containing 6.5 mmol/L citrate (pH 6.0) and endogenous peroxidase activity was
blocked with 2.5% hydrogen peroxide in methanol for 30 minutes at room temperature.
The slide was washed with Tris-buffered saline (TBS), incubated in 0.3% BSA/1X and
TBS for 30 minutes at room temperature to reduce nonspecific background, and then
stained with a combination of rabbit anti-AP-2 (Cl 8) (1:1600, Santa Cruz Biotechnology)
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and mouse monoclonal anti-SlOO, AM058 (Biogenex, San Ramon, CA) diluted in
BSA/TBS at 4°C overnight. The secondary antibodies, Alexa 546-conjugated goat
antirabbit (1:200, Molecular Probes, Eugene, OR) plus Envision antirabbit (neat; DAKO)
diluted in BSA/TBS were applied for 1 hour at room temperature. 4', 6-Diamidino-2phenylindole (DAPI) was included with the secondary antibodies to visualize nuclei. The
slide was washed with BSA/TBS (three times for 5 minutes) and then incubated with
Cy5-tyramide (Perkin-Elmer Life Science Products, Boston, MA) and activated by
horseradish peroxidase, resulting in the deposition of numerous covalently associated
Cy5 dyes immediately adjacent to the horseradish peroxidase-conjugated secondary
antibody. Cy5 was used because its emission peak (red) is well outside of the greenorange spectrum of tissue autofluorescence. The slides were sealed with coverslips with
an antifade-containing mounting medium (with 0.6% n-propyl gallate).
Automated Image Acquisition and Analysis.

The AQUA automated image acquisition and analysis was performed as described
previously.314 Briefly, images of the tissue microarray were captured through an
Olympus BX51 microscope with automated x, y, and z stage movement with an Olympus
Motorized Reflected Fluorescence System and software (IP lab v3.60, Scanalytics, Inc.,
Fairfax, VA) equipped with Cooke Sensicam QE High Performance camera. Low-power
images of the microarray were stitched together with multiple low-resolution images of
the microarray (64 X 64 pixels) at ~7-pm resolution. Areas of tumor were distinguished
from stroma and non-melanoma tissue by creating a mask with the S I00 signal tagged
with Alexa 546. Expression o f SI 00 protein was used to identify the tumor mask and 4',
6-diamidino-2-phenylindole (DAPI) was used to identify the nuclear compartment.
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Areas of the tumor mask without DAPI were considered 'nonnuclear' or 'cytoplasmic'.
The target marker, AP-2, was visualized with Cy5 (red). Rows and columns of the
histospots were then identified, missing histospots filled in, allowing each histospot to be
identified by its coordinates, and recorded based on its position in the grid. Subsequently,
monochromatic, high-resolution (1024 X 1024 pixel, 0.5-pm resolution) images were
obtained of each histospot, both in the plane of focus, and 8 pm below it, and recorded in
an image stack as bitmaps. A resolution of 0.5 pm is suitable for distinguishing between
large subcellular compartments such as the cell membrane/cytoplasm and nuclei. The
AP-2 signal from the cytoplasmic and nuclear compartment within the S100 tumor mask
was measured on a scale of 0 to 4095 and expressed as target signal intensity relative to
the respective cytoplasmic or nuclear compartment area.
Statistical Analysis

The number o f MART-1 and AP-2 positive cells was compared between the
diagnosis groups using a Kruskal-Wallis test or a Wilcoxon rank-sum test, as appropriate.
The M.D. Anderson Cancer Center tissue microarray was designed to assess markers
along the progression of normal melanocytic lesions to metastatic melanoma and was not
designed to be a prognostic array. Therefore, sub-cellular localization of AP-2
expression from the Yale University tissue microarray was used to determine its
association with melanoma-specific survival. The association between the consensus
score and AP-2 expression and clinicopathological parameters was assessed using the
Chi-square test. The prognostic significance of the clinicopathological parameters was
assessed for predictive value using the univariate and multivariate Cox proportional
hazards model with melanoma-specific survival as an end point. Survival curves were
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calculated using the Kaplan-Meier method, with significance evaluated using the MantelCox log-rank test. All analyses were performed using JMP or SAS (SAS Institute Inc.,
Cary, NC) at a significance level of 5%.
Results
Immunofluorescent staining of Melanoma Tissue Microarrays.

Previously, it has been reported that the progression of human melanoma is
associated with the loss of nuclear AP-2 expression in metastatic melanoma.301'303’306,309
Our results have been confirmed by other studies using tumor specimens. These studies,
however, were based on standard immunohistochemical analyses of total cellular AP-2
expression in primary tumors or human melanoma cell lines using semiquantitative
methods.
To simultaneously measure AP-2 expression in MART-1 or SI 00-positive cells
by LSC or AQUA, respectively, specific labeling conditions were established for optimal
data acquisition. For LSC, we selected fluorescent probes that were compatible with the
laser and filter configuration to minimize non-specific emission and false-positive
signals. Likewise, probes outside the spectrum of tissue autofluorescence were selected
for use with the AQUA system Tissue microarrays stained with anti-MART-1 (Figure
18A) or S I00 (Figure 18B) and anti-AP-2 were visually inspected to verify the quality of
immunofluorescent antigen detection. A serial section from each tissue microarray was
stained with hematoxylin and eosin (H&E) to pathologically verify the presence of
diagnostic lesional cells and facilitate selection of the scan region, excluding unwanted or
necrotic regions from the analysis. Tissue cores deemed uninterpretable had insufficient
tumor cells in the spot, loss of tissue, or large areas of necrotic tissue.
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F ig u r e 1 8 . Automated detection of AP-2 in melanocytes. Tissue microarrays were immunofluorescently

stained for A, MART-1 (red) orS , S100 and AP-2 (green) as described in Materials and Methods. A, A
representative LSC-generated image of a case from a DN reveals optimization o f antigen detection for
MART-1 and AP-2. Co-localization o f MART-1 and AP-2-positive cells appears yellow in the overlay
image. Original magnification, x200. B, Representative images display tissue cores evaluated by the
AQUA system for compartment-specific expression of AP-2. S100 protein (visualized under the 546
wavelength; green) defines the melanoma mask and DAPI (blue) defines the nuclear compartment. The
compartment-specific AQUA scores were determined within the melanoma nuclear and melanoma non
nuclear (i.e., cytoplasmic) compartments. Note that the primary melanoma displays strong AP-2 nuclear
expression (nuclear compartment, 842; cytoplasmic compartment, 270) and the metastatic melanoma core
reveals strong AP-2 cytoplasmic staining (cytoplasmic compartment, 781; nuclear compartment, 490).
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Automated Analysis of AP-2 Expression in Melanoma.
The M. D. Anderson tissue microarray was designed to assess markers in the
progression o f melanoma and not prognosis. Therefore, LSC- and AQUA-based analyses
were used to characterize the subcellular expression pattern of AP-2 in each diagnosis
group. Peripheral contouring capabilities of the LSC permit the simultaneous
measurement of expression in the cytoplasm and nuclear compartment of each cell nuclei
(Figure 19A). Because expression of MART-1 has been shown to be a prognostic factor
for cutaneous melanoma 322, we first used the LSC to measure the number of MART-1positive cells in each diagnostic group (Figure 19B, quadrants 2 and 4). Importantly,
three-color quantitative analysis demonstrated no significant difference in the number of
MART-1-positive cells between the benign nevi, dysplastic nevi, primary or metastatic
melanoma groups (Table 13). We therefore used MART-1 as a melanocytic reference for
LSC automated analysis of AP-2 in each diagnostic group. After scanning each tissue
microarray, the nuclear and cytoplasmic levels of AP-2 in MART-1-positive cells were
determined by selecting each case using LSC-generated coordinate position maps and
replaying the data file (Figure 19B). LSC-mediated analysis revealed a statistically
significant decrease (p < 0.0001) in nuclear expression of AP-2 in the benign nevi group
(11.85%) to a complete loss of AP-2 (0.39%) in the metastatic melanoma group (Figure
19C). In contrast, cytoplasmic expression o f AP-2 significantly increased (p < 0.001)
with melanoma progression (Figure 19D).
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Figure 19. LSC-based quantitative analysis of subcellular AP-2 expression. A, LSC-mediated peripheral
contour analysis. A representative LSC-scanned image of a single cell indicates the nuclear contour (red
outline) and peripheral or cytoplasmic boundaries (two yellow lines). During laser scanning, quantitative
information is acquired for each compartment (nuclear or cytoplasmic) based on the fluorescent intensity of
each probe. Original magnification, x400, digital magnification 4X. B, Stained tissue microarrays were
scanned by LSC and individual cases from each diagnostic group were selected from the tissue map to
determine the number of MART-1 and AP-2 positive cells (quadrants 2). Representative scattergrams from
a BN and MMM case reveal that the percentage of MART-1-positive cells (x-axis) and AP-2-positive cells
(y-axis) decreased 8-fold, from 16% in the BN to 1.9% in the MMM group (quadrant 2 ). Gates were set
based on the negative staining controls. Note that the number of MART-1-positive cells (quadrants 2 and
4) was similar between the two groups (approximately 17%). C, Nuclear expression of AP-2 from each
case were analyzed. A box plot displays the median (middle line) and the minimum and maximum range
(outside lines) of MART-l/AP-2-positive cells by diagnosis group. D, Cytoplasmic expression of AP-2.
Levels of AP-2 cytoplasmic expression from each case were analyzed using a Kruskal-Wallis test as
described in Materials and Methods. A box plot displays the median (middle line) and the minimum and
maximum range (outside lines) of MART-l/AP-2-positive cells by diagnosis group. Note that the median
levels of AP-2 slightly increased with progression of melanoma.

Table 13. Characteristics of Tissue Cores Analyzed using LSC.

Group
Benign Nevi
Dysplastic Nevi
Melanoma
Metastatic Melanoma

n No. of Cells Analyzed per Core
18
287 ± 402
21
265± 196
20
1450± 1082
27
420 ±315

No. of MART-1 Cells3
18% ±3.53
17% ±2.82
14% ±7.77
16% ±2.82

aNo significant difference between groups

A different section of the same TMA was analyzed by AQUA, in which S100 was
used to detect the cells of melanocytic origin and DAPI was used to define the nuclear
compartment. The melanoma-specific cytoplasmic compartment was defined by
subtracting the DAPI image from the S I00 image (after appropriate gating). Although
overall expression of AP-2 tended to increase in the progression from benign nevi to
malignant melanoma (Figure 20A & B), there were significant differences in the ratio of
cytoplasmic to nuclear expression relative to lesion progression. Advanced lesions
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demonstrated significantly more cytoplasmic over nuclear AP2 relative to benign nevi
(Figure 20C and Table 14).
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Table 14. Subcellular Expression of AP-2 by Tissue Type
Group

n

N ucleus
M ean (SE)

Cytoplasm
P '

B enign rsevi

15

9 4 2 ,3 9 (4 1 4 4 }

Oysplahiiie nevi

13

1,032.23 ( 60.28)

03615

P :

M ean (SE)

0.1531

642.08 (38228)

Ratio

p.

p ’

M ean (SE)

0.0007

0.68 ( 0.03)

P
<0.01X11

717.22 (50.95)

0.2-119

0.70 (0.02)

0.6772

M e la n o m a

16

1,185.06 (76.08)

0.1550

912.77 (42.091

0.0059

0.80 (0.04)

O.Ot 14

M e ia s la lic r a d a m im a

23

3.041,62 (76,87 )

0.2055

945.48 (69,80)

0.7213

0.91 (0.03)

0.017)

'/

te st c-om piired w ith g ro u p above.

*ANOVA.

Survival Analysis and Clinicopathological Correlations.

The decrease in nuclear AP2 and increase in cytoplasmic AP2 with progression
suggested that the differential expression pattern may be useful as a prognostic marker in
melanoma. To assess this, we analyzed a cohort of nearly 600 cases of melanoma collected
retrospectively at Yale University Department of Pathology. In order to assess this large
cohort, a second fluorescence-based system of automated analysis was used.

After image

acquisition for each tissue core, AQUA was performed to establish the intensity of AP-2
expression per unit area within each core. Consistent with our LSC-generated results, strong
nuclear AP-2 expression was noticeable in the primary melanoma cores whereas the
metastatic cores displayed diffuse cytoplasmic staining (Figure 18B). Therefore, the
cytoplasmic and nuclear AP-2 expression levels generated from the Yale University tissue
microarray were used to determine their potential association with melanoma-specific
survival. Statistical analysis of total AP-2 expression revealed no significant association with
survival (data not shown). Hazard ratios determined by Cox univarate analysis of the AQUA
scores for cytoplasmic and nuclear AP-2 expression were 1.000 (95% Cl: 1.000-1.001,
p=0.4846) and 1.000 (95% Cl: 0.999-1.000, p=0.2969), respectively. When analyses were
restricted to primary melanoma specimens, the HR’s remained non-significant. In contrast,
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analysis of the subcellular levels of AP-2 (ratio of cytoplasmic to nuclear expression)
revealed a significant association with metastases (p < 0.01) and survival [HR: 2.795 (95%
Cl: 1.609-4.857, p=0.0003), Figure 21A and Table 15]. In the primary specimens, the AP-2
ratio maintained prediction of poor survival [Relative Risk 4.337 (95% Cl: 1.294-14.536, p =
0.0174), Figure 21B and Table 15]. Analysis of other clinicopathological factors revealed
that the AP-2 ratio correlated with Breslow depth (R=0.334, p < 0.001, not shown), and was
associated with microscopic satellitosis (p = 0.0373, not shown). Continuous AQUA scores
were then divided into quartiles, based on the size of the cohort, reflecting the use of routine
statistical divisions in the absence of an underlying justification for division of expression
levels. Kaplan Meier analysis of the cohort is shown in figure 3. Using the ratio of
cytoplasmic over nuclear AP-2 shows that the ratio is highly predictive of outcome, in both
the total cohort (Figure 21A) and the subset of only primary lesions (Figure 21B). Log rank
values for each are highly statistically significant (p<0.0001 and p=0.0094, respectively).
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Figure 21. Melanoma tissue microarray analysis of subcellular AP-2 expression using AQUA. Kaplan-Meier
survival curves were generated for AP-2 compartmental expression for the A, overall cohort and B, primary
melanoma, with time given in months, showing the four quartiles of intensities of cytoplasmic to nuclear
expression.

Table 15. Cox U nivariate Survival A nalysis o f C ontinuous V ariables.
Compartmentalized AQUA Score
AP2 in Cytoplasm
A.P2 in Nucleus
AP2 Ratio (Cytoplasmic
AP2/Nuclear AP2)

All Specimens
(H R (95% Cl))
1.000
(1.000-1.001)
1.000
(0.999-1.000)
2.795
(1.609-4.857)

P
value
0.4846
0.2969
0.0003

Primary
Specimens
1.000
(0.999-1.001)
1.000
(0.999-1.001)
4.337
(1.294-14.536)
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p value
0.7540
0.4927
0.0174

To assess the independent predictive value of the AP-2 ratio, we performed a
multivariate analysis on the primary cutaneous lesions. In addition to the AP-2 ratio, we
included the following histopathologic variables in a Cox proportional hazards model:
Breslow depth, Clark level, ulceration, microscopic satellites, tumor-infiltrating lymphocytes.
The model (Table 16) demonstrates that the AP-2 ratio maintains prognostic significance
(p=0.0082) after adjustment for the standard prognostic factors.
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Table 16. Multivariate Suvival Analysis of AP2 Expression Pattern and Standard
Histopathological Variables Among Primary Lesions
Variable
Tumor Infiltrating Lymphocytes
(Absent vs. Present)
Breslow Depth
(>2.00 mm vs. <2.00 mm)
Clark Level
(IV-V vs. I-III)
Ulceration
(Present vs. Absent)
Microscopic Satellites
(Present vs. Absent)
Cytoplasmic by Nuclear AP2 Ratio
(Top 25% vs. Bottom 75%)

Hazard Ratio (95% Cl)

p value

3.44(1.52-7.76)

0.003

2.18(1.11-4.25)

0.0229

1.57 (0.79-3.13)

0.2022

1.29 (0.77-2.17)

0.3267

0.96 (0.55-1.70)

0.9003

2.14(1.22-3.76)

0.0082

Discussion
Our goal in this study was to quantitatively assess the subcellular expression of AP-2
on a large cohort o f melanoma specimens. Using two independent, automated quantitative
systems to evaluate localization of AP-2 expression in two independent tissue microarrays
from two separate institutions, we reached the same conclusion. Specifically, we
demonstrate for the first time that the ratio of AP-2 cytoplasmic to nuclear expression pattern
correlates with both progression of melanocytic lesions and survival.
Because AP-2 is a transcription factor, we hypothesized that AP-2 should be active in
the nucleus, while cytoplasmic expression should be associated with loss of function.
Analysis of the cohort from The University o f Texas M. D. Anderson Cancer Center using
LSC revealed almost a complete loss of AP-2 nuclear expression in the metastatic melanoma
group. Our results are consistent with other studies demonstrating that AP-2 is lost in
metastatic melanoma.306,309 However, most of these studies were based on categorical
scoring of total cellular expression and were not able to distinguish subtle expression patterns
between cellular compartments. Application of the LSC and AQUA automated quantitative
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analysis revealed that the ratio between cytoplasmic to nuclear AP-2 expression changes with
melanoma progression. Together, these data strongly suggest that translocation of AP-2 from
the cytoplasm to the nucleus is disrupted during melanoma progression by an unknown
mechanism. Our findings suggest that changes in subcellular AP-2 expression in
melanocytes, particularly from benign nevi to dysplastic nevi (2-fold decrease), is a critical
step in the genesis and progression of melanoma. Automated analysis of subcellular AP-2
expression in melanocytes may serve as a sensitive marker to monitor the progression of
melanoma. It seems therefore, that the major deficiency in AP-2 activity in metastatic
melanoma is the loss of nuclear translocation. We hypothesize that this deficiency may be
due to changes in the nuclear translocation signal within the AP-2 protein itself or
modifications in other chaperone or ‘cargo’ proteins. The precise mechanism is being
investigated in the laboratory of our collaborator, Menashe Bar-Eli.
Both the LSC and AQUA systems offer advantages for quantitative analyses of tissue
microarrays that are not practical using conventional methods. LSC-based quantification lies
in its analytical power: tens of thousands of cells can be analyzed in a consistent manner
between each tissue section, as opposed to hundreds of cells typically evaluated using
conventional immunohistochemistry. Here, we demonstrate the peripheral contouring
feature of the LSC which allows for accurate quantification of cytoplasmic and nuclear
protein expression. In addition, the laser platform has the ability to simultaneously quantify
up to five fluorescent probes and determination of positive and negative is accomplished
objectively by gating against staining controls.323 Together, these features permit
investigators to evaluate levels of a protein in specific cell types, e.g., AP-2 in MART-1 or
S100-positive cells, in a manner that is more reproducible between tissue cores and generates
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consistent results in the hands of different investigators. The PM-1000 device and
subsequent AQUA analysis is similarly quantitative. AQUA based quantitative analysis of
AP-2 expression results in continuous scores that are directly proportional to the
concentration, rather than subjective pathologist-based divisions of staining into categorical
scores (0-3) or ‘positive’ and ‘negative’. Both automated systems are excellent for analysis
of subcellular localization, but the PM-1000 does not require laser illumination and has a
much higher throughput which makes it ideal for analysis of large tissue microarrays as the
one in this study. Thus, the ability to quantify subcellular localization of markers using
automated, quantitative-based systems may be crucial in assessing their potential as
prognostic indicators when analyzing tissue microarrays.
To further confirm whether the changes in AP-2 subcellular expression had any
potential prognostic benefit, we used the AQUA system to analyze a separate tissue
microarray containing a much larger cohort of melanoma specimens from Yale University.
Statistical analyses of nuclear or cytoplasmic AP-2 expression levels alone were not
significantly associated with survival, suggesting that there may be case to case variability
that obscures the overall analysis. Intriguingly, the ratio of cytoplasmic to nuclear AP-2
expression levels correlated with survival, with high levels in the cytoplasm predicting an
unfavorable outcome. These results illustrate the power of the ratio. Case to case variability,
either real or artifact, is internally normalized by calculation of a ratio.
Heterogeneity is often an issue that is difficult to assess, but is generally addressed by
repetition of the analysis with a second set of tissue cores (second fold redundancy). Indeed,
these results were reproducible using a second melanoma tissue array containing different
cores from the same patients suggesting that the levels of AP-2 are homogenously expressed
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throughout the tumor. Furthermore, the subcellular expression patterns of AP-2 obtained
using AQUA were further confirmed by their consistency using LSC to analyze a separate
cohort.
This study demonstrates two powerful methods for automated, quantitative profiling
of tissue microarrays. The automated nature of LSC and AQUA-based technology should
facilitate high-throughput molecular profiling of tissue microarrays for use in a variety of
applications such as target discovery and prognostic and diagnostic biomarker validation.
When compared with conventional immunohistochemistry, these methods demonstrate the
importance of quantifying expression based on fluorescence and subcellular localization.
The ratio-based data would not be achievable using traditional DAB-based staining methods.
Thus, the LSC and AQUA systems provide a useful tool for quantitative analysis of
compartmental protein expression in a reproducible fashion, free of the subjectivity
associated with pathologist-based scoring.
In summary, the data presented here add further support that the loss (or cytoplasmic
translocation) of nuclear AP-2 is a crucial event in the progression of melanoma. Two
quantitative methods, AQUA and LSC, were used successfully to demonstrate the
importance of quantifying compartmental AP-2 expression and provide evidence that the loss
of nuclear AP-2 correlates with progression in melanocytic lesions and also, when calculated
as a ratio, predicts survival.
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Chapter 5: Improvement of Outcome Prediction in Primary Cutaneous Melanoma by
Multiplexed Quantitative (AQUA™) Analysis of Tissue Biomarkers

Abstract
OBJECTIVE: Breslow depth is currently the most reliable predictor of metastatic potential
and clinical outcome in primary cutaneous melanoma. We hypothesize that multiplexed
analysis of in situ protein expression in melanoma could augment the prognostic value of
Breslow depth.
METHODS: A 521-case tissue microarray, including 214 primary melanomas, 293
metastases, and a series of controls was constructed with complete clinical annotation.
Candidate biomarkers were selected from previous studies evaluating prognostic potential of
markers, gene expression profiling studies (cDNA, oligonucleotide, etc.), and functional
studies on individual genes and gene products. The AQUA™ (Automated Quantitative
Analysis) technology was used to determine exact expression levels of protein biomarkers
within nuclear, non-nuclear (i.e., cytoplasmic) and total melanocytic compartments. Several
statistical methods were then used to build statistical models that improve, or exceed, the
prognostic value of current methods. Briefly, Cox univariate analysis was used to select
those markers most closely associated with melanoma-specific survival. Hierarchical
clustering, multivariate regression models and genetic algorithms (GA) were then used to
determine the optimal number of biomarkers and the optimal cut-points for each marker.
Patients were classified by Breslow depth and GA score. Association with melanomaspecific death over 20 years was ultimately measured by Kaplan-Meier analysis.
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RESULTS: Thirteen of the 66 variables (derived from 48 independent protein assays)
analyzed were significantly (p<0.1) associated with outcome (N-cadherin, E-cadherin, p i 20,
Beta-catenin, CD44, Tenascin C, p21, PCNA, Fibronectin, MDM2, ATF2, pl6, AP2). GA
software was run to convergence (>20X106 generations) multiple times and the runs
repeatedly resulted in the same five-marker solution: ATF2_ratio of cytoplasm by nuclear;
nuclear p21; pl6_ratio of cytoplasm by nuclear; Beta catenin; and Fibronectin. In this
training cohort, limited to 129 primary tumors for which all data points were available,
Kaplan-Meier analyses show patients with Breslow depth <1.00 mm have a 78.1% 10-year
survival compared to patients with depth >1.00 mm with a 45.4% 10-year survival(p<0.001).
Addition of the GA information further stratifies the patients. Patients with Breslow depth
<1.00 mm are split into “low-risk” (86.4% survival) and “high-risk” groups (60% survival)
while those with Breslow >1.00 mm split into “low-risk” (80.5%) and “high-risk” (19.6%)
(pO.0001).
CONCLUSION: These training set data suggest that it is possible to improve upon the best
prognostic index in primary melanoma (i.e., Breslow depth) by using multiplexed in situ
measurement of protein expression. We are in the process of validating our results on an
independent cohort o f patients with known sentinel lymph node outcomes to determine if this
Breslow+GA assay is more accurate than sentinel node biopsy in the prediction of melanoma
recurrence.
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Introduction
Melanoma is the sixth most common cancer in the United States, and its yearly
incidence is rising faster than that of any other cancer, with 47,700 new cases and 7,300
deaths in the year 2000; these numbers are estimated at 53,600 and 7,400 for the current
year.2 Initial management of the primary lesion is by surgery. The surgical treatment of
melanoma can range from a marginal biopsy to wide local excision with regional
lymphadenectomy, and advance in some cases to include extraction of distant metastases.
It has been suggested that metastatic melanoma will become a treatable disease in the
coming years as specific inhibitors are being developed against most major targets. 148
Whether this does, in fact, occur remains to be seen. What is clear is that genome-wide
screening approaches at the DNA, RNA and protein levels are yielding an increasing number
of biomarker candidates that may serve as diagnostic, prognostic, selection of treatment and
treatment follow-up markers.
Much success has been demonstrated in the genomic assessment of melanoma, with
the majority of studies evaluating global mRNA expression. This has created a bottleneck in
biomarker development. Hundreds to thousands of potential biomarkers can be discovered
through genomic profiling studies. However, the verification and validation of initial
selections from these screening studies requires demonstration on human tissue specimens.
The use of tissue microarrays provides the next step in biomarker assessment and evaluation.
While the morphological biology of melanoma progression is well described, the
genetic changes that take place as lesions invade deeper and ultimately become metastatic are
not well understood. Work is under way in a number of laboratories to reveal these changes
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and use them for their prognostic potential (to help predict aggressive potential) and
ultimately develop therapies that target these changes.
A number of studies have been published, indicating the prognostic potential of
various immunohistochemical markers in melanoma. Although some of the studies have
already demonstrated that the levels of melanoma-associated proteins can serve as markers to
predict disease outcome, there are a multitude of genes and gene products with prognostic
potential in patients with localized melanoma. The expression of thousands of genes in
melanoma tumors and cell lines can be surveyed using cDNA microarrays. It has been
proposed for various cancers that a discrete and previously unrecognizable cancer taxonomy
can be identified by assessing the systemized data acquired from gene expression
experiments.15 Most gene expression studies reported thus far have been based on cell lines,
which may not be entirely representative of in vivo tumor biology. The data acquired must
be validated on in vivo models and patient samples.
Melanoma is truly an unpredictable cancer. It is not clear what genetic changes take
place in melanoma progression. As this cancer remains refractory to virtually every
pharmacologic treatment, and has an incredible potential for aggressive growth, it is not
surprising that many melanoma patients submit themselves to toxic and experimental
therapies.116 The products from cDNA microarray analyses not only provide validation of
previously identified biomarkers, but also offer new genes that might be useful in molecular
diagnosis, pathogenesis studies, and possible molecular targets for therapeutic interventions.
Prognosis in melanoma is currently determined by a number of factors unique to the
primary lesion, as well as the presence of loco-regional (lymph node and in-transit
metastases) and distant metastatic disease. This information is distilled into the recently
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revised Melanoma Staging System of the American Joint Committee on Cancer (AJCC).
The first published reports of variables to predict survival in primary melanoma came with
publications from A Breslow ’ and WH Clark in the 1970s. The models they described
have changed little and remain the most powerful and reliable predictors of survival based on
characteristics of the primary cutaneous lesion. In addition to Breslow depth and Clark level,
a number of other histopathological characteristics in melanoma have been observed to
correlate with disease outcome. The strongest histological predictors of outcome are: tumor
thickness (Breslow), anatomic depth of invasion (Clark)324, presence of ulceration35’41'46,
mitotic rate47, presence of microscopic satellites (discrete nests of tumor cells separated from
the main body of the tumor by normal subcutaneous tissue). Less powerful histopathological
factors include: histologic subtype (i.e., superficial spreading, nodular, lentigo maligna, acral
lentiginous, desmoplastic; acral and nodular melanomas may be more aggressive than other
types4), angiogenesis48, vascular invasion, regression, and tumor infiltrating lymphocytes. Of
all clinical and pathological criteria, the majority o f studies demonstrate that tumor thickness
98

tc iq

(Breslow) is the most reliable independent prognostic factor in cutaneous melanoma. ’ ’ ’
4 0 ,4 2 ,4 3 ,4 9 -5 4

In spite of the fact that these parameters represent the standard of care and the pillars
of the AJCC staging system, these histopathologic characteristics of the primary tumor may
not necessarily be indicative of tumor aggressiveness. There are a surprisingly large number
of cases of melanoma in which tumor thickness does not predict outcome; cases in which
thin melanoma turns out to be aggressive36,38,44,54-76 or thick melanoma indolent77'80.
Significant efforts over the past 30 years have sought to discover molecular markers that
could be used, but no marker has replaced or even matched the physical descriptors above.
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Initially, markers were accrued and tested in a somewhat random fashion, based on success
in other tumors or a defined role in tumorgenesis in a model system. A long list of these
markers can be found in the literature and are reviewed by Li et al.250 We have contributed
to this list282,325"327, yet none have been broadly adopted, most likely due to the lack of
standardization of these prognostic markers, or more significantly, the lack of a multi-center
prospective clinical trial for molecular prognostic indicators.
Perhaps the most significant recent change in the management of melanoma is
sentinel lymph node biopsy. This is a procedure initially developed in the treatment of penile
cancer where a dye, and/or radiotracer, is injected into the tumor to identify the primary
nodal drainage of a particular region, and then the identified nodes are removed for histologic
analysis. This can determine if a patient has metastatic disease—regional or distant—and
result in more accurate (or at least less morbid) initial staging and management. If the
sentinel lymph node is negative for disease, it can be assumed that the rest of the regional
nodes are also negative, and the patient will be spared an “unnecessary”, invasive and
debilitating procedure. The decision to perform a sentinel lymph node biopsy (in the absence
of clinically apparent LN disease) is typically based upon the Breslow depth of the primary
lesion. Generally, the threshold for performing a sentinel lymph node biopsy is a primary
lesion around 1 mm thick , but the procedure is becoming the standard of care for patients
with primary melanoma greater than 1 mm in thickness86 or less328. Although this method is
considered an accurate mechanism for predicting the pathologic status of regional lymph
nodes, as well as in the prediction of patient outcome 83 , it is far from faultless. However, it is
now an essential component of the AJCC TNM classification of melanoma.
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Sentinel node biopsies, while valuable, are not perfect. The false negative rate for the
procedure is around 5-10%, but more significantly, nearly 25% of patients may be ultimately
upstaged, especially if molecular tests are used.329 Perhaps more importantly, as many as
90% of the sentinel nodes are negative, suggesting the test was unnecessary. Thus,
management of melanoma could be improved if there were a method to determine metastasis
without removing the nodes and without false negative tests.
Many groups have described promising single biomarkers for melanoma. While
these biomarkers may have value, none have successfully transitioned to standard practice in
melanoma management. There may be many reasons for this, including the subjective nature
of assessment of these markers, the non-reproducibility of these assays, and the fact that
assessment of a single marker has limited potential to describe specific biological disease
classifications. Even with the addition of quantitative information, it is not clear that a single
marker is the optimal way to define outcome classes.
Multiplexing of markers and definition of disease classifications has been a strength
of the cDNA array technologies. The work of the Botstein and Brown group330 and the
•
group from the Netherlands Cancer Institute 234 in breast cancer or the Trent group m

melanoma15 has provided a model for this paradigm. In each case (and many others not
referenced), a series o f cDNA markers is used with a hierarchical clustering algorithm to
produce a relatively small group of disease classifications that show significant differences in
the disease outcomes. The classes are generally defined by groups of 70-200 or more
markers. While these (and many other studies) show the power of multiplexing for
classification, they also illustrate the weaknesses. Perhaps the most significant weakness is
the difficulty of translating this technology to clinically useful tests. Not only is RNA
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difficult to obtain for routine clinical testing, but the genes discovered by each group show
relatively little overlap, suggesting that RNA may not be the most appropriate platform for
multiplexing. Some efforts have been made to do multiplex analysis of protein expression,
using tissue microarrays. 269 However, the non-quantitative and discontinuous nature of the
scoring systems has resulted in results that are likely to lack reproducibility, and tend to be
the subject to the same criticisms leveled at conventional immunohistochemistry. Use of a
quantitative approach to tissue microarray analysis has the potential to solve this problem. In
the present study, we assess numerous protein biomarkers on our large-cohort malignant
melanoma tissue microarrays using our automated quantitative analysis (AQUA) system.
After establishing biomarkers that are most closely associated with aggressive disease, we
develop a prognostic model to predict patient outcome.
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Materials and Methods
Tissue M icroarray Construction and Cohort Descriptions.

Tissue microarrays were constructed as previously described, with 0.6mm diameter
cores spaced 0.8mm apart. Representative tumor regions were selected for coring and
placement in the tissue microarray using a Tissue Microarrayer (Beecher Instruments, Silver
Spring, MD). The tissue microarrys were then cut to 5 pm sections and placed onto slides
using an adhesive tape-transfer system (Instrumedics, Inc., Hackensack, NJ) and UV
crosslinking.
In collaboration with our laboratory, the Yale Cancer Center TMA Facility has
constructed two melanoma tissue microarrays that were used for this study. Each of these is
accompanied by a wealth of clinical and pathological data. Long-term follow-up data,
including recurrence and survival, as well as cause of death, is available for the majority of
the cases. These data have been acquired from YNHH medical records, the Yale University
Department o f Pathology, and the Connecticut Tumor Registry.
The first array (Melanoma Discovery TMA; YTMA 20 / 59) contains 553 melanoma
specimens (with redundancy for some specimens), and 17 normal skin biopsies collected
between 1959 and 1994, as well as nevi, melanoma cell line, and normal melanocyte
controls. Regarding patient representation, there are 214 primary melanomas and 293
metastases. Median and mean age at the time of diagnosis were 56 and 55 years,
respectively. The median follow-up time is 19 years. The value of this array lies in the
exceptionally large cohort size and the availability of long-term survival data. When
analyzed for outcome, the specimens collected on this tissue microarray are representative of
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the overall melanoma population in the U.S., conforming to expected results based on current
staging criteria (refer to Figure 16).
The second cohort {Melanoma Validation TMA; YTMA 76) contains 270 primary
melanoma specimens with known SLN status, as well as 50 controls from YTMA 20/59,
including 21 primary specimens, 38 metastatic specimens, 14 cell line controls. All of these
patients underwent sentinel lymph node biopsy performed by the same surgeon (Dr. Stephan
Ariyan). As most of these specimens were collected rather recently, the median follow-up
time on the second cohort is approximately 12 months, with the last follow-up for many of
the patients being the SLN post-operative visit. However, follow-up data collection on these
patients occurs continuously and is a work-in-progress.
Biom arker Selection.
Through gene expression profiling studies, we117, and others15’116,120_123’125,146>331>3325
have sought to identify molecular changes that take place in melanoma progression. Specific
details of these studies can be found in Chapter 1. Table 17 displays the initial list of
potential protein biomarkers for assessment of aggressive/metastatic potential in melanoma.
Many of these markers were selected based on the potential they demonstrate in functional
(cell biological) or small pre-clinical studies in melanoma. Others were selected from gene
expression studies, and they were selected based on the significance of differential
expression, as well as intersection on multiple studies with different experimental designs.
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Table 17. INITIAL LIST OF MELANOMA BIOMARKERS
Selected by gene expression profiling, immunohistochemistry, and/or cell biology
Adhesion M olecules
ALCAM (a c tiv a te d
leu k o cy te
a d h e s io n
m o lecu le)/C D 1 6 6
C D 44
Cyr61
E -cad h e rin
(CD H 1)
F asc in (F S C N )
F ibronectin (FN 1)
F lyaluronan
1CAM
ICAM2
ILK
Integrins
02)31
(C D49B)

a4pi
(C D49D)
a6pi
avpi
(C D29)

avp3
(CD61)
avp6
L1 (C D 171)
LECTINS
HPA
LPH A

Muc1
M uc18 (MCAM)
N -cad h erin
(CD H 2)
P -c a d h e rin
(CD H 3)
S k eletro p h in
sy n d ecan 4
T e n a s c in C
T h ro m b o sp o n d in

1
T h ro m b o sp o n d in

2
VCAM1
V E -ca d h erin
(CD H 5)
V ersica n
a -c a te n in
3 -c a te n in
y -caten in
Apoptosis-related Factors
A C S/T M S1
APAF-1
B ad
B ax
Bcl-X
Bcl-2
Bid
DR4
DR5
FA S (C D 95)
FA S -ligand
(CD 95L)

FLIP
Survivin
TRAIL
bHLH
HEY1
T w ist
G row th Factors/Receptors
CTGF
EGF
EG FR
E ndothelin re c e p to r B
E phA 2 (Ephrin
R e c e p to r A2)
E phrin A1
F G F 2 (b asic)
FG FR -1 (Fig)
IG F B P 3
IG F B P 5
IG F B P 6
IG F B P 7
KDR (V EG FR )
Im m unoregulatory
C D 20
C D 26 (D P P 4 , A D C P 2)
C D 40 (T N F R S F 5, B
cell re cep to r)
C D 59
CXCR4
HLA C la s s I
HLA C la s s II
M elanom a-associated
C D 63
MAGE-A1
M AGE-A3
MART-1
MiTF
Motility
T ro p o m y o sin 1 (alp h a)
R hoC
N eural/Neural Crest
Myelin b a s ic protein
G alN A c-T
GFAP
G row th a s s o c ia te d
pro tein 43
Pax3
P h o s p h o g ly c e ra te
m u ta s e 1 (brain)
s y n u d e in , a lp h a
O ther
A polipoprotein C-ll
A polipoprotein D
H IF 1a
F lydroxyacyl-C oA
D e h y d ro g e n a s e ; FIADFI
M etallothionein
MTAP
(m e th y lth io a d e n o sin
p h o s p h o ry la s e )
N a/K A T P a se , b e ta 1
O s te o n e c tin (S P A R C )

PFK L
pirin
T ro p o m o d u lin
D e sm o g lein 2
h-C D /C N h1
F5AB2
RhoC
UCHL1
Proliferation M olecules
AXL re c e p to r tyrosine
k in a s e
CDK2
c-kit
C y d in D1
GADD
Ki67/MIB-1
p16IN K 4a
P21W AF1
p27kip1
PC N A
SKI
W N T 5A
Proteases/-related Factors
C a th e p s in B
C a th e p s in D
C a th e p s in L
EM M PRIN
FA P (fibroblast activatio n
p ro tein )
MMP1 (CLG, fibroblast
c o lla g e n a s e )
M M P13
M M P2 (T ype IV
c o lla g e n a s e )
M M P3
M M P9
M T1-M M P (M M P14)
P A sy s te m (uPA , tPA, PA I's)
PAI-1
PAI-2
TIMP1
TIM P2
TIM P3
tP A
uP A
uP A R
R egulatory M olecules
A nnexin I (Lipocortin 1)
A nnexin II (Lipocortin 2)
HDM2
M e lastatin
MIA
P53
Rb
Signaling
Akt/PKB
PTEN
T ranscrip tion Factors
A P -2
ATF-1
A T F-2
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When possible, antibodies to the targets listed above were selected based on their
publication record, or other data supporting their specificity and accuracy in
immunohistochemisty. In some cases, however, we needed to engage our own antibody
validation techniques; typically involving various methods (e.g., Western blots, IHC,
peptide competition assays on positive- and negative- control cell lines). Table 18
demonstrates target molecules that have been successfully evaluated on our melanoma
cohort, including clone and species information, as well as source and dilution
information.
Immunohistochemistry.
Tissue microarray slides were deparaffinized in xylene, followed by rehydration
through a graded ethanol series and washed with tris-buffered saline (TBS). The slides
then underwent antigen retrieval, which involved 15-minute heat treatment in a pressure
cooker containing 6.5 mmol/L citrate, pH 6.0 (except in the cases of ATF2 and HDM2,
which were boiled in a pressure cooker containing 1 mM EDTA, pH 7.5). Endogenous
peroxidase activity was blocked with 2.5% hydrogen peroxide in methanol for 30
minutes at room temperature. After washing with TBS, the slides were incubated at room
temperature for 30 minutes in 0.3% bovine serum albumin in TBS to reduce non-specific
background staining.
Immunohistochemical staining was performed on these slides using 50 different
antibodies (source and concentration listed in Table 18). Antibodies used in this study
were selected for their potential— or previously reported—role in the prediction of
melanoma outcome, and/or for their role in key aspects of cell cycle, apoptosis, signal
transduction, and melanoma differentiation. Prior to staining these antibodies on the
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Discovery Melanoma TMA, each antibody was subjected to a series of dilution titrations
on test TMAs to determine the optimal antibody concentration for detecting differences
in expression levels. Depending on the species of the antibody, a cocktail was created
with an anti-SlOO protein antibody of a different species; rabbit polyclonal anti-SlOO
(1:6,000, DAKO Corporation, Carpinteria, CA) in the case of mouse antibodies or mouse
monoclonal anti-SlOO, AM058 (Biogenex, San Ramon, CA) in the case of rabbit (or
other nonmouse species). In all cases, the slides were incubated overnight at 4°C in a
humidity chamber.
Secondary antibodies, an Alexa 546-conjugated goat antibody directed against the
anti-SlOO antibody (anti-mouse or anti-rabbit) (1:200, Molecular Probes, Eugene, OR)
diluted in Envision— an HRP tagged polymer—directed against the ‘target’ antibody
(neat; DAKO) were applied for 1 hour at room temperature. 4', 6-Diamidino-2phenylindole (DAPI) was included with the secondary antibodies to visualize nuclei.
Slides were then washed with BSA/TBS (three times for 5 minutes) and then incubated
with Cy5-tyramide (Perkin-Elmer Life Science Products, Boston, MA) and activated by
horseradish peroxidase, resulting in the deposition of numerous covalently associated
Cy5 dyes immediately adjacent to the horseradish peroxidase-conjugated secondary
antibody. Cy5 was used because its emission peak (red) is well outside of the greenorange spectrum of tissue autofluorescence. The slides were sealed with coverslips with
an antifade-containing mounting medium (with 0.6% n-propyl gallate). Negative
controls were obtained by omitting the primary antibody.
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Table 18. Antibodies Examined in the Study, indicating Source, Clone, and Dilution
Protein

Clone (Cat No.)

Host
Species

FN1 (F ib ro n ectin )

ab299

R a b b it

S P A R C /O N (O ste o n e c tin )

A O N -5031

M o u se

MMP1 (M atrix m e ta llo p ro te in a s e 1)
M M P3 (M atrix m e ta llo p ro te in a s e 3)

IM35L
A B 810

M o u se
R a b b it

T IM P3 (T is su e inhibitor o f M M P3)
TIM P2 (T is su e Ihibitor o f M M P2)
MT (M etallothionein)
F S C N (F a scin )
ANXA1 (A nnexin A1)
CDH1 (E -c a d h e rin )
C D H 2 (N -ca d h erin )
C D H 3 (P -c a d h e rin )
L1CAM (L1 n e u ra l cell a d h e s io n m o lecu le)
CTNNA1 (a -c a te n in )
CTNNB1 (P -C a ten in )
CTNND1 (p 1 2 0 -c a te n in )
C D 44 (H yaluronic a c id re c e p to r)
C D 61/IT G B 3 (integrin, b e ta 3)
ILK (Integrin-linked k in a s e )
APAF1 (a p o p to tic p r o te a s e activ atin g facto r)
B ad (B c l-a ss o c ia te d d e a th p ro m o te r)
B d -2 (B-cell C L L /lym phom a 2)
Bcl-X (BCL2-like 1)
Bid (BH 3 interactin g d o m ain d e a th a g o n is t)
clA P (inhibitor of a p o p to s is )
XIAP (X-linked inhibitor of a p o p to s is )
DR4/TRAILR1 (D e a th re c e p to r 4)
D R 5/T R A IL R 2/T N F R S F 10B (D e a th re c e p to r 5)
Survivin
B ax (Bcl-2 h o m o lo g y protein, p ro -ap o p to tic)
C T G F (C o n n e c tiv e tis s u e grow th factor)
EFNA1 (E p h rin A I)
E PH A 2 (E P H re c e p to r A2)
TW IST
TN C (T e n a s c in C)
MBP (M yelin B a sic P ro te in )
HEY1 (h a iry /e n h a n c e r-o f-sp lit re la te d with Y R P W
m otif 1)
LPHA (L eu k o y te p h y to h em ag g lu tin in — re c o g n iz e s
3 1 ,6 -b ra n c h e d o lig o s a c c h a rid e s )
C D 63 (M elan o m a 1 a n tig e n )
MAGEA1 (M elan o m a a n tig e n fam ily A, 1)
MITF (M icropthalm ia tran scrip tio n facto r)
HDM2 (H u m an hom ol. of m u rin e d o u b le m in u te 2)
ATF2 (A ctivating tran scrip tio n fa c to r 2)
A P2a
PC N A (P roliferating cell n u c le a r a n tig en )
Ki-67
c-kit (kit o n c o g e n e )
p16/C D K N 2A /IN K 4a (c y d in -d e p e n d e n t k in a s e
inhibitor 2A (m e la n o m a , p 1 6 , inhibits CDK 4)
p21/C ip1/C D K N 1A (c y c lin -d e p e n d e n t k in a se
inhibitor 1A)
p27/K ip1/C D K N 1B (c y c lin -d e p e n d e n t k in a s e
inhibitor 1B)

Source

Dilution
1 700

1 75
1 400
1 250
1 1000
1 400
1 150
1 2 50
S u p ern at
1 150
1 2500
1 400
1 200
1 50
1 3 00
1 100
1 250
1 30
1 1600
1 100
1 6 00
1 100
1 80
1 350
1 800
1 1500
1 650
1 250
1 200
1 250
1 600
1 300
1 200

136-13H 4

M o u se

3A4 (1 8 -7 3 5 1 )
M 0639
55K -2 (M 3567)
2 9 (6 1 0 0 6 6 )
3 2 (6 1 0 1 8 2 )
3B 9 (18-0 2 2 4 )
5 6 (6 1 0 2 2 8 )
L1-11A
aC A T -7A 4 (1 8 -0 2 2 5 )
14 (6 1 0 1 5 4 )
9 8 (6 1 0 1 3 3 )
2C 5
SZ 21 (0540)
K A P -S T 203
H -324 (S C 8 3 3 9 )
4 8 (6 1 0 3 9 1 )
124 (M 0887)
P oly (6 1 0 2 1 1 )

M o u se
M o u se
M o u se
M o u se
M o u se
M o u se
M o u se
M o u se
M o u se
M o u se
M o u se
M ouse
M o u se
R a b b it
R a b b it
M o u se
M o u se
R a b b it
R a b b it
G oat
M o u se
M o u se
M ouse
R a b b it
R a b b it
R a b b it
R a b b it
R a b b it
R a b b it
R a b b it
R a b b it

A b eam
H a e m a to lo g ic
T e c h n o lo g ie s
C a lb io ch e m
C h e m ico n
O ncogene
R e s e a r c h P ro d u c ts
Zym ed
DAKO
DAKO
T ra n s d u c tio n L abs
T ra n s d u c tio n L abs
Z ym ed
T ra n s d u c tio n L abs
Gift of P au l A ltevogt
Zym ed
T ra n s d u c tio n L abs
T ra n s d u c tio n L abs
R&D S y s te m s
B eckm an
S tr e s s g e n
S a n ta C ru z
T ra n s d u c tio n L abs
DAKO
T ra n s d u c tio n L abs
Gift from Gil Mor
S a n ta C ru z
Gift from Gil Mor
R&D S y s te m s
R&D S y s te m s
R&D S y s te m s
DAKO
A b eam
S a n ta C ru z
S a n ta C ru z
S a n ta C ru z
S a n ta C ru z
Zym ed

R a b b it

S a n ta C ru z

A -13 (S C 1 2 4 1 0 )
6 9 0 3 6 (M AB347)
15 2 4 1 5 (M A B 6312)
A F 886
A 3533
ab6992
12 2 0 3 (S C 9 1 1 )
SC 924
H-81 (S C 1 5 3 9 3 )
SC20932
(18-0 0 3 8 )

1 8000
1 550
1 3000
1 10

B -1115

N/A

V e c to r

1 :1 0 0 0 0

FC -5.01 (1 8 -7 3 0 0 )
M A 454 (1 8 -7 3 5 3 )
C 5+ D 5 (0 8 -8 3 6 9 )
1B10
C 1 9 (S C 1 8 7 )
K 2403 (S C 1 8 4 )
P C 1 0 (1 8 -0 1 1 0 )
B 56 (5 5 6 0 0 3 )
2 E 4 (1 8 -0 3 8 4 )

M o u se
M o u se
M o u se
M o u se
R a b b it
R a b b it
M o u se
M o u se
M o u se

Zym ed
Zym ed
Zym ed
N o v o c a s tra
S a n ta C ru z
S a n ta C ru z
Z ym ed
T ra n s d u c tio n L abs
Z ym ed

1:50
1:90
P re d ilu ted
1 100
1 250
1 1600
1 10000
1 500
1 50

G 1 75-405 (5 5 4 0 7 0 )

M ouse

T ra n s d u c tio n L abs

1 500

S X 1 18 (5 5 6 4 3 0 )

M o u se

T ra n s d u c tio n L abs

1 :1 0 0

G 1 7 3 -5 2 4 (5 5 4 0 6 9 )

M o u se

T ra n s d u c tio n L abs

1 :3 0 0

138

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Automated image acquisition and analysis.
The AQUA automated image acquisition and analysis was performed as described
previously.314 Briefly, images of the tissue microarray were captured through an
Olympus BX 51 microscope with automated x, y, and z stage movement with an Olympus
Motorized Reflected Fluorescence System and software (IP lab v3.60, Scanalytics, Inc.,
Fairfax, VA) equipped with Cooke Sensicam QE High Performance camera. Low-power
images o f the microarray were stitched together with multiple low-resolution images of
the microarray (64 X 64 pixels) at ~7-pm resolution.
Areas of tumor were distinguished from stroma and non-melanoma tissue by
creating a mask with the S I00 signal tagged with Alexa 546. Expression of S I00 protein
was used to identify the tumor mask and 4', 6-diamidino-2-phenylindole (DAPI) was
used to identify the nuclear compartment. Areas o f the tumor mask without DAPI were
considered 'nonnuclear' or 'cytoplasmic'. The target markers were visualized with Cy5
(red). Rows and columns of the histospots were then identified, missing histospots filled
in, allowing each histospot to be identified by its coordinates, and recorded based on its
position in the grid. Subsequently, monochromatic, high-resolution (1024 X 1024 pixel,
0.5-pm resolution) images were obtained of each histospot, both in the plane of focus,
and 8 pm below it, and recorded in an image stack as bitmaps. A resolution of 0.5 pm is
suitable for distinguishing between large subcellular compartments such as the cell
membrane/cytoplasm and nuclei. The ‘target’ signal from the cytoplasmic and nuclear
compartment within the S I00 tumor mask was measured on a scale of 0 to 255 and
expressed as target signal intensity relative to the respective cytoplasmic or nuclear
compartment area.
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Data analysis.
Clinical data and immunohistochemistry scores were performed blind, and data
were compiled only after all analyses were completed. Histospots containing <10%
tumor, as assessed either subjectively (manual) or by mask area (automated), were
usually excluded from further analysis. Our previous studies have demonstrated that
scores from one to two histospots matches the score from an entire tissue section >95%
of the time.
Hierarchical Clustering.

A general description of clustering methods can be found in Chapter 1. In order
to perform clustering analyses, Z-score transformation

was utilized to normalize

AQUA data between experiments. Z-score formula:
[(AQUA Score) - (mean of AQUA Scores on TMA) / standard deviation.]
The computer program CLUSTER118 was used to perform unsupervised average
linkage hierarchical clustering on unweighted z-score transformed AQUA data. The
results were then visualized with TREEVIEW118. For the 50-marker clustering, cases
shown include those with at least 75% of the marker values present.
Univariate logistic regression followed by Classification Error / ROC fitting for
multivariate logistic regression models .

Tumor thickness (Breslow) has been repeatedly described as the best overall
predictor of disease survival in melanoma patients. We aim to pair Breslow depth with
protein expression patterns from tumor tissue microarrays in order to improve the
prediction of disease outcome. The data consist of 71 tumor microarray variables—
protein expression levels as well as combination variables—in 211 patients with primary
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melanoma. The outcome variable is 5-year recurrence (binary). Missing values were
imputed by using the column mean. We used a two-step variable selection approach to
determine the optimal number of variables to be included in a model to best predict 5year recurrence.
First, we performed univariate logistic regression to find the top scoring variables
with a P value <0.05. This step resulted in a list of 15 variables.(Table 20)
Then, we then performed an exhaustive search over all variable combinations to
find the best predictive set of variables using 10-fold cross-validation. We used two
scoring functions: misclassification error and the area under ROC curve (AUC). The
model was iteratively trained on 9/10 of the data, and then tested on the remaining 1/10
of the data. An attempt to build models based solely on traditional clinico-pathologic
variables (e.g., Breslow depth, Clark level, ulceration, microscopic satellitosis, tumor
infiltrating lymphocytes), in the absence of molecular marker information, was also
attempted.
Cox Multivariate Analysis and Aiken Information Coefficient (AIC).

We used survival time as the only end point in this analysis. Firstly, we performed
univariate Cox proportional hazard regression to assess the statistical significance of each
candidate potential factor, and the factor was retained if a significance level of p<0.05
was attained. Factors showing statistical significance as a predictor were further
analyzed using a multivariate Cox proportional hazard regression model with stepwise
selection of variables based on the Akaike information criterion (AIC). AIC is a measure
of the goodness of fit (log likelihood) with a "penalty score" for the complexity of the
model (number of variables included), defined as: AIC = -2 x (maximum log likelihood)
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+ 2 x (total number of parameters), and the optimum (that is, simplest effective) model
gives the lowest AIC value.
Genetic Algorithm.

A general description of genetic algorithms can be found in Chapter 1. A genetic
algorithm was used to develop a multiplex marker assay for separation of prognostic
groups based on the expression of markers closely associated with outcome. First, those
markers mostly closely associated with survival in the primary melanoma specimens
were identified by Cox univariate survival analysis (p<0.1). (Table 21 & Table 22).
These markers were then used as a starting point for the development of a genetic
algorithm.
The genetic algorithm software (component of X-tile, written by Robert Camp)
applies the elements of Darwinian evolution to optimization problems (e.g., mutation,
recombination, selection) in order to the find the best combination of potential solutions
to a problem. Each gene/algorithm represents an equation that is a true/false statement,
such that the marker value is either ‘greater than’ (>) or ‘less than or equal to’ (<) a
particular AQUA score. Each patient is given one point for each ‘true’ statement and a
zero for ‘false’ statements. A chromosome/solution then consists of the optimal number
of if/then statements that can be calculated as true or false. Chromosomes/solutions were
subjected to multiple iterations by mutation (i.e., randomly changing cutpoint) and/or
cross-overs (i.e., mixing and matching elements of from one gene/algorithm with those of
another) until the model converged on a maximum predictive value, measured as relative
risk or chi-square. This process was repeated multiple times until the end-point (relative
risk or chi-square) values converged. The genetic algorithm repeatedly resulted in a 5-
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member model containing the same five variables: ATF2_ratio, Fibronectin, Beta
Catenin, pl6_ratio, p21_nuclear. Patients were then assigned to risk group based on the
genetic algorithm score.
Survival analysis.

Complete follow-up survival data were available for the Discovery cohort.
Overall survival analysis was assessed using Kaplan-Meier analysis and the Mantel-Cox
log-rank score for assessment of statistical significance. Relative risk was assessed using
univariate and multivariate Cox-proportional hazards model analyses. All statistical
analyses were carried out using SPSS v. 13 (SPSS Inc., Chicago, IL).
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Results
Protein Expression Profiling of Melanoma.
The results of expression profiling, in which primary cutaneous melanoma
specimens were compared to metastatic melanoma specimens is demonstrated in Table
19. Significant differences (p<0.05) were observed for the following markers: Higher
expression in primary specimens: Beta-catenin, MMP3, TIMP2, ATF2, HDM2, Ecadherin, P-cadherin, N-cadherin, CD61, HEY1, MAGE1, pl6, Bcl-2; Higher expression
in metastatic specimens: Fibronectin, CTGF, TIMP3, Ll-CAM, alpha-catenin, Bad, Bax,
Bcl-X, Bid, XIAP, Survivin, EphA2, Twist, Fascin, PCNA, Thioredoxin, LPHA, p21,
Metallothionein.
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Table 19. Comparison of Protein Expression Levels in Primary versus Metatstatic Specimens

Protein
FN1
CTGF
S P A R C /O N
MMP1
MM P3
TIM P3
TIM P2
HDM2
A TF2
E -cad
P -c a d
N -cad
L1
a -c a te n in
P -C aten in
p120
A PAF1
B ad
B ax
Bcl-2
Bcl-X
Bid
clA P
XIAP
D R4
D R5
Survivin
CD61
ILK
E phrinA I
E phA 2
T w ist
T e n a s c in C
MBP
A nnexin 1
MITF
F asc in
HEY1
PCNA
Ki-67
T hioredoxin
LPHA
MAGE1
A P2
C D 63
c-kit
p16
P21
P27
M etallothionein
C D 44

Primary
Specimens

M etastatic
Specim ens

Mean ± SD

Mean ± SD

4 7 .5 9 ± 1 4 .7 9
6 6 .0 7 1 1 8 .1 2
2 0 .5 3 1 1 5 .3 3
3 7 .4 1 1 1 9 .8 8
2 0 .4 4 1 1 1 .5 2
4 0 .9 4 1 1 6 .6 6
5 6 .4 0 1 1 6 .0 7
5 2 .3 8 1 1 8 .0 6
6 9 .2 1 1 4 0 .2 4
37 .4 6 1 1 9 .5 1
3 5 .6 8 1 7 .2 3
1 9 .0 0 1 1 4 .7 7
6 .5 2 1 3 .3 5
1 1 .6 0 1 2 .1 5
4 8 .2 5 1 1 5 .8 1
1 8 .5 9 1 1 0 .3 2
3 2 .2 1 1 2 0 .0 3
4 0 .8 9 1 1 5 .3 5
1 0 .6 0 1 5 .7 5
1 9 .6 1 1 2 0 .1 9
1 7 .5 0 1 8 .1 0
1 4 .3 6 1 7 .5 7
3 9 .5 8 1 2 0 .6 4
1 0 .5 5 1 7 .9 8
3 5 .8 0 1 1 1 .8 3
5 3 .6 4 1 1 5 .3 3
3 6 .2 6 1 1 8 .2 0
3 0 .5 2 1 1 1 .1 8
4 3 .2 0 + 1 4 .0 0
4 5 .8 5 1 1 6 .3 0
4 9 .8 2 1 1 6 .4 5
2 4 .6 4 1 1 1 .8 2
2 6 .1 1 1 2 1 .6 6
4 5 .2 4 1 1 7 .3 2
4 0 .4 3 + 2 0 .8 0
1 6 .7 4 1 1 3 .5 9
2 2 .9 7 1 2 2 .3 8
5 9 .2 1 1 2 3 .6 5
2 0 .0 5 + 1 4 .1 2
1 8 .8 9 1 6 .8 0
4 .3 3 1 2 .3 6
2 1 .4 0 1 2 1 .6 5
1 4 .4 5 1 1 3 .0 8
2 1 .7 4 1 1 2 .3 3
1 5 .1 6 1 1 7 .0 7
3 2 .7 1 1 1 6 .8 9
2 9 .4 4 1 2 3 .1 1
1 3 .0 1 1 4 .9 0
3 8 .8 9 1 1 9 .5 5
3 1 .0 0 1 2 5 .6 5
5 1 .0 3 1 1 5 .6 3

6 3 .1 0 1 2 4 .1 1
7 2 .9 3 1 1 8 .2 3
2 1 .3 8 1 1 7 .4 0
3 7 .2 8 1 2 2 .8 0
1 3 .7 8 1 6 .8 9
4 7 .1 8 + 1 7 .5 4
5 0 .6 7 1 1 2 .3 5
4 3 .2 6 1 1 6 .8 4
6 0 .3 6 1 3 9 .7 8
2 9 .8 5 1 1 8 .0 5
3 2 .7 0 1 5 .7 4
1 3 .3 8 1 1 2 .9 6
8 .1 7 1 4 .2 9
1 4 .5517.21
4 0 .7 4 1 1 2 .2 8
1 8 .2 6 + 9 .2 3
3 1 .6 6 1 1 7 .5 9
4 8 .7 1 1 2 2 .8 2
1 3 .0 5 1 9 .0 9
1 5 .4 3 1 1 7 .1 6
2 1 .2 3 1 1 2 .3 2
2 0 .2 1 1 1 0 .2 9
4 4 .9 3 + 2 1 .7 9
1 3 .6 1 1 9 .6 4
3 4 .0 1 + 1 1 .0 3
5 4 .3 4 1 1 6 .2 1
4 3 .3 2 1 1 5 .4 9
2 6 .2 5 1 7 .5 4
4 4 .8 6 + 1 4 .3 0
4 3 .6 7 1 1 4 .7 5
5 4 .1 9 1 1 4 .1 3
2 8 .8 1 1 1 5 .1 0
2 9 .4 5 1 2 9 .1 1
4 3 .2 7 1 1 5 .7 5
4 0 .0 4 + 2 5 .8 5
1 3 .4 1 1 1 3 .0 5
3 0 .9 4 1 2 6 .8 6
4 6 .3 2 1 2 5 .4 4
2 8 .2 5 1 1 6 .7 3
2 0 .3 5 1 8 .1 7
5 .9 2 + 5 .1 2
2 7 .9 4 1 1 6 .1 0
1 1 .1 1 1 7 .1 6
2 0 .6 4 1 1 1 .3 4
1 5 .5 8 1 1 4 .6 7
3 4 .5 3 1 1 5 .3 3
2 3 .8 8 1 1 9 .2 2
1 3 .8 5 1 5 .4 6
4 0 .6 4 1 2 1 .3 3
3 7 .2 1 1 3 0 .8 6
4 9 .1 4 1 1 6 .5 0

Mean
Difference
15.51
6 .8 6
0 .8 5
-0 .1 3 6
-6 .6 6
6 .2 4
-5 .7 3
-9 .1 2
-8 .8 5
-7.61
-2 .9 7
-5 .6 2
1.65
2 .9 5
-7 .5 0
-0 .3 2 7
-0 .5 4 4
7 .8 3
2 .4 5
-4 .1 7
3 .7 3
5 .8 6
5 .3 6
3 .0 6
-1 .7 9
0 .7 0
7 .0 6
-4 .2 7
1.65
-2 .1 8
4 .3 7
4 .1 7
3 .3 3
-1.97
-0 .3 8 4
-3 .3 3
7 .9 7
-1 2 .8 9
8 .2
1.46
1.59
6 .5 4
-3 .3 4
-1.1
0.421
1.82
-5 .5 7
1.84
1.75
6.21
-1 .8 9

t value

p value

7 .5 5
3 .6 4
0 .5
-0 .0 6
-6 .4 7 4
3 .6 7
-3 .3 9
-5 .2 5
-2 .5 2
-3 .4 3
-4 .3 8
-3 .9 2
3.71
4 .3 6
-5 .1 5
-0.31
-0 .2 0 9
2 .9 7
2 .2 7
-1 .9 8
2 .8 4
4 .1 9
1.88
2 .5 4
-1.11
0 .2 9
3 .5 5
-4.01
1.13
-1.31
2 .5 3
2 .8 2
1.21
-1 .0 4
-0 .1 6
-2 .2 7
2 .7 7
-4 .9 0
4 .5 2
1.91
2 .8 4
2 .9
-2 .8 7
-0 .8 7
0 .2 3
0 .9 9
-2 .6 5
3 .5 7 8
0 .8 6
2 .0 0
-1.01

<.0001
0 .0 0 0 3
0 .6 1 7 7
0 .9 5 2 4
<.0001
0 .0 0 0 3
0 .0 0 0 8
<.0001
0.0121
0 .0 0 0 7
<.0001
0.0001
0 .0 0 0 2
<.0001
<.0001
0 .7 5 6 9
0 .8 3 4 4
0 .0 0 3 3
0 .0 2 4
0 .0 4 8 4
0 .0 0 4 9
<.0001
0 .0 6 0 8
0 .0 1 1 6
0 .2 6 7 5
0 .7 7 0 6
0 .0 0 0 5
<.0001
0 .2 6 1 2
0 .1 8 9 7
0 .0 1 2
0.0051
0 .2 2 7 5
0 .3 0 0 6
0.8741
0.0241
0 .0 0 5 9
<.0001
<.0001
0 .0 5 6 4
0 .0 0 5
0 .0 0 4
0 .0 0 4 4
0 .3 8 4 2
0 .8 1 5
0 .3 2 2
0 .0 0 8 4
0 .0 0 0 4
0 .3 9 4 8
0 .0 4 5 9
0 .3 1 1 3
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Clustering Analysis.
Clustering models are a good preliminary method of analysis to potentially detect
molecular subclasses of disease that may not be recognized otherwise. Although they
may not necessarily produce prognostically relevant classifications, the analysis
illustrates the strength o f multiplexing of quantitative values of protein expression, and
may provide some clues to melanoma biology.
We have performed AQUA analysis on 50 proteins using our 521 case Discovery
Melanoma Tissue Microarray. When subsets of these proteins are clustered using
unsupervised hierarchical clustering algorithms, the patient population can be divided
into smaller subclasses (Figure 22A). However, these subclasses tend not to be
prognostically relevant (Figure 22B & C). One method for improving our understanding
of molecular subclasses, while using clinical information already available to us is semi
supervised clustering analysis. Semi-supervised clustering analysis involves the use of
clinical data to identify a list of genes that correlate with a clinical variable of interest
(melanoma-specific survival in this case) and then applying unsupervised clustering
techniques to this subset of genes. After using Cox univariate survival data to identify
those markers most closely associated with survival, unsupervised clustering analysis was
used to identify groups o f patients that have significantly different rates of melanomaspecific survival (Figure 23).

146

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Figure 22.Unsupervised hierarchical clustering o f protein expression. Average linkage cluster
analysis o f protein expression, measured by AQUA analysis, in melanoma patient specimens. A,
Clustergram. The rows represent patients and the columns represent proteins. Scores were
normalized to the mean by Z-score calculation. B, Kaplan-Meier plot demonstrating survival for
the highest level of classification. C, Kaplan-Meier plot demonstrating survival for the second
highest level of classification.
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Kaplan-Meier Cum. Survival Plot for Year 5 Time
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Figure 23. Semi-supervised hierarchical clustering. Molecular markers closely associated with
survival by Cox regression analysis (p<0.1) were subjected to unsupervised hierarchical
clustering. Clades were established and examined by Kaplan-Meier analysis. A, Clustergram.
The rows represent patients and the columns represent proteins. Scores were normalized to the
mean by Z-score calculation. B, Hierarchical clustering o f proteins. C&D, Kaplan-Meier plots (C,
all patients; D, primary specimens only) demonstrating survival for the clades identified in
clustergram.

148

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Univariate logistic regression followed by Classification Error Determination for
multivariate logistic regression models.

We have found 15 variables that show prognostic value using univariate logistic
regression analysis for death (as a surrogate marker of recurrence). These are listed in
Table 20.
Table 20. Top scoring variables in univariate regression
Variable Name
BRESLOW
ATF2inCyto
Ecadherin
N cadherin
ATF2
PCNA Nuclei
CD44
PCNA Tumor Mask
Fibronectin
ATF2 nucbycyto
ATF2inNuc
Tenascin C
Beta catenin
Bid
Survivin

coefficient
-0.823
0.549
0.499
0.601
0.501
-0.405
0.438
-0.373
-0.353
-0.405
0.348
-0.302
0.314
-0.327
0.325

P value
1.38e-06
0.00234
0.0039
0.00424
0.00568
0.0086
0.00869
0.0148
0.0205
0.032
0.038
0.0415
0.0473
0.0477
0.049

Multivariate prognostic models were then constructed and tested through 10-fold
cross-validation. Each possible model was trained on 9/10 of the population, followed by
testing on the remaining 1/10 of the population; this process was then repeated 10 times.
The results of these analyses (i.e., the ability o f the model to correctly classify those
patients who will ‘recur’ versus those who will not) can be measured as a classification
error.
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Model Including Clinicopathologic Factors Alone
-

Input: 15 variables
•
•
•
•
•
•
•

BRESLOW
ATF2_Cytopl
asm
E-cadherin
N-cadherin
ATF2
PCNA Nuclei
CD44

PCNA_Tumor Mask
Fibronectin
ATF2_nucbycyto
ATF2_Nuclei
Tenascin C
Betacatenin
Bid
Survivin

0.45

0.4

0.35

0.3

0.25

0.2

variable s e t size
F ig u r e 2 4 . Missclassification error and 95% Cl for Models including Molecular Markers + Breslow Depth

A plot of misclassification error (Figure 24) demonstrates the
generalization/prediction error for models of different variable set sizes. As
demonstrated in Figure 24, a prognostic model with 5-7 variables results in a
misclassification error o f about .26, down from .34 when using only one variable alone.
This demonstrates that the addition of variables to Breslow depth improves the ability of
the model to determine which patients will ‘recur’ up to a point, after which, the addition
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of variables convolutes the picture. However, the direct utility of these markers is not
entirely clear, or easy to apply to a prospective cohort, as they remain continuous
variables in the constructed models.

Model Including Clinicopathologic Factors Alone
-

Input: 11 variables
•
•
•
•

Breslow
Clark
Ulceration
TILs

Microscopic Satellites
Histologic subtype
Lesion site
Sex
Age

MISS.CLASSIFICATION ERROR MELANOMA 5 YEAR RECURRENCE

0.31

0.305

0.3

0.295

0.29

0.285

0

2

3

4

5

6

NUMBER OF MODEL VAR IABLES

Figure 25. Missclassification error and 95% Cl for Models including Clinicopathologic Variables

For a point of reference, and to determine the economic reality of the molecular
assay, the same process was performed on the available standard clinicopathologic
variables alone, in the absence of molecular markers.(Figure 25) The analyses
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demonstrate that models constructed using only clinicopathologic variables do not
dramatically improve the prediction of recurrence by Breslow alone.

Cox Proportional Hazard and AIC.

Univariate Cox proportional hazard analysis of the training data set revealed that
13 factors were significantly associated with prognosis of melanoma patients (Table 22).
We included Breslow, which showed remarkable significance (p<0.0001), and performed
multivariate analysis on the 14 factors with stepwise selection o f variables using the AIC.
Not surprisingly, a Cox multivariate modeling system produced similar results to those
obtained with multivariate logistic regression, demonstrating that 5-8 markers provide the
most reliable estimate of survival. (Figure 26)
AIC COX MULTIVARIATE ANALYSIS FOR MELANOMA SURVIVAL
935

925

920

915

910
Number of mode! variables

Figure 26. Plot o f Akaike Information Coefficient (AIC) score by number of variables included in
Cox multivariate models.
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Table 21. Univariate Prediction of Melanoma-Specific Death at 20 year follow-up:
Associated with poor outcome:

Associated with good outcome:

M arker
A TF2

cont. pvalue
0 .0 0 0 5 9

Relative Risk
50%
25%
10%
vs
vs
vs
50%
75%
90%
1.45
2 .0 6
2.4 0

B e ta c a te n in

0 .0 0 0 7

3 .4 9

1.68

1.43

N c a d h e rin
C D 44
E c a d h e rin
MDM2

0 .0 0 1 3
0.0071
0 .0 0 8 7
0.01

1.97
2 .0 8 ^
1.28
2.41

1.95
1.58
1.88
1.79

1.61
1.22
1.69
1.27

A TF2 N u clear
MDM2 N u clear
CD61
p 1 6 _ N u c le a r by
p1 6 C y to p la sm
p1 6 N u c le a r
P c a d h e rin

0 .0 1 3
0 .0 1 8
0 .0 2 3

2 .0 0
2 .5 2
2 .1 5

1.65
1.57
1.39

1.33
1.22
1.29

0 .0 2 6
0 .0 3 3
0 .0 6 7

1.33
1.92
1.41

1.63
1.57
1.04

1.49
1.38
1.22

p 1 2 0 c a te n in
MDM2 C y to p lasm
TIM P2
MM P3
E phA 2
A P 2 N u c le a r

0 .0 8 3
0 .0 9
0 .0 9 7
0.1
0 .1 2
0 .1 3

1.75
1.73
1.18
2 .0 5
1.85
1.71

1.43
1.47
1.33
1.47
1.16
1.45

1.18
1.33
1.22
1.22
1.05
1.08

p 1 6 T u m o r M ask
E phrinA I
ckit T u m o r M ask
MBP
p 1 6 C y to p la sm
LPHA
MITF N u clear
CD 63
MAGE1
Hev1
p 27 N u clear
A p af 1
A P 2 T u m o r M ask
Bel x
ILK
T hioredoxin
L1

0 .1 3
0 .1 5
0 .2
0 .2 2
0 .2 6
0 .2 7
0 .2 9
0.41
0.51
0 .5 4
0 .6 4
0 .6 9
0 .7 5
0 .7 7
0 .8 3
0 .8 8
0 .9 8

1.42
1.11
1.22
1.47
1.31
1.14
1.66
0 .7 4
1.59
1.60
1.42
1.60
1.72
0 .8 0
0.81
1.10
0 .5 8

1.41
1.45
1.34
1.28
1.29
1.05
1.09
1.26
1.11
1.23
1.07
1.31
1.07
1.08
1.14
0 .9 8
0 .6 9

1.43
1.24
1.44
1.14
1.32
1.05
1.29
1.20
1.34
1.00
1.03
1.06
0 .9 7
1.33
1.11
0 .8 5
0 .7 9

M arker
B R ESL O W
A T F 2 _ n u c le a r by
A T F2 c y to p lasm
A P 2 _ C y to p lasm
b y A P 2 N u clear
F ibronectin
P C N A N u clear
O s te o n e c tin
p 1 6 _ C y to p lasm
b y p 1 6 N u clear
M etallothionein
p21 N u clear
p21 C y to p lasm
Ki67 N u clear
F asc in
p 2 7 _ C y to p la sm
by p 2 7 N u clear
p21 T u m o r M ask
MMP1
CTGF
B ax
Bid
p 2 1 _ N u c le a r by
p21 C y to p lasm
TIM P3
XIAP
T w ist
A P 2 C y to p lasm
B ad
p 2 7 C y to p la sm
Survivin
T e n a s c in C
clA P
D R4
p2 7 T u m o r M ask
a lp h a c a te n in
TRAIL D R5
A nnexin 1

cont. pvalue
6 .0 0 E -1 3

Relative Risk
50%
25%
10%
vs
vs
vs
50%
75%
90%
4 .1 0
7.33
1 1.95

3 .2 0 E -7

2 .2 9

1.74

1.39

2 .2 0 E -5
0 .0 0 0 7 1
0 .0 0 9 5
0 .0 2 6

1.62
1.62
2 .4 3
1.04

2 .0 9
2.13
1.51
1.22

1.83
1.57
1.36
1.22

0 .0 2 6
0 .0 4 8
0 .0 5 8

1.33
1.12
1.48

1.62
1.49
1.12

1.54
1.34
1.30

0 .0 6 6
0 .0 8
0.091

1.20
1.45
1.29

1.73
1.35
0.97

1.27
1 .1 5
1.08

0.1
0.11
0 .1 4
0 .1 4
0 .2 3
0 .2 9

1.09
0 .9 7
1.35
1.88
1.88
1.66

1.37
1.34
1.31
1.10
1.28
1.29

1.31
1.29
1.06
1.29
1.32
1.0 6

0 .3
0 .3 4
0 .3 5
0 .4 3
0 .4 9
0 .5
0 .5 2
0 .5 7
0 .5 7
0 .6 2
0 .8 8
0 .9 4
0 .9 8
0 .9 8
0 .9 9

0 .9 9
1.14
1.21
1.25
0 .8 0
1.39
1.04
1.17
0 .9 0
0 .8 9
1.05
0.91
1.01
1.03
0 .5 2

1.01
1.40
1.09
1.16
1.04
0 .9 7
1.02
1.24
0.94
1.06
1.07
0 .9 5
0 .9 8
0 .9 5
0.92

0 .9 9
1 .05
1 .00
1 .29
1 .07
1.0 9
1 .0 6
1 .0 8
0.9 0
1.07
0 .8 8
0 .9 9
0 .9 0
0 .9 0
1.07
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Table 22. Univariate Prediction of Melanoma-Specific Death at 20 year follow-up
(Only Prim ary Specimens):
Associated with poor outcome:

Associated with good outcome:

M arker
A T F2 C y to p lasm

cont. pvalue
0 .00041

Relative Risk
50%
25%
10%
vs
vs
vs
50%
75%
90%
2 .0 6
3 .5 6
6.34

A T F2
E c a d h e rin
N c a d h e rin

0 .0 0 1 2
0.0031
0 .0 0 3 3

5.75
3.3 2
4 .8 5

2 .9 0
2 .2 0
3 .2 3

2 .0 4
2 .1 7
2 .2 8

B e ta caten in
C D 44

0 .0 0 4 8
0 .0 0 9 5

5 .8 9
2.57

2 .8 9
2 .3 2

1.61
1.63

A T F2 N u c le a r
MDM2
MDM2 N u c le a r
p 1 6 _ N u c le a r by
p 1 6 C y to p la sm

0 .0 1 9
0 .0 2 7
0 .0 3 3

2 .5 5
3.44
3 .0 8

2 .2 4
2 .2 3
2 .0 4

1.82
1.20
1.15

0 .0 3 3

0.81

1.55

1.82

MDM2 C y to p la sm
p 1 2 0 c a te n in
a lp h a c a te n in
ckit T u m o r M ask
E phrinA I
p 1 6 N u clear
P c a d h e rin
E ohA 2
MBP
MITF N u c le a r

0 .0 5 6
0 .0 8 7
0.11
0 .1 3
0 .1 6
0.21
0 .2 3
0 .2 8
0 .3 8
0 .4 2

2.72
2 .1 5
2 .9 5
1.43
1.62
1.81
3 .1 9
1.91
1.63
1.04

1.86
2 .2 8
1.39
2 .2 0
1.56
1.61
1.01
0 .9 7
1.26
1.56

1.46
1.17
1.26
1.96
1.52
1.27
1.09
1.08
1.13
1.27

MM P3
p 1 6 T u m o r M ask
Survivin
LPHA
p 2 7 N u c le a r
CD61
A p af 1
A P 2 N u clear
p 1 6 C y to p la sm
ILK

0 .4 6
0 .4 7
0 .5
0 .5 3
0 .5 3
0 .5 8
0 .5 8
0 .5 8
0 .6
0 .7 2

1.23
1.18
1.26
2 .2 3
1.76
1.65
2 .1 2
1.59
1.31
0 .7 7

1.52
1.23
1.41
0 .8 8
0 .9 6
1.04
0 .9 7
1.28
1.38
1.43

1.58
1.41
0 .8 7
1.28
1.01
1.01
1.11
0 .9 9
1.32
1.36

Hey1
T hio redoxin
C D 63
p 2 7 T u m o r M ask
TIM P2
A P 2 T u m o r M ask

0 .7 4
0 .8 5
0 .8 6
0 .8 8
0 .9 5
0 .9 6

0 .9 5
2 .8 8
0 .6 8
1.23
1.12
1.64

0 .9 0
1.11
1.25
1.04
1.01
0 .9 5

1.15
0 .8 2
1.13
1.01
0 .8 6
0 .9 7

M arker
B R ESL O W
A T F 2 _ n u c le a r by
A T F2 c y to p la sm
P C N A N u c le a r
F ibronectin
A P 2 _ C y to p la sm
b y A P 2 N u c le a r
Bid
p 1 6 _ C y to p la sm
b y p 1 6 N u clear
T e n a s c in C
p21 N u clear
p 2 7 _ C y to p la sm
by p2 7 N u clear
p 2 1 _ T u m o r_ M a s
k
O s te o n e c tin
p21 C y to p la sm
M etallothionein
MMP1
F asc in
T w ist
A nnexin 1
Ki67 N u clear
L1
p 2 1 _ N u c le a r by
p21 C y to p lasm
D R4
B ax
XIAP
TRAIL D R 5
A P 2 C y to p la sm
CTGF
clA P
MAGE1
p 2 7 C y to p la sm
p 2 1 _ C y to p la s m
by p21 N u c le a r
T IM P3
B ad
Bel x

cont. pvalue
9 .0 0 E -1 2

Relative Risk
50%
25%
10%
vs
vs
vs
50%
75%
90%
4 .1 4
9 .5 8
9 .4 8

4 .1 0 E -0 5
0 .0 0 1 2
0 .0 0 8 7

1.91
4 .2 4
2 .8 8

2 .0 6
2 .7 4
1.65

1.43
1.28
1.17

0 .0 1 8
0 .0 6 5

1.66
5.11

2 .0 0
1.27

1.63
1 .09

0 .0 8 8
0 .0 9 3
0 .0 9 3

0 .9 9
1 .2 9
1.54

1.63
1.18
1.25

1 .85
0.8 9
0.91

0.11

1.50

1.41

1.35

0 .1 2
0 .1 8
0 .2 2
0 .2 4
0 .2 5
0.31
0 .3 2
0 .3 5
0 .3 5
0 .3 8

2 .0 5
1.44
1.57
0 .7 8
1 .8 9
0.91
1.71
1.07
1 .2 9
1 .2 9

1.31
1.65
1.19
1.20
1.50
0 .9 0
1.26
1.55
1.29
1.65

0 .9 3
1.14
0 .8 9
1.43
1.13
0 .7 8
1.36
1 .16
1.20
1.61

0 .3 8
0 .6
0.61
0 .6 7
0 .6 8
0 .6 8
0 .7 4
0 .7 9
0.81
0.81

1.46
1 .4 5
2 .0 2
0 .4 7
1.23
0 .6 9
1 .4 5
1.40
1.10
0 .9 3

1.04
1.12
1.16
0 .5 0
1.01
1.06
0 .8 2
1.08
0 .7 6
1.01

0 .9 4
0 .9 5
0 .7 8
0.81
0 .8 9
1.13
0 .8 9
0 .8 5
0 .7 8
1 .1 3

0 .8 3
0 .8 5
0 .9 3
0 .9 5

0 .7 7
1 .6 6
1 .0 9
1 .5 4

0 .9 3
1.13
0 .6 9
0 .6 0

1 .0 2
0 .9 0
0 .8 7
0 .7 2
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Genetic Algorithm.

In order to develop a prognostic model with results that can be applied to future
cohorts, or be used in a prospective trial, we applied genetic algorithm software to
determine the optimal combination of markers, as well as optimal outpoints for each
marker. Thirteen of the 66 variables (derived from 50 independent protein assays)
analyzed were significantly (p<0.1) associated with outcome (N-cadherin, E-cadherin,
p i 20, Beta-catenin, CD44, Tenascin C, p21, PCNA, Fibronectin, MDM2, ATF2, p i 6,
AP2) by Cox univariate analysis. GA software was run to convergence (>20X106
generations) multiple times (Figure 27A) and the runs repeatedly resulted in the same
five-marker solution: ATF2_ratio of cytoplasm by nuclear; nuclear p21; pl6_ratio of
cytoplasm by nuclear; Beta catenin; and Fibronectin (Figure 27B).
It is interesting to note that the genetic algorithm resulted in a similar number of
genes (five) in the ‘optimal model’ to optimal models derived from logistic and Cox
multivariate regression models, which consider the variables in a linear fashion. The
application of the GA model to the training set (Discovery cohort) is depicted in Figure
28. The groups were pooled 0-3 (high risk) and 4-5 (low risk) based on similar outcomes
amongst the groups.
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A

Molecular Markers Alone

25
20
15

10
5

0
0.0

2 .0 E + 0 6

4 .0 E + 0 6

6 .0 E + 0 6

8 .0 E + 0 6

1 .0 E + 0 7

1 .2 E + 0 7

1 .4 E + 0 7

1 .6 E + 0 7

1 .8E + 07

Generation Number
-♦— S e r ie s 1 —■— S e r ie s 2

B

S e r ie s 3

x

S e r ie s 4 —

Se r i e s 5

Gene 1: ATF2 (Cyto by Nuc) > -0.052
Gene 2: p21_Nuclei > 12.98
Gene 3: p l6 (Cyto by Nuc) < -0.083
Gene 4: Beta_catenin > 38.68

Chi Square = 23.13
p-value = 1.54E-06

Gene 5: Fibronectin < 57.93
Figure 27. A, Plot of risk ratio by generation number amonst genetic algorithms, demonstrating
progressive improvement of chi-square as generation number increases. B, Optimal gene set with
optimal cut-points for each biomarker. The patient is assigned 1-point for each condition that is
true, in an additive fashion.
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Figure 28. Kaplan-Meier plot of genetic algorithm applied to primary melanoma specimens. Risk
groups were assigned based on stratification seen when plotting each individual score category.

In this training cohort, limited to 129 primary tumors for which all data points
were available, Kaplan-Meier analyses show patients with Breslow depth <1.0 mm have
a 78.1% 10-year survival compared to patients with depth >1.0 mm with a 45.4% 10-year
survival (p<0.001). Addition of the GA information further stratifies the patients.
Patients with Breslow depth <1.00mm are split into “low-risk” (86.4% survival) and
“high-risk” groups (60% survival) while those with Breslow > 1.00mm split into “lowrisk” (80.5%) and “high-risk” (19.6%) (p<0.0001). This information is presented in
Figure 29.
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Figure 29. Kaplan-Meier plot demonstrating stratification of patients by Breslow depth (1.00 mm
cut point; the ‘standard’ used by surgeons in determination of which patients receive sentinel
lymph node biopsy) and genetic algorithm risk score.

This training set data suggests that it is possible to improve upon the best
prognostic index in primary melanoma (i.e., Breslow depth) by using multiplexed in situ
measurement of protein expression.
We are in the process of validating of our results on an independent cohort of
patients with known sentinel lymph node outcomes to determine if the genetic algorithm
(GA) assay is more accurate than sentinel node biopsy in predicting
recurrence/metastasis. The preliminary data follow.
In the Validation cohort of 270 primary melanoma specimens, all patients
underwent sentinel lymph node biopsy (SLNB). The mean time from wide local excision
(WLE) to SLNB was 47 days. Patient and tumor characteristics include the following.
There are 112 female and 158 male patients. The mean age at diagnosis is 58 years ± 17
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years (range: 5 years - 98 years). The mean follow-up time is 23 months ± 18 months
(range: 21 days - 74 months). The results of SLNB were positive in 33 cases (12.2%).
The majority of these patients received their SLNB within the last year and a half.
As a result, recurrence/metastasis data on this cohort is somewhat limited. Using the
restricted recurrence data available to us, we seek to examine the ability of Breslow
depth, SLN status, and our GA risk test to predict metastasis. However, we first
demonstrate the ability of Breslow depth to predict SLN status (Figure 30).

l r °-6~

UC=0.723
0.0

o.o

0,2

0.4

0.6

0.8

1.0

1 - Specificity

Figure 30. Receiver-operator characteristic curve for prediction of SLN status by Breslow depth.

Regarding recurrence, there are currently 30 patients (10.8%) who have
developed metastases. Only seven of these patients had positive SLN results. In terms of
prediction of recurrence, Kaplan-Meier plots demonstrate that Breslow depth (Figure 31),
SLN status (Figure 32), and the GA risk test (Figure 33) are able to predict metastasis.
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Figure 31. Prediction of metastasis by Breslow depth in SLN (YTMA 76) cohort. Time to recurrence is
measured in days.
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Figure 32. Prediction of metastasis by SLN status in SLN (YTMA 76) cohort. Time to recurrence is
measured in days.
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Figure 33. Prediction of metastasis by GA risk test on SLN (YTMA 76) cohort. Time to recurrence is
measured in months.

161

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Discussion
We have demonstrated a set of molecular markers that can be used as an
independent predictor of survival, to potentially be used on a regular basis to aid in
patient prognosis. It should be recognized, however, that these prognostic models should
be tested on an independent validation set before being applied in a prospective clinical
trial. We hope that these models will serve as an initial assessment to aid clinicians in the
prognosis o f their patient’s disease, and possibly provide therapeutic guidance. Though
the current aim of this project is to define aggressive melanoma from ‘benign—less
aggressive’ melanoma, a number of molecular targets have been identified that may have
therapeutic potential.
Tissue microarray technology, uniquely, provides the capacity for detecting
multiple proteins in large series of patients. To our knowledge, only one study has
demonstrated evidence o f the feasibility of protein expression profiling for the prognosis
•
•
109 282
of melanoma269 , and only a few papers based on the expression single
proteins
’
I ' ) ’!

'I 1

'X

325-

have been published. Bom out of the unparalleled ability to control many of the

ambiguities of immunohistochemistry, tissue microarray technology combined with
automated quantitative analysis allows one to approximate molecular concentration
measurements of a particular protein without loss of spatial information.
Many o f the genes (i.e,. gene products) that demonstrate closest association with
outcome in this study have an established role in melanoma progression. Others have a
purported role that requires further investigation at the cellular and molecular biology
level. All of them, however, are potential therapeutic targets in the treatment of
melanoma.
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Cyclins and cyclin-dependent kinases (CDKs) are evolutionarily conserved
proteins that are essential for cell-cycle control in eukaryotes. Cyclins (regulatory
subunits) bind to CDKs to form complexes that regulate the progression of the cell cycle.
The activity of these complexes is modulated by activating and inhibitory
phosphorylation events, as well as interactions with small regulatory proteins, including
p i 6, p21, p27 and others. These proteins, referred to as inhibitors of CDK activity
(CDKIs), bind to cyclins, CDKs, or their complexes.334
The pi 6INK4a gene, found at 9p21, is a tumor-suppressor gene that has long been
known to be involved in familial and sporadic melanoma. The p l6 protein has been
identified as a specific inhibitor of CDK4, blocking CDK4 substrate phosphorylation.

335

Deletion of the INK4a/ARF (CDKN2a) locus is a common genetic lesion, detected in
-50% of primary tumors and nearly all melanoma cell lines.336,337 Work on mouse
models has suggested that p ld 11'* 43 plays an important role in limiting inappropriate or
aberrant cellular proliferation.338 Previous studies have demonstrated that loss of nuclear
p l6 occurs more commonly in melanomas than benign nevi339,340, and that this
occurrence in primary melanoma is also associated with increased proliferation
(measured by Ki-67) and poor prognosis.341
Most papers approach the cytoplasmic localization of p i 6 as a nonspecific
artifact. However, recent studies have suggested that cytoplasmic localization of p i 6
may represent prognostically-relevant subclasses of cancer. Emig et al. reported that in
breast cancer, cytoplasmic accumulation of p i 6 identifies a subset of tumors with
accelerated proliferation and other unfavorable parameters.342 Another study
demonstrated that nuclear and cytoplasmic p i 6 overexpression in breast cancer was
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associated with a highly malignant tumor phenotype.343 On the other hand, cytoplasmic
p l6 localization in colon cancers is associated with a good prognosis.344 In an attempt to
elucidate whether cytoplasmic p i 6 staining is specific or an artifact due to tissue fixation
and/or nonspecific binding of the applied antibodies, Evangelou et al. used
immunoelectronmicroscopy to demonstrate that p i 6 can, in fact, be present in the
cytoplasm.345
An abundance of nuclear factors in the cytoplasm likely represents a defect in the
cytoplasmic-nuclear shuttling system.346 However, the mechanism is not fully
understood. As p l6 lacks Nuclear Location Signals (NLS) and Nuclear Export Signals
(NES), the defect may lie in the nuclear chaperone group of proteins. The significance of
these proteins has been shown in cases of APC and BRCA1 where destruction of NLS
does not impede shuttling in the nucleus.345 An alternative explanation is that
cytoplasmic p i 6 may represent a protective response to over expression of CDK4.
According to this scenario, a portion of p i 6 binds to CDK4 in the cytoplasm and inhibits
its passage into the nucleus due to the large size of the complex, whereas the unbound
protein enters the nucleus to exert its oncosuppressor activity.344 In any event, based on
our results, an aggressive phenotype is expected in melanoma when cytoplasmic
concentrations of p l6 exceed those in the nucleus.
The WAF1 gene, which encodes the p21WAF1 protein, is located at 6p21. It is has
been shown to be under the transcriptional control of p53, and the p21 protein is known
to inhibit progression of the cell cycle at the Glto G2 phase.347 The WAF1 gene is rarely
mutated in metastatic melanoma, and expression is not always correlated with p53
expression.348 Regarding melanocytic lesions, expression of p21 is found to be
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low/undetectable in benign melanocytic lesions, while higher expression seen in
malignant melanomas.349 Additionally, increasing expression of p21 has been found to
correlate with Clark level and Breslow thickness.349,350 However, the association of p21
•
•
with patient prognosis is
not entirely
clear or intuitive. 351

Fibronectin is an extracellular glycoprotein that serves as a ligand for the integrin
family of cell adhesion receptors and regulates cytoskeletal organization. Previous
studies have demonstrated that fibronectin expression is associated with tumorigenesis352
and metastasis353. Enhanced expression of extracellular matrix (ECM) proteins, such as
fibronectin, may promote tumor cell survival or angiogenesis.354 Experiments by Clark et
al. demonstrate that metastatic transformation of relatively indolent cell lines is
associated with upregulation of several genes that encode ECM proteins.123 We have also
previously demonstrated, through genomic analysis, that fibronectin expression is
significantly increased in melanoma cell lines relative to normal melanocytes.117 This is
the first time, to our knowledge, that anyone has demonstrated that fibronectin expression
by melanoma cells is associated with an invasive phenotype and poor prognosis.
The cadherin/catenin complex is critical for the formation and maintenance of
cell-cell adhesion. E-cadherin, a calcium-dependent intercellular adhesion receptor, is
the primary epithelial cell adhesion regulator.355 Its functional role in melanocytes is to
maintain melanocyte-keratinocyte adhesion.356 The extracellular domain works like a
molecular zipper, while the cytoplasmic tail is linked to the actin cytoskeleton via
catenins.357 Loss of E-cadherin expression has been implicated in tumor progression for
a variety of tumor types, including malignant melanomas.358"364 Recent studies show that
E-cadherin is not only involved in cell-cell contact but multiple signaling pathways are
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activated or repressed by E-cadherin. The most commonly discussed pathway is the (3catenin/LEF/TCF signaling cascade.365,366 However, E-cadherin is also involved in the
regulation o f other pathways as well, including MAP kinase

'K fn

and NF kB

TSR

pathways.

N-cadherin, the neuronal equivalent of E-cadherin, is also expressed by melanoma
and has been reported to be upregulated in melanoma cell lines when E-cadherin is
downregulated.

T SO

Additionally, strong N-cadherin expression in single melanomas has

been reported in the literature.362 These observations suggest that this shift in cadherin
profiles may endow melanocytic cells with new adhesive properties that favor
uncontrolled proliferation, migration, and invasion. However, examination of a larger
cohort of tumor specimens demonstrates that only a minor percentage of invasive
melanomas demonstrate N-cadherin expression.368 Based on previous data and our
results, it is unlikely that the E- to N-cadherin “switch” actually takes place in vivo. The
role of cadherins as causative factors in melanoma tumor progression remains to be
proven. It is likely, however, that overall cadherin expression, in general, is indicative of
the differentiation status of a tumor. Based on our results, it is clear that maintenance of
E- and/or N-cadherin expression is an excellent predictor of outcome in melanoma.
Regarding the cadherins, our results indicate that it does not matter which
cadherin is present at the cell surface. Both E- and N-cadherin are significantly
associated with survival in a positive fashion. That is, it is unlikely that the E- to Ncadherin shift is an actual in vivo phenomenon. The mere presence of one of these
cadherins at the cell surface is probably sufficient to stabilize melanoma cells and retard
their invasion.
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Catenins are the cytoplasmic proteins that regulate and effect cadherin function.
P- and y-catenin bind directly to the cytoplasmic carboxy-terminal domain of E-cadherin,
forming mutually exclusive complexes, while a-catenin links the bound P- and y-catenin
to actin microfilaments of the cellular cytoskeleton.369 The catenins are thought to have a
signaling role through the cytoplasmic adenomatous polyposis coli (APC) protein, which
is the product of a tumor suppressor gene mutated in colorectal and other cancers. They
are also known to interact with the epidermal growth factor (EGF) and hepatocyte growth
factor (E1GF) receptors, becoming tyrosine phosphorylated upon activation by these
growth factors.

7 7 0 77 1

’

A fourth member of the catenin family is pl20-catenin (pi 20).

Although it was originally identified as a Src substrate, p i 20 regulates cell-cell adhesion
through its interaction with the cytoplasmic tail of cadherins. It is purported to regulate
cadherin turnover at the cell surface, thereby controlling the amount of cadherin available
for cell-cell adhesion, p i 20 also modulates the activities of RhoA, Rac, and Cdc42,
suggesting that along with other Src substrates, p i 20 regulates actin dynamics.

779

Thus,

p i 20, a regulator of cadherin abundance and activity, likely participates in regulating the
balance between adhesive and motile cellular phenotypes.
Very little data is available regarding expression of the catenins in melanoma. A
relatively small study performed by Zhang et al. demonstrated that there is no correlation
between the expression of a-, (3-, y-catenins. However, P- and pl20-catenin showed
coordinated expression levels, a-catenin exhibited an inverse correlation with tumor
thickness, as well as lower expression levels in advanced primary melanoma and
metastases.373 Studies also show that expression of P-catenin is reduced in metastatic
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compared with primary melanoma lesions,100’362,374 and reduced (3-catenin expression in
superficial spreading melanomas is associated with a poor prognosis375.
Based on our results, all members of the catenin family are associated with
improved disease-specific survival. However, expression of P-catenin is most closely
associated with outcome. This likely corresponds to the presence of functional cadherincatenin complexes, representing ‘stable’ melanoma cells. However, it has also been
suggested that P-catenin participates in induction of apoptosis in early lesions and that the
expression is lost or down-regulated in the more advanced tumors.375
Transcriptional regulation of the genes that are critical in melanoma progression
is beginning to be elucidated. Transcription factors that have been implicated in
melanoma progression include AP-2, ATF-2, SNAIL, MITF, and NFkB.376

A s

demonstrated in chapters two and four, the transcription factors ATF-2 and AP-2 are
closely associated with outcome in melanoma.

989

’

977

These are likely master regulators

in the development of melanoma, with AP-2 inhibiting tumorigenicity and metastasis and
ATF-2 promoting these qualities. In fact, AP-2 has been shown to directly affect
transcription of c-KIT, MCAM/MUC18, MMP-2, and PAR-1,378'380 and also influence
expression of E-cadherin, p21, HER2, PAI-1, Bcl-2, VEGF, and IGFR-1.376 ATF-2 has
been shown to be associated with tumor growth and metastasis

251 252

’

in cell culture and

animal models, and its prognostic role in melanoma is demonstrated in this dissertation.
MITF, the microophthalmia transcription factor, plays an important role in the
differentiation o f melanocytes and other neural crest-derived cells. Although its role in
this process is still poorly understood, MITF has multiple functions.381 In the Appendix
(Garraway et al. publication in Nature382) , we show that although protein levels of MITF
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are not significantly associated with patient outcome, genetic aberrations (i.e., gains in
DNA copy number of the MITF gene detected by fluorescence in situ hybridization)
predict a poor outcome in metastatic malignant melanoma.
Many factors influence tumor initiation, proliferation, invasion, and metastasis,
including alterations in multiple genes affecting cell cycle regulation, cell-cell interaction,
adhesion to extracellular matrix, and vascularization. Using an objective measurement of
expression levels in a large cohort of melanoma specimens, we have demonstrated some
of the most promising prognostic biomarkers in malignant melanoma.
These preliminary analyses demonstrate great promise for predicting metastasis
based on molecular information. Sentinel lymph node biopsy only identifies those
melanomas that metastasize through the lymphatic system. Melanoma, however, can
metastasize through other routes, including direct extension and hematogenous
dissemination. In the era before sentinel lymph node biopsy, initial presentation of
melanoma metastases occurred in the lymph nodes only 50% of the time, with
satellite/in-transit metastases (15-20%) and distant metastases (30-35%) representing the
remaining patients who develop metastatic disease.383,384 It is likely that the
development o f metastatic disease through these different pathways represents different
biological classes of melanoma; a reasonable explanation for the low sensitivity and high
“false negative” rate (up to 25%)

09

of SLNB for melanoma. The goal of our test is to

identify those patients who are likely to have (or develop) a metastasis, regardless of their
Breslow depth and despite the presence of negative lymph nodes.
Further studies are needed to validate the current models we have constructed and
are in the process of constructing. Although the risk test we have developed through
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genetic algorithms is intuitive, and easy to apply to future patients (in a prospective
fashion), it may be too simple in its current form. Plans are in place to develop more
complex models that will impart weightings to the score given to markers, as their
contribution to outcome prediction is probably not equal (as the current model assumes).
Additionally, patient follow-up on our validation cohort is a work in progress.
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